Journal of Pathology and Translational Medicine

Original Articles

E-cadherin expression and tumor-stroma ratio as prognostic biomarkers of peritoneal recurrence in advanced gastric cancer: a digital image analysis-based stratification study: Somang Lee, Binnari Kim; J Pathol Transl Med. 2025;59(6):408-420. Published online November 6, 2025; DOI: https://doi.org/10.4132/jptm.2025.08.27

1,902 View
102 Download

Abstract PDF: Background
Gastric cancer remains a significant global health burden, with a high peritoneal recurrence rates after curative surgery. E-cadherin and the tumor-stroma ratio (TSR) have been proposed as prognostic indicators, but their combined prognostic utility remains unclear. Methods: This retrospective study included 130 patients with T3/T4a gastric cancer who underwent curative gastrectomy at Ulsan University Hospital between 2014 and 2019. Immunohistochemistry for E-cadherin and Vimentin was performed. Digital image analysis using QuPath’s object classifier quantified E-cadherin expression and TSR. Results: Low E-cadherin expression was associated with diffuse-type histology and advanced T stage. Low TSR was linked to younger age, female sex, and XELOX treatment. In Kaplan-Meier analysis, low TSR showed a non-significant trend toward higher peritoneal recurrence (p = .054), while low E-cadherin expression was significantly associated with increased peritoneal recurrence (p = .002). Combined biomarker analysis also revealed a significant difference in recurrence-free survival (RFS) among the four groups (p = .005); patients with both high TSR and high E-cadherin expression experienced the most favorable RFS. In multivariable analysis, E-cadherin expression remained the only independent predictor of peritoneal recurrence (high vs. low; hazard ratio, 0.348; 95% confidence interval, 0.149 to 0.816; p = .015). Conclusions: E-cadherin and TSR reflect distinct tumor biology such as epithelial integrity and stromal composition, and their combined evaluation improves prognostic stratification. Digital image analysis enhances reproducibility and objectivity, supporting their integration into clinical workflows.

Clinicopathological implications of miR-3127 in melanoma: Truong Phan-Xuan Nguyen, Minh-Khang Le, Chau M. Bui, Vuong Gia Huy; J Pathol Transl Med. 2025;59(6):371-381. Published online October 16, 2025; DOI: https://doi.org/10.4132/jptm.2025.07.08

3,105 View
138 Download

Abstract PDF Supplementary Material: Background
Cutaneous melanoma is the most lethal of all skin cancers. Recent studies suggested that miR-3127 is dysregulated in multiple tumor types and has important roles in tumorigenesis and cancer progression, giving it potential as a prognostic biomarker. The aim of this study was to use bioinformatic analysis to assess miR-3127 expression and correlate expression patterns with disease course in patients with cutaneous melanoma. Methods: miRNA, mRNA sequencing, DNA methylation data, and clinical information of cutaneous melanoma cases were downloaded from the Human Cancer Atlas – Skin Cutaneous Melanoma (TCGA-SKCM). miR-3127 expression was classified into miR-3127–low and miR-3127–high clusters using maximally selected rank statistics. Results: Clustering analysis showed that high expression of miR-3127 (≥20.3 reads per million) was associated with worse progression-free (p < .001) and overall (p = .011) survival compared to low miR-3127 expression. More than five thousand differentially expressed genes between the two miR-3127 sample groups encoded cell differentiation markers, cytokines, growth factors, translocated cancer genes, and oncogenes. Pathway analysis revealed that miR-3127–high samples related to activity of proliferation, DNA repair, and ultraviolet response. Conclusions: The expression level of miR-3127 could act as a prognostic indicator for patients with melanoma.

Low Ki-67 labeling index is a clinically useful predictive factor for recurrence-free survival in patients with papillary thyroid carcinoma: Takashi Masui, Katsunari Yane, Ichiro Ota, Kennichi Kakudo, Tomoko Wakasa, Satoru Koike, Hirotaka Kinugawa, Ryuji Yasumatsu, Tadashi Kitahara; J Pathol Transl Med. 2025;59(2):115-124. Published online February 18, 2025; DOI: https://doi.org/10.4132/jptm.2024.11.08

5,192 View
241 Download
2 Web of Science
3 Crossref

Abstract PDF

Background
We report a new risk stratification of invasive stage papillary thyroid carcinomas (PTCs) by combining invasive status, using extrathyroid invasion (Ex) status, and tumor growth speed using the Ki-67 labeling index (LI). Methods: We examined tumor recurrence in 167 patients with PTC who were surgically treated at the Kindai University Nara Hospital between 2010 and 2022. The patients were classified according to the degree of invasion [negative (Ex0) or positive (Ex1, Ex2, and Ex3)] and tumor growth speed expressed with Ki-67 LI, as low (<5%) or high (>5%). This study confirmed previous findings that the disease-free survival (DFS) rate in PTCs significantly differed between patients with a high and low Ki-67 index. Results: When combining Ex status (negative or positive) and Ki-67 proliferation status (low or high), the DFS rate of invasion in the negative, low Ki-67 LI group was only 1.1%, while that of invasion in the positive, high Ki-67 LI was 44.1%. This study reports for the first time that recurrence risks can be stratified accurately when combining carcinoma’s essential two features of extrathyroid invasion status and tumor growth speed. Conclusions: We believe the evidence for low tumor recurrence risk may contribute to use of more conservative treatment options for invasive-stage PTCs and help alleviate patient anxiety about tumor recurrence and death.

Citations

Citations to this article as recorded by

Research Progress on the Correlation between Three Biomarkers, Ki-67, CAIX and VEGF and Clear Cell Renal Cell Carcinoma
锦容马
Advances in Clinical Medicine.2025; 15(09): 326. CrossRef
Immunophenotypic Panel for Comprehensive Characterization of Aggressive Thyroid Carcinomas
Mihail Ceausu, Mihai Alin Publik, Dana Terzea, Carmen Adina Cristea, Dumitru Ioachim, Dana Manda, Sorina Schipor
Cells.2025; 14(19): 1554. CrossRef
High Ki-67 labeling index correlates with aggressive clinicopathological features in papillary thyroid carcinoma: a retrospective study
Defi Nurlia Erdian, Maria Francisca Ham, Dina Khoirunnisa, Agnes Stephanie Harahap
Thyroid Research.2025;[Epub] CrossRef

Review

Cytologic hallmarks and differential diagnosis of papillary thyroid carcinoma subtypes: Agnes Stephanie Harahap, Chan Kwon Jung; J Pathol Transl Med. 2024;58(6):265-282. Published online November 7, 2024; DOI: https://doi.org/10.4132/jptm.2024.10.11

13,919 View
598 Download
9 Web of Science
8 Crossref

Abstract PDF

Papillary thyroid carcinoma (PTC) is the most common thyroid malignancy, characterized by a range of subtypes that differ in their cytologic features, clinical behavior, and prognosis. Accurate cytologic evaluation of PTC using fine-needle aspiration is essential but can be challenging due to the morphologic diversity among subtypes. This review focuses on the distinct cytologic characteristics of various PTC subtypes, including the classic type, follicular variant, tall cell, columnar cell, hobnail, diffuse sclerosing, Warthin-like, solid/trabecular, and oncocytic PTCs. Each subtype demonstrates unique nuclear features, architectural patterns, and background elements essential for diagnosis and differentiation from other thyroid lesions. Recognizing these distinct cytologic patterns is essential for identifying aggressive subtypes like tall cell, hobnail, and columnar cell PTCs, which have a higher risk of recurrence, metastasis, and poorer clinical outcomes. Additionally, rare subtypes such as diffuse sclerosing and Warthin-like PTCs present unique cytologic profiles that must be carefully interpreted to avoid diagnostic errors. The review also highlights the cytologic indicators of lymph node metastasis and high-grade features, such as differentiated high-grade thyroid carcinoma. The integration of molecular testing can further refine subtype diagnosis by identifying specific genetic mutations. A thorough understanding of these subtype-specific cytologic features and molecular profiles is vital for accurate diagnosis, risk stratification, and personalized management of PTC patients. Future improvements in diagnostic techniques and standardization are needed to enhance cytologic evaluation and clinical decision-making in thyroid cancer.

Citations

Citations to this article as recorded by

Oncocytic Thyroid Tumours With Pathogenic FLCN Mutations Mimic Oncocytic Papillary Thyroid Carcinoma on Fine‐Needle Aspiration
Adeel M. Ashraf, Faisal Hassan, Adrian A. Dawkins, Julie C. Dueber, Derek B. Allison, Thèrése J. Bocklage
Cytopathology.2026; 37(1): 108. CrossRef
Using a new type of visible light-based emission fluorescence microscope to identify the benign and malignant nature of thyroid tissue during the surgical process: Analysis of diagnostic results
Yu Miao, Liu Xiaowei, Li Muyang, Gao Jian, Chen Lu
Photodiagnosis and Photodynamic Therapy.2026; 57: 105324. CrossRef
Nuclear pseudoinclusion is associated with BRAFV600E mutation: Analysis of nuclear features in papillary thyroid carcinoma
Agnes Stephanie Harahap, Dina Khoirunnisa, Salinah, Maria Francisca Ham
Annals of Diagnostic Pathology.2025; 75: 152434. CrossRef
2025 Korean Thyroid Association Clinical Management Guideline on Active Surveillance for Low-Risk Papillary Thyroid Carcinoma
Eun Kyung Lee, Min Joo Kim, Seung Heon Kang, Bon Seok Koo, Kyungsik Kim, Mijin Kim, Bo Hyun Kim, Ji-hoon Kim, Shin Je Moon, Kyorim Back, Young Shin Song, Jong-hyuk Ahn, Hwa Young Ahn, Ho-Ryun Won, Won Sang Yoo, Min Kyoung Lee, Jeongmin Lee, Ji Ye Lee, Kyo
International Journal of Thyroidology.2025; 18(1): 30. CrossRef
Structure-based molecular screening and dynamic simulation of phytocompounds targeting VEGFR-2: a novel therapeutic approach for papillary thyroid carcinoma
Shuai Wang, Lingqian Zhang, Wenjun Zhang, Xiong Zeng, Jie Mei, Weidong Xiao, Lijie Yang
Frontiers in Pharmacology.2025;[Epub] CrossRef
2025 Korean Thyroid Association Clinical Management Guideline on Active Surveillance for Low-Risk Papillary Thyroid Carcinoma
Eun Kyung Lee, Min Joo Kim, Seung Heon Kang, Bon Seok Koo, Kyungsik Kim, Mijin Kim, Bo Hyun Kim, Ji-hoon Kim, Shinje Moon, Kyorim Back, Young Shin Song, Jong-hyuk Ahn, Hwa Young Ahn, Ho-Ryun Won, Won Sang Yoo, Min Kyoung Lee, Jeongmin Lee, Ji Ye Lee, Kyon
Endocrinology and Metabolism.2025; 40(3): 307. CrossRef
A Case of Warthin-Like Variant of Papillary Thyroid Cancer
Amy Chow, Israa Laklouk
Cureus.2025;[Epub] CrossRef
Propensity score-matched analysis of the ‘2+2’ parathyroid strategy in total thyroidectomy with central neck dissection
Hao Gong, Simei Yao, Tianyuchen Jiang, Yi Yang, Yuhan Jiang, Zhujuan Wu, Anping Su
Frontiers in Endocrinology.2025;[Epub] CrossRef

Original Articles

TERT mutations and aggressive histopathologic characteristics of radioiodine-refractory papillary thyroid cancer: Ju Yeon Pyo, Yoon Jin Cha, SoonWon Hong; J Pathol Transl Med. 2024;58(6):310-320. Published online September 12, 2024; DOI: https://doi.org/10.4132/jptm.2024.07.29

4,743 View
343 Download
4 Web of Science
5 Crossref

Abstract PDF

Background
Radioiodine (RI) ablation following thyroid-stimulating hormone suppression is an effective treatment for papillary thyroid cancer (PTC), typically leading to favorable outcomes. However, RI-refractory tumors exhibit aggressive behavior and poor prognoses. Recent studies highlight the role of genetic abnormalities in PTC signaling pathways, including the activation of telomerase reverse transcriptase (TERT), and the correlation of mutations with adverse outcomes.
Methods
This study analyzed mutations in BRAF V600E and the TERT-promoter genes, comparing clinicopathological features between RI-refractory and RI-responsive PTCs. Among 82 RI-refractory patients, formalin-fixed, paraffin-embedded tissues from initial surgeries were available for 26. Another 89 without distant metastasis over 5 years formed a matched RI-responsive control group.
Results
Histopathologically, RI-refractory PTCs showed increased frequencies of small tumor clusters without fibrovascular cores, hobnail features, and a high height-to-width ratio of tumor cells. These tumors were more likely to exhibit necrosis, mitosis, lymph node metastasis, extrathyroidal extension, and involvement of resection margins. TERT-promoter mutations were statistically significantly associated with these aggressive clinicopathologic features. Immunohistochemically, decreased expression of sodium iodide symporter and thyroglobulin stimulating hormone receptor proteins was common in RI-refractory PTCs, along with lower levels of oncogenic proteins such as vascular endothelial cell growth factor, vascular endothelial cell growth factor receptor 2, and nuclear factor kappa-light-chain-enhancer of activated B cells. Total loss of PTEN expression was occasionally observed. In contrast, all cases tested positive for cytoplasmic β-catenin.
Conclusions
RI-refractory PTCs are linked to TERT mutations and exhibit specific aggressive histopathologic features, particularly in tumor centers.

Citations

Citations to this article as recorded by

Characterizing thyroid carcinomas in the elderly: Histological subtypes and TERT promoter mutation analysis based on the latest WHO classification
Myoung Ju Koh, Songmi Noh, Jin Kyong Kim, Gi Jeong Kim
Annals of Diagnostic Pathology.2026; 80: 152578. CrossRef
The ability of anexelekto (AXL) expression and TERT promoter mutation to predict radioiodine-refractory differentiated thyroid carcinoma
Hasrayati Agustina, Tutik Nur Ayni, Yohana Azhar, Erwin Affandi Soeriadi, Bethy Suryawathy Hernowo
Diagnostic Pathology.2025;[Epub] CrossRef
Clinicopathologic characteristics of papillary thyroid carcinoma, tall cell subtype and subtype with tall cell features, an institutional experience
Xueting Jin, Shunsuke Koga, Xiao Zhou, Niaz Z. Khan, Zubair W. Baloch
Human Pathology.2025; 161: 105867. CrossRef
Calcifying nested stromal-epithelial tumor of the liver: Report of two cases revealing novel WT1 mutation and distinct epigenetic features
Andrea Strakova-Peterikova, Franco Fedeli, Boris Rychly, Jiri Soukup, Michael Michal, Petr Martinek, Marian Grendar, Elaheh Mosaieby, Nikola Ptakova, Maryna Slisarenko, Michal Michal, Kvetoslava Michalova
Virchows Archiv.2025;[Epub] CrossRef
Insulin resistance and metabolic dysfunction in thyroid nodules and differentiated thyroid cancer
Stefano Iuliano, Maria Mirabelli, Stefania Giuliano, Antonio Brunetti
Current Opinion in Oncology.2025;[Epub] CrossRef

Diagnostic challenges in the assessment of thyroid neoplasms using nuclear features and vascular and capsular invasion: a multi-center interobserver agreement study: Agnes Stephanie Harahap, Mutiah Mutmainnah, Maria Francisca Ham, Dina Khoirunnisa, Abdillah Hasbi Assadyk, Husni Cangara, Aswiyanti Asri, Diah Prabawati Retnani, Fairuz Quzwain, Hasrayati Agustina, Hermawan Istiadi, Indri Windarti, Krisna Murti, Muhammad Takbir, Ni Made Mahastuti, Nila Kurniasari, Nungki Anggorowati, Pamela Abineno, Yulita Pundewi Setyorini, Kennichi Kakudo; J Pathol Transl Med. 2024;58(6):299-309. Published online September 12, 2024; DOI: https://doi.org/10.4132/jptm.2024.07.25; Correction in: J Pathol Transl Med 2025;59(3):201

5,030 View
407 Download
1 Web of Science
1 Crossref

Abstract PDF Supplementary Material

Background
The diagnosis of thyroid neoplasms necessitates the identification of distinct histological features. Various education/hospital centers located in cities across Indonesia likely result in discordances among pathologists when diagnosing thyroid neoplasms.
Methods
This study examined the concordance among Indonesian pathologists in assessing nuclear features and capsular and vascular invasion of thyroid tumors. Fifteen pathologists from different centers independently assessed the same 14 digital slides of thyroid tumor specimens. All the specimens were thyroid neoplasms with known BRAFV600E and RAS mutational status, from a single center. We evaluated the pre- and post-training agreement using the Fleiss kappa. The significance of the training was evaluated using a paired T-test.
Results
Baseline agreement on nuclear features was slight to fair based on a 3-point scoring system (k = 0.14 to 0.28) and poor to fair based on an eight-point system (k = –0.02 to 0.24). Agreements on vascular (κ = 0.35) and capsular invasion (κ = 0.27) were fair, whereas the estimated molecular type showed substantial agreement (κ = 0.74). Following the training, agreement using the eight-point system significantly improved (p = 0.001).
Conclusions
The level of concordance among Indonesian pathologists in diagnosing thyroid neoplasm was relatively poor. Consensus in pathology assessment requires ongoing collaboration and education to refine diagnostic criteria.

Citations

Citations to this article as recorded by

Nuclear pseudoinclusion is associated with BRAFV600E mutation: Analysis of nuclear features in papillary thyroid carcinoma
Agnes Stephanie Harahap, Dina Khoirunnisa, Salinah, Maria Francisca Ham
Annals of Diagnostic Pathology.2025; 75: 152434. CrossRef

Review

Clinical practice recommendations for the use of next-generation sequencing in patients with solid cancer: a joint report from KSMO and KSP: Miso Kim, Hyo Sup Shim, Sheehyun Kim, In Hee Lee, Jihun Kim, Shinkyo Yoon, Hyung-Don Kim, Inkeun Park, Jae Ho Jeong, Changhoon Yoo, Jaekyung Cheon, In-Ho Kim, Jieun Lee, Sook Hee Hong, Sehhoon Park, Hyun Ae Jung, Jin Won Kim, Han Jo Kim, Yongjun Cha, Sun Min Lim, Han Sang Kim, Choong-Kun Lee, Jee Hung Kim, Sang Hoon Chun, Jina Yun, So Yeon Park, Hye Seung Lee, Yong Mee Cho, Soo Jeong Nam, Kiyong Na, Sun Och Yoon, Ahwon Lee, Kee-Taek Jang, Hongseok Yun, Sungyoung Lee, Jee Hyun Kim, Wan-Seop Kim; J Pathol Transl Med. 2024;58(4):147-164. Published online January 10, 2024; DOI: https://doi.org/10.4132/jptm.2023.11.01

8,535 View
494 Download
1 Web of Science
2 Crossref

Abstract PDF

In recent years, next-generation sequencing (NGS)–based genetic testing has become crucial in cancer care. While its primary objective is to identify actionable genetic alterations to guide treatment decisions, its scope has broadened to encompass aiding in pathological diagnosis and exploring resistance mechanisms. With the ongoing expansion in NGS application and reliance, a compelling necessity arises for expert consensus on its application in solid cancers. To address this demand, the forthcoming recommendations not only provide pragmatic guidance for the clinical use of NGS but also systematically classify actionable genes based on specific cancer types. Additionally, these recommendations will incorporate expert perspectives on crucial biomarkers, ensuring informed decisions regarding circulating tumor DNA panel testing.

Citations

Citations to this article as recorded by

Apport de la génomique dans la prise en charge des cancers
Étienne Rouleau, Lucie Karayan-Tapon, Marie-Dominique Galibert, Alexandre Harlé, Isabelle Soubeyran
Revue Francophone des Laboratoires.2025; 2025(568): 67. CrossRef
The Redox–Adhesion–Exosome (RAX) Hub in Cancer: Lipid Peroxidation-Driven EMT Plasticity and Ferroptosis Defense with HNE/MDA Signaling and Lipidomic Perspectives
Moon Nyeo Park, Jinwon Choi, Rosy Iara Maciel de Azambuja Ribeiro, Domenico V. Delfino, Seong-Gyu Ko, Bonglee Kim
Antioxidants.2025; 14(12): 1474. CrossRef

Original Article

Diagnostic distribution and pitfalls of glandular abnormalities in cervical cytology: a 25-year single-center study: Jung-A Sung, Ilias P. Nikas, Haeryoung Kim, Han Suk Ryu, Cheol Lee; J Pathol Transl Med. 2022;56(6):354-360. Published online November 9, 2022; DOI: https://doi.org/10.4132/jptm.2022.09.05

8,298 View
154 Download
5 Web of Science
3 Crossref

Abstract PDF

Background
Detection of glandular abnormalities in Papanicolaou (Pap) tests is challenging. This study aimed to review our institute’s experience interpreting such abnormalities, assess cytohistologic concordance, and identify cytomorphologic features associated with malignancy in follow-up histology.
Methods
Patients with cytologically-detected glandular lesions identified in our pathology records from 1995 to 2020 were included in this study.
Results
Of the 683,197 Pap tests performed, 985 (0.144%) exhibited glandular abnormalities, 657 of which had tissue follow-up available. One hundred eighty-eight cases were cytologically interpreted as adenocarcinoma and histologically diagnosed as malignant tumors of various origins. There were 213 cases reported as atypical glandular cells (AGC) and nine cases as adenocarcinoma in cytology, yet they were found to be benign in follow-up histology. In addition, 48 cases diagnosed with AGC and six with adenocarcinoma cytology were found to have cervical squamous lesions in follow-up histology, including four squamous cell carcinomas. Among the cytomorphological features examined, nuclear membrane irregularity, three-dimensional clusters, single-cell pattern, and presence of mitoses were associated with malignant histology in follow-up.
Conclusions
This study showed our institute’s experience detecting glandular abnormalities in cervical cytology over a 25-year period, revealing the difficulty of this task. Nonetheless, the present study indicates that several cytological findings such as membrane irregularity, three-dimensional clusters, single-cell pattern, and evidence of proliferation could help distinguishing malignancy from a benign lesion.

Citations

Citations to this article as recorded by

“Atypical Glandular Cells” on Cervical Cytology: Correlation Between Glandular Cell Component Volume and Histological Follow‐Up
Havva Gokce Terzioglu, Alessa Aragao, Julieta E. Barroeta
Diagnostic Cytopathology.2026; 54(2): 71. CrossRef
Expertise in Gynecological Pathology Impacts Diagnosis of Atypical Glandular Cell Category in Cervical Cytology
Havva Gökce Terzioglu, Alessa Aragao, Julieta E. Barroeta
Journal of Lower Genital Tract Disease.2025; 29(4): 297. CrossRef
Analysis of atypical glandular cells in ThinPrep Pap smear and follow-up histopathology
Tengfei Wang, Yinan Hua, Lina Liu, Bing Leng
Baylor University Medical Center Proceedings.2024; 37(3): 403. CrossRef

Review

The application of high-throughput proteomics in cytopathology: Ilias P. Nikas, Han Suk Ryu; J Pathol Transl Med. 2022;56(6):309-318. Published online November 9, 2022; DOI: https://doi.org/10.4132/jptm.2022.08.30

7,189 View
154 Download
2 Web of Science
2 Crossref

Abstract PDF

High-throughput genomics and transcriptomics are often applied in routine pathology practice to facilitate cancer diagnosis, assess prognosis, and predict response to therapy. However, the proteins rather than nucleic acids are the functional molecules defining the cellular phenotype in health and disease, whereas genomic profiling cannot evaluate processes such as the RNA splicing or posttranslational modifications and gene expression does not necessarily correlate with protein expression. Proteomic applications have recently advanced, overcoming the issue of low depth, inconsistency, and suboptimal accuracy, also enabling the use of minimal patient-derived specimens. This review aims to present the recent evidence regarding the use of high-throughput proteomics in both exfoliative and fine-needle aspiration cytology. Most studies used mass spectrometry, as this is associated with high depth, sensitivity, and specificity, and aimed to complement the traditional cytomorphologic diagnosis, in addition to identify novel cancer biomarkers. Examples of diagnostic dilemmas subjected to proteomic analysis included the evaluation of indeterminate thyroid nodules or prediction of lymph node metastasis from thyroid cancer, also the differentiation between benign and malignant serous effusions, pancreatic cancer from autoimmune pancreatitis, non-neoplastic from malignant biliary strictures, and benign from malignant salivary gland tumors. A few cancer biomarkers—related to diverse cancers involving the breast, thyroid, bladder, lung, serous cavities, salivary glands, and bone marrow—were also discovered. Notably, residual liquid-based cytology samples were suitable for satisfactory and reproducible proteomic analysis. Proteomics could become another routine pathology platform in the near future, potentially by using validated multi-omics protocols.

Citations

Citations to this article as recorded by

Mass spectrometry-based proteomics of FFPE tissues: progress, limitations, and clinical translation barriers
Sara Abdulmohsen AlHammadi, Lamar Nabil Nagshabandi, Huzaifa Muhammad, Hatouf H. Sukkarieh, Ahmad Aljada
Clinical Proteomics.2025;[Epub] CrossRef
Identification of NIFTP-Specific mRNA Markers for Reliable Molecular Diagnosis of Thyroid Tumors
So-Yeon Lee, Jong-Lyul Park, Kwangsoon Kim, Ja Seong Bae, Jae-Yoon Kim, Seon-Young Kim, Chan Kwon Jung
Endocrine Pathology.2023; 34(3): 311. CrossRef

Case Studies

Clinically undetected plasmacytoid urothelial carcinoma of the urinary bladder with non-mass-forming metastases in multiple organs: an autopsy case: Yuya Asano, Kosuke Miyai, Shinya Yoshimatsu, Makoto Sasaki, Katsunori Ikewaki, Susumu Matsukuma; J Pathol Transl Med. 2022;56(4):217-224. Published online May 3, 2022; DOI: https://doi.org/10.4132/jptm.2022.03.15

8,502 View
167 Download
3 Web of Science
5 Crossref

Abstract PDF

This case report outlines a clinically undetected urinary bladder plasmacytoid urothelial carcinoma (PUC) with multiple metastases detected at autopsy. An 89-year-old man presented with edema in the lower limbs. Pleural fluid cytology revealed discohesive carcinomatous cells, although imaging studies failed to identify the primary site of tumor. The patient died of respiratory failure. Autopsy disclosed a prostate tumor and diffusely thickened urinary bladder and rectum without distinct tumorous lesions. Histologically, the tumor consisted of acinar-type prostate adenocarcinoma with no signs of metastasis. Additionally, small, plasmacytoid tumor cells were observed in the urinary bladder/rectum as isolated or small clustering fashions. These metastasized to the lungs, intestine, generalized lymph nodes in a non-mass-forming manner. Combined with immunohistochemical studies, these tumor cells were diagnosed PUC derived from the urinary bladder. Both clinicians and pathologists should recognize PUC as an aggressive histological variant, which can represent a rapid systemic progression without mass-forming lesions.

Citations

Citations to this article as recorded by

Severe Rectal Stenosis as the First Clinical Appearance of a Metastasis Originating from the Bladder: A Case Report and Literature Review
Claudiu Daha, Eugen Brătucu, Ioan Burlănescu, Virgiliu-Mihail Prunoiu, Hortensia-Alina Moisă, Ștefania Ariana Neicu, Laurențiu Simion
Life.2025; 15(5): 682. CrossRef
Carcinomatous Meningitis and Hydrocephalus in Plasmacytoid Urothelial Carcinoma of the Urinary Bladder With Extremely Elevated CA19-9 Levels
Fumiaki Henmi, Kayako Ukai, Atsuhito Nakayama, Yutaka Takazawa, Yoshikazu Uesaka
Cureus.2024;[Epub] CrossRef
Current Advances in the Management of Nonurothelial Subtypes of Bladder Cancer
Evangelia Vlachou, Burles Avner Johnson, Ezra Baraban, Rosa Nadal, Jean Hoffman-Censits
American Society of Clinical Oncology Educational Book.2024;[Epub] CrossRef
Plasmacytoid urothelial carcinoma: a multidisciplinary approach to the diagnosis and management
Marcus Zorovich, Jude Khatib, Aysha Mubeen, Katie Gardner, Nayana Patel
Abdominal Radiology.2024;[Epub] CrossRef
Divergent Histology in Bladder Cancer: What We Need to Know?
Shashank Agrawal, Arun Ramdas Menon, Ginil Kumar Pooleri
UroCancer Clinics of India.2024; 2(2): 100. CrossRef

Recurrent malignant solitary fibrous tumor of the scalp: a case report and literature review: Ahmed Rabie, Abdulkarim Hasan, Yasein Mohammed, Ayman Abdelmaksoud, Ali A. Rabaan; J Pathol Transl Med. 2022;56(2):103-108. Published online January 21, 2022; DOI: https://doi.org/10.4132/jptm.2021.10.29

9,260 View
136 Download
4 Web of Science
7 Crossref

Abstract PDF

Solitary fibrous tumor (SFT) is a rare type of mesenchymal neoplasm that first was discovered in the pleura but can also affect the peritoneum, lungs, mediastinum, and skin. Cutaneous malignant SFT is an extremely rare tumor that resembles dermatofibrosacoma protuberance (DFSP) histologically and immunohistochemically. Herein, we describe a case of malignant SFT that presented as a recurrent mass on the scalp. The first lesion was totally excised one year before recurrence and was diagnosed as a DFSP based on the histopathology and cluster of differentiation 34 immunostaining positivity. Re-examination of the previously examined specimen was considered. Activator of transcription 6 positivity was also detected in the tissue, confirming the diagnosis of a recurrent malignant SFT rather than DFSP. There was no evidence of recurrence, locoregional, or distant metastases at six months after lesion removal with a safety margin.

Citations

Citations to this article as recorded by

Malignant solitary fibrous tumor of the temporal bone with NAB2 ex6::STAT6 ex16 fusion: a case report with literature review
Nasser Almadan, Doaa Ali AlGhamdi, Mohammed Tashkandi, Saad Alghamdi, Abdulaziz Alzeer
World Journal of Surgical Oncology.2025;[Epub] CrossRef
Prolonged generalized osteomalacia associated with a sinonasal cavity phosphaturic mesenchymal tumor: A case report
Mehdi Montazer, Naser Tayyebi Meibodi, Elmira Teymouri, Zohreh Mousavi, Sedigheh Reisian, Motahare Ebrahimnejad
Clinical Case Reports.2024;[Epub] CrossRef
Giant Cell Tumor of Soft Tissue on the Forearm Skin: Case Report and Literature Review
Abdulkarim Hasan, Khalid Nafie, Mohamed Adwi, Ayman Abdelmaksoud, Mohammed S. Abdelwahed, Abdulhadi Samman, Mohammad A. Alghamdi, Hasan S. Al-Ghamdi, Hind Ali Hendi, S. K. A. Horsu
Open Access Macedonian Journal of Medical Sciences.2023; 11(C): 71. CrossRef
Primary sclerosing liposarcoma of the ovary: Case report and a review of the literature
Thyagaraja Dhanurjaya, Turnbull Hilary, Jasenka Mazibrada
International Journal of Surgery Case Reports.2023; 109: 108513. CrossRef
Favorable outcome of a histiocytic sarcoma patient treated with immune checkpoint inhibitor: a case report
Long Thanh Nguyen, Giang Hoang Pham, Phuong Thi Vu, Hyeon Gyu Yi
Annals of Medicine & Surgery.2023; 85(12): 6274. CrossRef
Adrenal Solitary Fibrous Tumor: A Case Report
Elena Casademunt-Gras, Isabel Salinas, Pau Moreno Santabarbara, Gustavo Tapia Melendo, Jordi L Reverter
Cureus.2023;[Epub] CrossRef
A Rare Case of Malignant Solitary Fibrous Tumor on the Scalp
Kwang-Ryeol Kim, Ki Hong Kim
Keimyung Medical Journal.2023; 42(2): 107. CrossRef

Original Article

Prediction of TP53 mutations by p53 immunohistochemistry and their prognostic significance in gastric cancer: Hye Jung Hwang, Soo Kyung Nam, Hyunjin Park, Yujun Park, Jiwon Koh, Hee Young Na, Yoonjin Kwak, Woo Ho Kim, Hye Seung Lee; J Pathol Transl Med. 2020;54(5):378-386. Published online July 1, 2020; DOI: https://doi.org/10.4132/jptm.2020.06.01

12,858 View
287 Download
41 Web of Science
37 Crossref

Abstract PDF Supplementary Material

Background
Recently, molecular classifications of gastric cancer (GC) have been proposed that include TP53 mutations and their functional activity. We aimed to demonstrate the correlation between p53 immunohistochemistry (IHC) and TP53 mutations as well as their clinicopathological significance in GC.
Methods
Deep targeted sequencing was performed using surgical or biopsy specimens from 120 patients with GC. IHC for p53 was performed and interpreted as strong, weak, or negative expression. In 18 cases (15.0%) with discrepant TP53 mutation and p53 IHC results, p53 IHC was repeated.
Results
Strong expression of p53 was associated with TP53 missense mutations, negative expression with other types of mutations, and weak expression with wild-type TP53 (p<.001). The sensitivity for each category was 90.9%, 79.0%, and 80.9%, and the specificity was 95.4%, 88.1%, and 92.3%, respectively. The TNM stage at initial diagnosis exhibited a significant correlation with both TP53 mutation type (p=.004) and p53 expression status (p=.029). The Kaplan-Meier survival analysis for 109 stage II and III GC cases showed that patients with TP53 missense mutations had worse overall survival than those in the wild-type and other mutation groups (p=.028). Strong expression of p53 was also associated with worse overall survival in comparison to negative and weak expression (p=.035).
Conclusions
Results of IHC of the p53 protein may be used as a simple surrogate marker of TP53 mutations. However, negative expression of p53 and other types of mutations of TP53 should be carefully interpreted because of its lower sensitivity and different prognostic implications.

Citations

Citations to this article as recorded by

The future is now: advancing p53 immunohistochemistry in Barrett's oesophagus and its implication for the everyday pathologist
Yevgen Chornenkyy, Monika Vyas, Vikram Deshpande
Histopathology.2026; 88(2): 380. CrossRef
Advancement in preclinical development of cancer treatment agents through modulation of Rac1: From EHop-016 to natural products
Yingyi Liu, Sze-Nga Wong, Aiping Lyu, Joshua Ka-Shun Ko
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2026; 1881(1): 189522. CrossRef
Tumor-Associated Macrophage Infiltration and PD-L1 Expression in Gastric Cancer According to a Modified TCGA-Based Classification
Boram Song, Dong-Hoe Koo, Eo Jin Kim, In-Gu Do, Jinah Chu, Kyungeun Kim, Hyebin Lee, Min-Jung Kwon, Jung Ho Park, Byung Ho Son, Chang Hak Yoo, Seoung Wan Chae
Journal of Gastric Cancer.2026;[Epub] CrossRef
Linking p53 immunostaining to TP53 mutation status in patients with non-small cell lung cancer
Taeyeong Kim, Suyeon Kim, Sangjin Lee, Soohyun Hwang, Joungho Han, Hoyeon Jeong, Yoon-La Choi
Pathology.2025; 57(7): 881. CrossRef
Correlation of TP53 Genetic Alterations with p53 Immunohistochemical Expression and Their Prognostic Significance in DLBCL
Chen Chen, Zijuan Hu, Min Ren, Longlong Bao, Ran Wei, Tian Tian, Xiaoli Zhu, Qianming Bai, Baohua Yu, Xiaoqiu Li, Xiaoyan Zhou
Current Oncology.2025; 32(9): 488. CrossRef
Immunophenotypic Panel for Comprehensive Characterization of Aggressive Thyroid Carcinomas
Mihail Ceausu, Mihai Alin Publik, Dana Terzea, Carmen Adina Cristea, Dumitru Ioachim, Dana Manda, Sorina Schipor
Cells.2025; 14(19): 1554. CrossRef
Multiple approaches revealed MGc80‐3 as a somatic hybrid with HeLa cells rather than a gastric cancer cell line
Fang Cao, Hao Sun, Zhenli Yang, Yanhua Bai, Xiao Hu, Yuhong Hou, Xiaocui Bian, Yuqin Liu
International Journal of Cancer.2024; 154(1): 155. CrossRef
In Response to p53 Immunohistochemical Staining and TP53 Gene Mutations in Endometrial Cancer: Does Null Pattern Correlate With Prognosis?
Ikuko Sakamoto, Keiko Kagami, Takahiro Nozaki, Yosuke Hirotsu, Kenji Amemiya, Toshio Oyama, Masao Omata
American Journal of Surgical Pathology.2024; 48(3): 374. CrossRef
CHEK2 germline variants identified in familial nonmedullary thyroid cancer lead to impaired protein structure and function
Carolina Pires, Inês J. Marques, Mariana Valério, Ana Saramago, Paulo E. Santo, Sandra Santos, Margarida Silva, Margarida M. Moura, João Matos, Teresa Pereira, Rafael Cabrera, Diana Lousa, Valeriano Leite, Tiago M. Bandeiras, João B. Vicente, Branca M. Ca
Journal of Biological Chemistry.2024; 300(3): 105767. CrossRef
The spectrum of TP53 mutations in Rwandan patients with gastric cancer
Augustin Nzitakera, Jean Bosco Surwumwe, Ella Larissa Ndoricyimpaye, Schifra Uwamungu, Delphine Uwamariya, Felix Manirakiza, Marie Claire Ndayisaba, Gervais Ntakirutimana, Benoit Seminega, Vincent Dusabejambo, Eric Rutaganda, Placide Kamali, François Ngab
Genes and Environment.2024;[Epub] CrossRef
Gastric cancer molecular classification based on immunohistochemistry and in‐situ hybridisation and mortality
Maarit Eskuri, Eva‐Maria Birkman, Joonas H Kauppila
Histopathology.2024; 85(2): 327. CrossRef
Redefining aberrant P53 expression of gastric cancer and its distinct clinical significance among molecular-histologic subtypes
Shih-Chiang Huang, Ian Yi-Feng Chang, Tse-Ching Chen, Hsiao-Ching Lin, Chun-Yi Tsai, Jun-Te Hsu, Chun-Nan Yeh, Shih-Cheng Chang, Ta-Sen Yeh
Asian Journal of Surgery.2024; 47(11): 4699. CrossRef
Assessment of TP53 and CDKN2A status as predictive markers of malignant transformation of sinonasal inverted papilloma
Soohyeon Kwon, Jeong-Whun Kim, Eun Sun Kim, Jin Ho Paik, Jin-Haeng Chung, Sung-Woo Cho, Tae-Bin Won, Chae-Seo Rhee, Jee Hye Wee, Hyojin Kim
Scientific Reports.2024;[Epub] CrossRef
Implementing an integrated molecular classification for gastric cancer from endoscopic biopsies using on-slide tests
Simona Costache, Adelina Baltan , Sofia Diaz McLinn , Mattia Pegoraro , Rebecca de Havilland , Matthew Porter , Ana Lerga , Teresa Thomas , Alina Elena Chefani
Romanian Journal of Morphology and Embryology.2024; 65(2): 257. CrossRef
Application of NGS molecular classification in the diagnosis of endometrial carcinoma: A supplement to traditional pathological diagnosis
Qunxian Rao, Jianwei Liao, Yangyang Li, Xin Zhang, Guocai Xu, Changbin Zhu, Shengya Tian, Qiuhong Chen, Hui Zhou, Bingzhong Zhang
Cancer Medicine.2023; 12(5): 5409. CrossRef
Predictive value of p53 and AXL immunostaining for the efficacy of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with epidermal growth factor-mutant non-small cell lung cancer
Kenji Morimoto, Tadaaki Yamada, Ryo Sawada, Koichi Azuma, Yasuhiro Goto, Taishi Harada, Shinsuke Shiotsu, Nobuyo Tamiya, Yusuke Chihara, Takayuki Takeda, Osamu Hiranuma, Isao Hasegawa, Satomi Tanaka, Akihiro Yoshimura, Masahiro Iwasaku, Shinsaku Tokuda, Y
Cancer Immunology, Immunotherapy.2023; 72(6): 1699. CrossRef
Validation of p53 Immunohistochemistry (PAb240 Clone) in Canine Tumors with Next-Generation Sequencing (NGS) Analysis
Barbara Brunetti, Dario de Biase, Giulia Dellapina, Luisa Vera Muscatello, Francesco Ingravalle, Giorgia Tura, Barbara Bacci
Animals.2023; 13(5): 899. CrossRef
Mesonephric‐like adenocarcinoma of the female genital tract: novel observations and detailed molecular characterisation of mixed tumours and mesonephric‐like carcinosarcomas
Jelena Mirkovic, Ekaterina Olkhov‐Mitsel, Yutaka Amemiya, Maysa Al‐Hussaini, Sharon Nofech‐Mozes, Bojana Djordjevic, Rachel Kupets, Arun Seth, W Glenn McCluggage
Histopathology.2023; 82(7): 978. CrossRef
Clinicopathologic characterization of cervical metastasis from an unknown primary tumor: a multicenter study in Korea
Miseon Lee, Uiree Jo, Joon Seon Song, Youn Soo Lee, Chang Gok Woo, Dong-Hoon Kim, Jung Yeon Kim, Sun Och Yoon, Kyung-Ja Cho
Journal of Pathology and Translational Medicine.2023; 57(3): 166. CrossRef
P53 in Penile Squamous Cell Carcinoma: A Pattern-Based Immunohistochemical Framework with Molecular Correlation
Isabel Trias, Adela Saco, Lorena Marimon, Ricardo López del Campo, Carolina Manzotti, Oriol Ordi, Marta del Pino, Francisco M. Pérez, Naiara Vega, Silvia Alós, Antonio Martínez, Leonardo Rodriguez-Carunchio, Oscar Reig, Pedro Jares, Cristina Teixido, Tare
Cancers.2023; 15(10): 2719. CrossRef
p53/TP53 Status Assessment in Gastroesophageal Adenocarcinoma
Elisa Boldrin, Maria Assunta Piano, Francesco Bernaudo, Rita Alfieri, Maria Raffaella Biasin, Isabella Monia Montagner, Alice Volpato, Genny Mattara, Francesco Lamacchia, Giovanna Magni, Antonio Rosato, Antonio Scapinello, Pierluigi Pilati, Matteo Curtare
Cancers.2023; 15(10): 2783. CrossRef
Genomic profiling of dedifferentiated endometrial carcinomas arising in the background of high‐grade carcinoma: a targeted next‐generation sequencing study
Ekaterina Olkhov‐Mitsel, Aurelia Busca, Carlos Parra‐Herran, Yutaka Amemiya, Sharon Nofech‐Mozes, Bojana Djordjevic, Marisa R Nucci, Arun Seth, Jelena Mirkovic
Histopathology.2023; 83(3): 366. CrossRef
Clinicopathologic Features and Prognostic Significance of Immunohistochemistry and In Situ Hybridization Based Molecular Classification in Gastric Carcinoma
Gizem Issin, İlyas Sayar, Fatih Demir, İrem Güvendir Bakkaloğlu, Mehmet Gamsizkan, Zeliha Yildiz, Ismail Yilmaz, Sevilay Akalp Özmen, Diren Vuslat Çağatay, Itır Ebru Zemheri, Murat Demiriz, Armağan Günal
Journal of Environmental Pathology, Toxicology and Oncology.2023; 42(4): 1. CrossRef
Clinicopathologic and Molecular Characterization of Anorectal Neuroendocrine Carcinomas Reveals Human Papillomavirus, p53, and c-Myc as Alternative Mechanisms of Carcinogenesis
Allison J. Cox, William E. Crowe, Qi Yang, Bin Zhang, Zoltán N. Oltvai, Xiaoyan Liao
Modern Pathology.2023; 36(11): 100295. CrossRef
Dedifferentiated Endometrial Carcinoma: A Rare Aggressive Neoplasm-Clinical, Morphological and Immunohistochemical Features
Giovanna Giordano, Elena Ferioli, Debora Guareschi, Alessandro Tafuni
Cancers.2023; 15(21): 5155. CrossRef
Characterization on the oncogenic effect of the missense mutations of p53 via machine learning
Qisheng Pan, Stephanie Portelli, Thanh Binh Nguyen, David B Ascher
Briefings in Bioinformatics.2023;[Epub] CrossRef
Adrenal Nodules Detected at Staging CT in Patients with Resectable Gastric Cancers Have a Low Incidence of Malignancy
Hae Young Kim, Won Chang, Yoon Jin Lee, Ji Hoon Park, Jungheum Cho, Hee Young Na, Hyungwoo Ahn, Sung Il Hwang, Hak Jong Lee, Young Hoon Kim, Kyoung Ho Lee
Radiology.2022; 302(1): 129. CrossRef
Intestinal-type gastric dysplasia in Helicobacter pylori-naïve patients
Kotaro Shibagaki, Ayako Itawaki, Yoichi Miyaoka, Kenichi Kishimoto, Yusuke Takahashi, Satoshi Kotani, Tsuyoshi Mishiro, Naoki Oshima, Kousaku Kawashima, Norihisa Ishimura, Hideyuki Onuma, Makoto Nagasaki, Mamiko Nagase, Asuka Araki, Kyuichi Kadota, Ryoji
Virchows Archiv.2022; 480(4): 783. CrossRef
Dedifferentiation-like tubular and solid carcinoma of the stomach shows phenotypic divergence and association with deficient SWI/SNF complex
Shih-Chiang Huang, Kuang-Hua Chen, Kwai-Fong Ng, I-Chieh Lin, Yi-Chun Chao, Ta-Sen Yeh, Huei-Chieh Chuang, Tse-Ching Chen
Virchows Archiv.2022; 480(4): 771. CrossRef
Distinct molecular phenotype and the potential prognostic value of immune prognostic index and tumor infiltrating lymphocytes in hepatoid adenocarcinoma of stomach
Muxing Kang, Xiaojing Ma, Jifei Shi, Guofeng Chen, Xiaoli Jin, Jun Wang, Lele Lin, Zhiwei Wu, Kaibo Chen, Jinghong Xu, Pintong Huang, Jian Chen
Translational Oncology.2022; 19: 101380. CrossRef
Evaluation of Tumor DNA Sequencing Results in Patients with Gastric and Gastroesophageal Junction Adenocarcinoma Stratified by TP53 Mutation Status
Anthony C Wood, Yonghong Zhang, Qianxing Mo, Ling Cen, Jacques Fontaine, Sarah E Hoffe, Jessica Frakes, Sean P Dineen, Jose M Pimiento, Christine M Walko, Rutika Mehta
The Oncologist.2022; 27(4): 307. CrossRef
Comprehensive Clinical Analysis of Gallbladder Neuroendocrine Neoplasms: A Large-Volume Multicenter Study During One Decade
Yangyang Wang, Bingfeng Huang, Qihan Fu, Jianing Wang, Mao Ye, Manyi Hu, Kai Qu, Kai Liu, Xiao Hu, Shumei Wei, Ke Sun, Wenbo Xiao, Bo Zhang, Haijun Li, Jingsong Li, Qi Zhang, Tingbo Liang
Annals of Surgical Oncology.2022; 29(12): 7619. CrossRef
Expression of SASP, DNA Damage Response, and Cell Proliferation Factors in Early Gastric Neoplastic Lesions: Correlations and Clinical Significance
Li Liang, Yijie Chai, Fei Chai, Haijing Liu, Ningning Ma, Hong Zhang, Shuang Zhang, Lin Nong, Ting Li, Bo Zhang
Pathology and Oncology Research.2022;[Epub] CrossRef
Systems biology and OMIC data integration to understand gastrointestinal cancers
Iasmin Moreira Costa Bispo, Henry Paul Granger, Palloma Porto Almeida, Patricia Belini Nishiyama, Leandro Martins de Freitas
World Journal of Clinical Oncology.2022; 13(10): 762. CrossRef
MicroRNA-552 expression in colorectal cancer and its clinicopathological significance
Joon Im, Soo Kyung Nam, Hye Seung Lee
Journal of Pathology and Translational Medicine.2021; 55(2): 125. CrossRef
Different effects of p53 protein overexpression on the survival of gastric cancer patients according to Lauren histologic classification: a retrospective study
Ki Wook Kim, Nayoung Kim, Yonghoon Choi, Won Seok Kim, Hyuk Yoon, Cheol Min Shin, Young Soo Park, Dong Ho Lee, Young Suk Park, Sang-Hoon Ahn, Do Joong Park, Hyung-Ho Kim, Hye Seung Lee, Ji-Won Kim, Jin Won Kim, Keun-Wook Lee, Won Chang, Ji Hoon Park, Yoon
Gastric Cancer.2021; 24(4): 844. CrossRef
The association between the expression of nuclear Yes-associated protein 1 (YAP1) and p53 protein expression profile in breast cancer patients
Yoon Jin Cha, Dooreh Kim, Soong June Bae, Sung Gwe Ahn, Joon Jeong, Min Kyung Cho, Pill Sun Paik, Tae-Kyung Yoo, Woo-Chan Park, Chang Ik Yoon, Elda Tagliabue
PLOS ONE.2021; 16(5): e0250986. CrossRef

Review

Current status and future perspectives of liquid biopsy in non-small cell lung cancer: Sunhee Chang, Jae Young Hur, Yoon-La Choi, Chang Hun Lee, Wan Seop Kim; J Pathol Transl Med. 2020;54(3):204-212. Published online April 15, 2020; DOI: https://doi.org/10.4132/jptm.2020.02.27

11,351 View
296 Download
20 Web of Science
19 Crossref

Abstract PDF

With advances in target therapy, molecular analysis of tumors is routinely required for treatment decisions in patients with advanced non-small cell lung cancer (NSCLC). Liquid biopsy refers to the sampling and analysis of circulating cell-free tumor DNA (ctDNA) in various body fluids, primarily blood. Because the technique is minimally invasive, liquid biopsies are the future in cancer management. Epidermal growth factor receptor (EGFR) ctDNA tests have been performed in routine clinical practice in advanced NSCLC patients to guide tyrosine kinase inhibitor treatment. In the near future, liquid biopsy will be a crucial prognostic, predictive, and diagnostic method in NSCLC. Here we present the current status and future perspectives of liquid biopsy in NSCLC.

Citations

Citations to this article as recorded by

Comparison of tissue-based and plasma-based testing for EGFR mutation in non–small cell lung cancer patients
Yoon Kyung Kang, Dong Hoon Shin, Joon Young Park, Chung Su Hwang, Hyun Jung Lee, Jung Hee Lee, Jee Yeon Kim, JooYoung Na
Journal of Pathology and Translational Medicine.2025; 59(1): 60. CrossRef
Lab-in-a-Fiber detection and capture of cells
João C. Varela, Achar V. Harish, Pawel Maniewski, Timothy Gibbon, Oana Tudoran, Rainer Heuchel, Matthias Löhr, Walter Margulis, Aman Russom, Fredrik Laurell
Scientific Reports.2025;[Epub] CrossRef
Lung Cancer Diagnosis and Prognostic Monitoring Through Cell-Free RNA via Liquid Biopsy
Yuanming Pan, Chongbo Jiang, Mengchan Ye, Dongmei Li, Jinghui Wang
Therapeutics and Clinical Risk Management.2025; Volume 21: 1615. CrossRef
Unlocking the future of cancer diagnosis – promises and challenges of ctDNA-based liquid biopsies in non-small cell lung cancer
Chiara Reina, Berina Šabanović, Chiara Lazzari, Vanesa Gregorc, Christopher Heeschen
Translational Research.2024; 272: 41. CrossRef
Tailored point-of-care biosensors for liquid biopsy in the field of oncology
Sima Singh, Pritam Saha Podder, Matt Russo, Charles Henry, Stefano Cinti
Lab on a Chip.2023; 23(1): 44. CrossRef
Emerging role of non-invasive and liquid biopsy biomarkers in pancreatic cancer
Akash Bararia, Prosenjeet Chakraborty, Paromita Roy, Bitan Kumar Chattopadhay, Amlan Das, Aniruddha Chatterjee, Nilabja Sikdar
World Journal of Gastroenterology.2023; 29(15): 2241. CrossRef
Liquid biopsy in the management of advanced lung cancer: Implementation and practical aspects
Gabriela Fernandes, Ana Rodrigues, Cláudia Matos, Fernando Barata, Luís Cirnes, Lurdes Ferreira, José Albino Lopes, Margarida Felizardo, Paula Fidalgo, Ulisses Brito, Bárbara Parente
Cancer Treatment and Research Communications.2023; 36: 100725. CrossRef
Tweezer PCR: A Highly Specific Method for Accurate Identification of Low-Abundance Mutations
Shanglin Li, Yin Gu, Zhi Geng, Kaiyi Li, Yawei Hu, Qiang Liu, Rongxin Fu, Peng Liu
Analytical Chemistry.2023; 95(48): 17679. CrossRef
Mesonephric-like Adenocarcinoma of the Ovary: Clinicopathological and Molecular Characteristics
Hyun Hee Koh, Eunhyang Park, Hyun-Soo Kim
Diagnostics.2022; 12(2): 326. CrossRef
Alveolar Soft Part Sarcoma of the Uterus: Clinicopathological and Molecular Characteristics
Yurimi Lee, Kiyong Na, Ha Young Woo, Hyun-Soo Kim
Diagnostics.2022; 12(5): 1102. CrossRef
Exosomal MicroRNA Analyses in Esophageal Squamous Cell Carcinoma Cell Lines
Sora Kim, Gwang Ha Kim, Su Jin Park, Chae Hwa Kwon, Hoseok I, Moon Won Lee, Bong Eun Lee
Journal of Clinical Medicine.2022; 11(15): 4426. CrossRef
Molecular biomarker testing for non–small cell lung cancer: consensus statement of the Korean Cardiopulmonary Pathology Study Group
Sunhee Chang, Hyo Sup Shim, Tae Jung Kim, Yoon-La Choi, Wan Seop Kim, Dong Hoon Shin, Lucia Kim, Heae Surng Park, Geon Kook Lee, Chang Hun Lee
Journal of Pathology and Translational Medicine.2021; 55(3): 181. CrossRef
Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer
Pamela Abdayem, David Planchard
European Respiratory Review.2021; 30(161): 200294. CrossRef
Dynamics of Specific cfDNA Fragments in the Plasma of Full Marathon Participants
Takehito Sugasawa, Shin-ichiro Fujita, Tomoaki Kuji, Noriyo Ishibashi, Kenshirou Tamai, Yasushi Kawakami, Kazuhiro Takekoshi
Genes.2021; 12(5): 676. CrossRef
Future Perspectives in Detecting EGFR and ALK Gene Alterations in Liquid Biopsies of Patients with NSCLC
Daniela Ferreira, Juliana Miranda, Paula Martins-Lopes, Filomena Adega, Raquel Chaves
International Journal of Molecular Sciences.2021; 22(8): 3815. CrossRef
Real-World Analysis of the EGFR Mutation Test in Tissue and Plasma Samples from Non-Small Cell Lung Cancer
Hyunwoo Lee, Joungho Han, Yoon-La Choi
Diagnostics.2021; 11(9): 1695. CrossRef
Objective Quantitation of EGFR Protein Levels using Quantitative Dot Blot Method for the Prognosis of Gastric Cancer Patients
Lei Xin, Fangrong Tang, Bo Song, Maozhou Yang, Jiandi Zhang
Journal of Gastric Cancer.2021; 21(4): 335. CrossRef
The Role of the Liquid Biopsy in Decision-Making for Patients with Non-Small Cell Lung Cancer
D. Akhoundova, J. Mosquera Martinez, L. E. Musmann, C. Britschgi, C. Rütsche, M. Rechsteiner, E. Nadal, M. R. Garcia Campelo, A. Curioni-Fontecedro
Journal of Clinical Medicine.2020; 9(11): 3674. CrossRef
Expanding opportunities in precision oncology
T Raja
Cancer Research, Statistics, and Treatment.2020; 3(4): 863. CrossRef

Original Article

Comparison of papanicolaou smear and human papillomavirus (HPV) test as cervical screening tools: can we rely on HPV test alone as a screening method? An 11-year retrospective experience at a single institution: Myunghee Kang, Seung Yeon Ha, Hyun Yee Cho, Dong Hae Chung, Na Rae Kim, Jungsuk An, Sangho Lee, Jae Yeon Seok, Juhyeon Jeong; J Pathol Transl Med. 2020;54(1):112-118. Published online January 15, 2020; DOI: https://doi.org/10.4132/jptm.2019.11.29

14,110 View
266 Download
20 Web of Science
23 Crossref

Abstract PDF

Background
The decrease in incidence of cervical dysplasia and carcinoma has not been as dramatic as expected with the development of improved research tools and test methods. The human papillomavirus (HPV) test alone has been suggested for screening in some countries. The National Cancer Screening Project in Korea has applied Papanicolaou smears (Pap smears) as the screening method for cervical dysplasia and carcinoma. We evaluated the value of Pap smear and HPV testing as diagnostic screening tools in a single institution.
Methods
Patients co-tested with HPV test and Pap smear simultaneously or within one month of each other were included in this study. Patients with only punch biopsy results were excluded because of sampling errors. A total of 999 cases were included, and the collected reports encompassed results of smear cytology, HPV subtypes, and histologic examinations.
Results
Sensitivity and specificity of detecting high-grade squamous intraepithelial lesion (HSIL) and squamous cell carcinoma (SCC) were higher for Pap smears than for HPV tests (sensitivity, 97.14%; specificity, 85.58% for Pap smears; sensitivity, 88.32%; specificity, 54.92% for HPV tests). HPV tests and Pap smears did not differ greatly in detection of low-grade squamous intraepithelial lesion (85.35% for HPV test, 80.31% for Pap smears). When atypical glandular cells were noted on Pap smears, the likelihood for histologic diagnosis of adenocarcinoma following Pap smear was higher than that of high-risk HPV test results (18.8 and 1.53, respectively).
Conclusions
Pap smears were more useful than HPV tests in the diagnosis of HSIL, SCC, and glandular lesions.

Citations

Citations to this article as recorded by

Development of a Nano-Real-Time Polymerase Chain Reaction (RT-PCR) Kit for Detection and Genotyping of High-Risk Human Papillomavirus (HPV) Strains Using Dedicated TaqMan Probes
Mohammad Panji, Mohammad Hossein Modarresi, Zahra Azizi, Moloud Absalan, Elahe Motevaseli
Cureus.2026;[Epub] CrossRef
Detection of cervical precancerous lesions and cancer by small-scale RT-qPCR analysis of oppositely deregulated mRNAs pairs in cytological smears
Anastasia A. Artyukh, Mikhail K. Ivanov, Sergei E. Titov, Victoria V. Dzyubenko, Sergey E. Krasilnikov, Anastasia O. Shumeikina, Nikita A. Afanasev, Anastasia V. Malek, Sergei A. Glushkov, Eduard F. Agletdinov
Frontiers in Oncology.2025;[Epub] CrossRef
High burden of abnormal cervical smears in South African primary health care: health programmes implications
Olufemi B Omole, Joel M Francis, John M Musonda, Pumla P Sodo, Elizabeth Reji, Nyundu S J Phukuta, Honey L M Mabuza, Joyce S Musonda, Jimmy Akii, John V Ndimande, Olalekan A Ayo-Yusuf
Health Promotion International.2025;[Epub] CrossRef
Bibliometric analysis: a study of the microenvironment in cervical cancer (2000-2024)
Yun-Tao Zhang, Yan-Ni Wei, Chen-Chen Liu, Mai-Qing Yang
Frontiers in Oncology.2025;[Epub] CrossRef
Liquid biopsy biomarkers in cervical cancer: A systematic review and meta-analysis
Isaac Kinyua Njangiru, Bizhar Ahmed Tayeb, Hazhmat Ali, Rafl M. Kamil
The Journal of Liquid Biopsy.2025; 10: 100328. CrossRef
Diagnostic Utility of Human Papilloma Virus Testing in Comparison with Pap Cytology and Histopathology in Unvaccinated Women with Cervical High-Grade Dysplasia and Carcinoma in Botswana
Patricia Setsile Rantshabeng, Nametso Dire, Andrew Khulekani Ndlovu, Ishmael Kasvosve
Venereology.2025; 4(4): 15. CrossRef
Challenges in the diagmosis of cervical pathologies
D. Y. Chernov, O. A. Tikhonovskaya, S. V. Logvinov, I. A. Petrov, Y. S. Yuriev, A. A. Zhdankina, A. V. Gerasimov, I. V. Zingalyuk, G. A. Mikheenko
Bulletin of Siberian Medicine.2024; 22(4): 201. CrossRef
“Barriers and Advantages of Self-Sampling Tests, for HPV Diagnosis: A Qualitative Field Experience Before Implementation in a Rural Community in Ecuador”
Bernardo Vega-Crespo, Vivian Alejandra Neira, Ruth Maldonado - Rengel, Diana López, Dayanara Delgado-López, Gabriela Guerra Astudillo, Veronique Verhoeven
International Journal of Women's Health.2024; Volume 16: 947. CrossRef
Cervical Human Papillomavirus Testing
Carol N. Rizkalla, Eric C. Huang
Surgical Pathology Clinics.2024; 17(3): 431. CrossRef
Segmentation of Overlapping Cells in Cervical Cytology Images: A Survey
E Chen, Hua-Nong Ting, Joon Huang Chuah, Jun Zhao
IEEE Access.2024; 12: 114170. CrossRef
Knowledge and awareness regarding pap test and HPV typing for cervical cancer screening in Edo North, Nigeria
Amina Momodu, Johnsolomon Eghosa Ohenhen, Godfrey Innocent Iyare, Musa Abidemi Muhibi, Godwin Avwioro
Discover Public Health.2024;[Epub] CrossRef
Colposcopy Value in Young Child-bearing Women: Is New Recommendations Necessary?
Fahimeh Sabet, Avishan Aminizad, Fariba Behnamfar, Tajossadat Allameh, Seyedeh Ghazal Shahrokh, Rostami Koushan, Amirmohammad Taravati, Leila Mousavi Seresht
Advanced Biomedical Research.2024;[Epub] CrossRef
Selection of endogenous control and identification of significant microRNA deregulations in cervical cancer
T. Stverakova, I. Baranova, P. Mikyskova, B. Gajdosova, H. Vosmikova, J. Laco, V. Palicka, H. Parova
Frontiers in Oncology.2023;[Epub] CrossRef
Cytology Versus Molecular Diagnosis of HPV for Cervical Cancer Screening. Comparison of the Diagnostic Properties of Four Tests in a Rural Community of Cuenca Ecuador
Bernardo Vega Crespo, Vivian Alejandra Neira, Rocío Murillo, Cristina Ochoa Avilés
ESPOCH Congresses: The Ecuadorian Journal of S.T.E.A.M..2023; 3(1): 139. CrossRef
Attitudes towards prevention of cervical cancer and early diagnosis among female academicians
Nurhan Doğan, Gamze Fışkın
Journal of Obstetrics and Gynaecology Research.2022; 48(6): 1433. CrossRef
Role of Self-Sampling for Cervical Cancer Screening: Diagnostic Test Properties of Three Tests for the Diagnosis of HPV in Rural Communities of Cuenca, Ecuador
Bernardo Vega Crespo, Vivian Alejandra Neira, José Ortíz Segarra, Ruth Maldonado Rengel, Diana López, María Paz Orellana, Andrea Gómez, María José Vicuña, Jorge Mejía, Ina Benoy, Tesifón Parrón Carreño, Veronique Verhoeven
International Journal of Environmental Research and Public Health.2022; 19(8): 4619. CrossRef
Utility of Scoring System for Screening and Early Warning of Cervical Cancer Based on Big Data Analysis
Dan Hou, Binjie Yang, Yangdan Li, Ming Sun
Frontiers in Public Health.2022;[Epub] CrossRef
Evaluation of Urine and Vaginal Self-Sampling versus Clinician-Based Sampling for Cervical Cancer Screening: A Field Comparison of the Acceptability of Three Sampling Tests in a Rural Community of Cuenca, Ecuador
Bernardo Vega Crespo, Vivian Alejandra Neira, José Ortíz S, Ruth Maldonado-Rengel, Diana López, Andrea Gómez, María José Vicuña, Jorge Mejía, Ina Benoy, Tesifón Parrón Carreño, Veronique Verhoeven
Healthcare.2022; 10(9): 1614. CrossRef
Diagnostic distribution and pitfalls of glandular abnormalities in cervical cytology: a 25-year single-center study
Jung-A Sung, Ilias P. Nikas, Haeryoung Kim, Han Suk Ryu, Cheol Lee
Journal of Pathology and Translational Medicine.2022; 56(6): 354. CrossRef
Primary screening of cervical cancer by Pap smear in women of reproductive age group
Ruchi Mishra, Dakshina Bisht, Manisha Gupta
Journal of Family Medicine and Primary Care.2022; 11(9): 5327. CrossRef
Comparison of Learning Transfer Using Simulation Problem-Based Learning and Demonstration: An Application of Papanicolaou Smear Nursing Education
Jeongim Lee, Hae Kyoung Son
International Journal of Environmental Research and Public Health.2021; 18(4): 1765. CrossRef
Investigating host-virus interaction mechanism and phylogenetic analysis of viral proteins involved in the pathogenesis
Ahmad Abu Turab Naqvi, Farah Anjum, Alaa Shafie, Sufian Badar, Abdelbaset Mohamed Elasbali, Dharmendra Kumar Yadav, Md. Imtaiyaz Hassan, Timir Tripathi
PLOS ONE.2021; 16(12): e0261497. CrossRef
Utility of Human Papillomavirus Testing for Cervical Cancer Screening in Korea
Mee-seon Kim, Eun Hee Lee, Moon-il Park, Jae Seok Lee, Kisu Kim, Mee Sook Roh, Hyoun Wook Lee
International Journal of Environmental Research and Public Health.2020; 17(5): 1726. CrossRef

Review

HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation: Soomin Ahn, Ji Won Woo, Kyoungyul Lee, So Yeon Park; J Pathol Transl Med. 2020;54(1):34-44. Published online November 6, 2019; DOI: https://doi.org/10.4132/jptm.2019.11.03

38,080 View
1,323 Download
189 Web of Science
187 Crossref

Abstract PDF

Human epidermal growth factor receptor 2 (HER2) protein overexpression and/or HER2 gene amplification is found in about 20% of invasive breast cancers. It is a sole predictive marker for treatment benefits from HER2 targeted therapy and thus, HER2 testing is a routine practice for newly diagnosed breast cancer in pathology. Currently, HER2 immunohistochemistry (IHC) is used for a screening test, and in situ hybridization is used as a confirmation test for HER2 IHC equivocal cases. Since the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines on HER2 testing was first released in 2007, it has been updated to provide clear instructions for HER2 testing and accurate determination of HER2 status in breast cancer. During HER2 interpretation, some pitfalls such as intratumoral HER2 heterogeneity and increase in chromosome enumeration probe 17 signals may lead to inaccurate assessment of HER2 status. Moreover, HER2 status can be altered after neoadjuvant chemotherapy or during metastatic progression, due to biologic or methodologic issues. This review addresses recent updates of ASCO/CAP guidelines and factors complicating in the interpretation of HER2 status in breast cancers.

Citations

Citations to this article as recorded by

A Comprehensive Model Outperformed the Single Radiomics Model in Noninvasively Predicting the HER2 Status in Patients with Breast Cancer
Weimin Liu, Yiqing Yang, Xiaohong Wang, Chao Li, Chen Liu, Xiaolei Li, Junzhe Wen, Xue Lin, Jie Qin
Academic Radiology.2025; 32(1): 24. CrossRef
Multiparametric MRI Radiomics With Machine Learning for Differentiating HER2-Zero, -Low, and -Positive Breast Cancer: Model Development, Testing, and Interpretability Analysis
Yongxin Chen, Siyi Chen, Wenjie Tang, Qingcong Kong, Zhidan Zhong, Xiaomeng Yu, Yi Sui, Wenke Hu, Xinqing Jiang, Yuan Guo
American Journal of Roentgenology.2025;[Epub] CrossRef
Cervical Lymph Node Metastasis of Unknown Origin and Remote Primary at a Tertiary Cancer Centre in North India: Case Series with Review of Literature
Kriti Grover, Siddharth Arora, Mansi Dey, Deepti Awasthi, Harshad Sharma, Bibhu Prasad Mishra, Nitesh Mohan, Cheena Garg, Arjun Agarwal
Indian Journal of Otolaryngology and Head & Neck Surgery.2025; 77(1): 424. CrossRef
Pooled clinical trial analyses evaluating outcomes of HER2-low vs HER2-0 expression in patients with metastatic breast cancer following chemotherapy
Elizabeth B. Lamont, Emily Stein, Paolo Tarantino, Sara M. Tolaney, Corinne Ahlberg, Krishna Chinnathambu, Jiezhi Qi, Jackie Bilan, Ruthie Davi, Lisa Ensign
Breast Cancer Research and Treatment.2025; 210(1): 11. CrossRef
Insights into AI advances in immunohistochemistry for effective breast cancer treatment: a literature review of ER, PR, and HER2 scoring
Genevieve Chyrmang, Kangkana Bora, Anup Kr. Das, Gazi N. Ahmed, Lopamudra Kakoti
Current Medical Research and Opinion.2025; 41(1): 115. CrossRef
Prediction of Lung Adenocarcinoma Driver Genes Through Protein–Protein Interaction Networks Utilizing GenePlexus
Fei Yuan, Yu‐Hang Zhang, FeiMing Huang, Xiaoyu Cao, Lei Chen, JiaBo Li, WenFeng Shen, KaiYan Feng, YuSheng Bao, Tao Huang, Yu‐Dong Cai
PROTEOMICS.2025;[Epub] CrossRef
Quantitative expression of estrogen, progesterone and human epidermal growth factor receptor-2 and their correlation with immunohistochemistry in breast cancer at Uganda Cancer Institute
Henry Wannume, Nixon Niyonzima, Sam Kalungi, Julius Boniface Okuni, Tonny Okecha, Edward Kakungulu, Steven Mpungu Kiwuwa, Geoffrey Waiswa, Sylvester Kadhumbula, Monica Namayanja, Martin Nabwana, Jackson Orem, Kenji Fujiwara
PLOS ONE.2025; 20(1): e0311185. CrossRef
Automated Quantification of HER2 Amplification Levels Using Deep Learning
Ching-Wei Wang, Kai-Lin Chu, Ting-Sheng Su, Keng-Wei Liu, Yi-Jia Lin, Tai-Kuang Chao
IEEE Journal of Biomedical and Health Informatics.2025; 29(1): 333. CrossRef
CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial
Kim A. Reiss, Mathew G. Angelos, E. Claire Dees, Yuan Yuan, Naoto T. Ueno, Paula R. Pohlmann, Melissa L. Johnson, Joseph Chao, Olga Shestova, Jonathan S. Serody, Maggie Schmierer, Madison Kremp, Michael Ball, Rehman Qureshi, Benjamin H. Schott, Poonam Son
Nature Medicine.2025; 31(4): 1171. CrossRef
Human Cytomegalovirus Infection and Breast Cancer: A Literature Review of Clinical and Experimental Data
Rancés Blanco, Juan P. Muñoz
Biology.2025; 14(2): 174. CrossRef
An antibody-photosensitiser bioconjugate overcomes trastuzumab resistance in HER2-positive breast cancer
Mireia Jordà-Redondo, Ana Piqueras, Ana Castillo, Pedro Luis Fernández, Roger Bresolí-Obach, Lidia Blay, Joan Francesc Julián Ibáñez, Santi Nonell
European Journal of Medicinal Chemistry.2025; 290: 117511. CrossRef
Dynamic HER2-low status among patients with triple negative breast cancer (TNBC) and the impact of repeat biopsies
Yael Bar, Geoffrey Fell, Aylin Dedeoglu, Natalie Moffett, Neelima Vidula, Laura Spring, Seth A. Wander, Aditya Bardia, Naomi Ko, Beverly Moy, Leif W. Ellisen, Steven J. Isakoff
npj Breast Cancer.2025;[Epub] CrossRef
Clinical significances of RPL15 gene expression in circulating tumor cells of patients with breast cancer
Ying Zhuang, Keli Su, Shushu Liu, Wei Fan, Huijuan Lv, Wei Zhong
Biomedical Reports.2025; 22(5): 1. CrossRef
Advancing Breast Cancer Treatment: The Role of Immunotherapy and Cancer Vaccines in Overcoming Therapeutic Challenges
Marco Palma
Vaccines.2025; 13(4): 344. CrossRef
Complete preclinical evaluation of the novel antibody mimetic Nanofitin-IRDye800CW for diverse non-invasive diagnostic applications in the management of HER-2 positive tumors
Margherita Iaboni, Federico Crivellin, Francesca Arena, Francesca La Cava, Alessia Cordaro, Francesco Stummo, Daniele Faletto, Simon Huet, Leo Candela, Jessy Pedrault, Eugenia R. Zanella, Andrea Bertotti, Francesco Blasi, Alessandro Maiocchi, Luisa Poggi,
Scientific Reports.2025;[Epub] CrossRef
New insights on Galectin-9 expression in cancer prognosis: An updated systemic review and meta-analysis
Chun Yan So, Yusong Li, Kwan Ting Chow, Xiaosheng Tan
PLOS ONE.2025; 20(3): e0320441. CrossRef
Role of artificial intelligence –based machine learning model in predicting HER2/neu gene status in breast cancer
Ghada Mohamed, Omar Hamdy, Anwar Alkallas, Youssef Tahoun, Mohammed Mohammed Gomaa, Inas Moaz, Ahmed Orabi, Yasmine Hany elzohery, AL-Shimaa Zakaria, Mahitab Ibrahim Eltohamy
Pathology - Research and Practice.2025; 270: 155927. CrossRef
HER2 mRNA Score From Quantitative ERBB2 mRNA Expression of Oncotype Dx
Hyunwoo Lee, Jai Min Ryu, Se Kyung Lee, Byung Joo Chae, Jonghan Yu, Jeong Eon Lee, Seok Won Kim, Seok Jin Nam, Yoon Ah Cho, Eun Yoon Cho
American Journal of Surgical Pathology.2025; 49(8): 807. CrossRef
Neratinib and metformin: A novel therapeutic approach against HER2-Positive Breast Cancer
Hadeel Kheraldine, Arij Fouzat Hassan, Sumayyah Saeed, Maysaloun Merhi, Jericha Miles Mateo, Monika Ulamec, Melita Peric-Balja, Semir Vranic, Hamda Al-Thawadi, Ala-Eddin Al Moustafa
Biomedicine & Pharmacotherapy.2025; 187: 118034. CrossRef
Machine learning prediction of HER2-low expression in breast cancers based on hematoxylin–eosin-stained slides
Jun Du, Jun Shi, Dongdong Sun, Yifei Wang, Guanfeng Liu, Jingru Chen, Wei Wang, Wenchao Zhou, Yushan Zheng, Haibo Wu
Breast Cancer Research.2025;[Epub] CrossRef
Predicting sentinel lymph node metastatic burden with intravoxel incoherent motion diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in clinical early-stage breast cancer patients
Mingli Jin, Fang Xiao, Qi Zhao, Ying Jiang, Zhihua Pan, Zhicai Duan, Juxi Jiang, Miaoqi Zhang, Jian Shu
Magnetic Resonance Imaging.2025; 121: 110397. CrossRef
HbA1c levels and breast cancer prognosis in women without diabetes
Jonas Busk Holm, Jens Meldgaard Bruun, Peer Christiansen, Reimar Wernich Thomsen, Jan Frystyk, Deirdre Cronin-Fenton, Signe Borgquist
BMC Cancer.2025;[Epub] CrossRef
Clinical Outcomes in Early-Stage HER2-Low and HER2-Zero Breast Cancer: Single-Center Experience
Jamshid Hamdard, Mehmet Haluk Yücel, Harun Muğlu, Özgür Açıkgöz, Aslı Çakır, Ahmet Bilici, Ömer Fatih Ölmez
Journal of Clinical Medicine.2025; 14(9): 2937. CrossRef
Molecular Mechanism of Breast Cancer and Predisposition of Mouse Mammary Tumor Virus Propagation Cycle
Arya Ghosh, Subash C.B. Gopinath
Current Medicinal Chemistry.2025; 32(12): 2330. CrossRef
ASSESSMENT OF RECEPTOR CONVERSION ROLE FOR ADVANCED BREAST CANCER ON THE CHEMORESISTANCE OCCURRENCE
Oleksii V. Movchan, Ivan I. Smolanka, Andriy O. Lyashenko, Anton D. Loboda, Iryna V. Dosenko, Oksana M. Ivankova
Clinical and Preventive Medicine.2025; (3): 56. CrossRef
Combining conventional magnetic resonance imaging (MRI) parameters with clinicopathologic data for differentiation of the three-tiered human epidermal growth factor receptor 2 (HER2) status in breast cancer
W. Liu, C. Liu, Y. Yang, Y. Chen, A. Muhetaier, Z. Lin, Z. Weng, X. Wang, P. Zhang, J. Qin
Clinical Radiology.2025; 86: 106955. CrossRef
IN SILICO STUDY: THE POTENTIAL OF KILEMO (Litsea cubeba) ENDEMIC PLANT FROM KALIMANTAN AS ANTI-BREAST CANCER THROUGH HER2 INHIBITION
Dwi Utami, Tarisha Elmaningtyas Zahro, Khairun Nisa, Muhammad Farid
JIIS (Jurnal Ilmiah Ibnu Sina): Ilmu Farmasi dan Kesehatan.2025; 10(1): 166. CrossRef
Trastuzumab Deruxtecan in Previously Treated HER2-Low Metastatic Breast Cancer: Real-World Multicentric Study in the Portuguese Population
Luísa Soares Miranda, Maria João Sousa, Miguel Martins Braga, Marisa Couto, Isabel Vieira Fernandes, Francisca Abreu, Inês Eiriz, Catarina Lopes Fernandes, Alice Fonseca Marques, Maria Teresa Marques, Raquel Romão, Fernando Gonçalves, Joana Simões, Antóni
Cancers.2025; 17(12): 1911. CrossRef
Factors influencing pathological complete response to neoadjuvant chemotherapy in resectable breast cancer: A retrospective study
Jian Kang, Huifen Xiong, Xiaoliu Jiang, Zhaohui Huang, Yonghong Guo, Yali Cao, Jingxian Ding
Oncology Letters.2025; 30(1): 1. CrossRef
Association of HER2-low with clinicopathological features in patients with early invasive lobular breast cancer: an international multicentric study
Karen Van Baelen, Ha-Linh Nguyen, François Richard, Gitte Zels, Maria Margarete Karsten, Guilherme Nader-Marta, Peter Vermeulen, Luc Dirix, Adam David Dordevic, Evandro de Azambuja, Denis Larsimont, Marion Maetens, Elia Biganzoli, Hans Wildiers, Ann Smeet
Breast Cancer Research.2025;[Epub] CrossRef
Collagenase type IV improves the quality of HER2 fluorescence in situ hybridization for breast cancers
Shang-En Lee, Sheng-Chi Hsu, Tsai-Hsien Hung, Kwai-Fong Ng, Tse-Ching Chen
American Journal of Clinical Pathology.2025; 164(3): 342. CrossRef
Resonant multi-focal scanning super-resolution microscopy with extended depth and field-of-view
Kidan Tadesse, Keyi Han, Wenhao Liu, Oliver S. Lee, Shu Jia
Cell Reports Physical Science.2025; 6(7): 102680. CrossRef
Scalable Nuclei Detection in HER2-SISH Whole Slide Images via Fine-Tuned Stardist with Expert-Annotated Regions of Interest
Zaka Ur Rehman, Mohammad Faizal Ahmad Fauzi, Wan Siti Halimatul Munirah Wan Ahmad, Fazly Salleh Abas, Phaik-Leng Cheah, Seow-Fan Chiew, Lai-Meng Looi
Diagnostics.2025; 15(13): 1584. CrossRef
Molecular landscape of HER2-mutated non-small cell lung cancer in Northeastern Brazil: Clinical, histopathological, and genomic insights
Cleto Dantas Nogueira, Samuel Frota, Huylmer Lucena Chaves, Juliana Cordeiro de Sousa, Guilherme de Sousa Veloso, Francisco Jonathan dos Santos Araujo, Gabriel Barbosa Silva, Samuel Silva Ferreira, Marclesson Santos Alves, Fabio Nasser, Ezequiel Rangel, F
Oncotarget.2025; 16(1): 467. CrossRef
Correlation between CTMP expression levels and resistance to trastuzumab in HER2 + metastatic breast cancer
Mania Makhoul, Maher Saifo, Fariz Ahmad, Jumana Saleh
Discover Oncology.2025;[Epub] CrossRef
The association between body mass index and neoadjuvant chemotherapy response in patients with breast cancer
Jonas Busk Holm, Stine Blaabjerg Skovbjerg, Hanne Melgaard Nielsen, Peer Christiansen, Jens Meldgaard Bruun, Jan Alsner, Deirdre Cronin-Fenton, Signe Borgquist
Breast Cancer Research.2025;[Epub] CrossRef
An immunohistochemical characterization of basal cell carcinoma in patients below 40 years of age
Vincent Waller, Myriam Boeschen, Thomas Lingscheidt, Mathias Stiller, Lena Eickenscheidt, Thomas Wilhelm, Sonja Grunewald, Mirjana Ziemer, Jan‐Christoph Simon, Hendrik Bläker, Maximilian von Laffert
JDDG: Journal der Deutschen Dermatologischen Gesellschaft.2025; 23(11): 1414. CrossRef
Clinical Relationship Between Serum ApoB, HER2, and Myocardial Ischemia Risk in Breast Cancer Patients
Yeyan Lei, Dongmei Li, Shuang Bai, Xing Zeng, Rongyuan Yang, Qing Liu
Cancer Reports.2025;[Epub] CrossRef
Dual-targeting and steric hindrance resolution in HER2 IHC: a novel approach to improve diagnostic sensitivity
Li Luo, Xi Zhang, Linqiong Chen, Zhuohan Chen, Yuchen Wang, Kaihao Huang, Xiaoyun Lin, Hongxiang Zhu, Wangqi Du
BMC Cancer.2025;[Epub] CrossRef
Time‐Dependent Diffusion MRI‐Based Microstructural Mapping for Characterizing HER2‐Zero, ‐Low, ‐Ultra‐Low, and ‐Positive Breast Cancer
Xiaoxia Wang, Yao Huang, Ying Cao, Huifang Chen, Xueqin Gong, Xiaosong Lan, Jiuquan Zhang, Zhaoxiang Ye
Journal of Magnetic Resonance Imaging.2025; 62(6): 1754. CrossRef
Digital pathology enabling lean management of HER2/neu testing in breast Cancer
Aishwarya Sharma, Prarthna Shah, Manali Ranade, Trupti Pai, Ayushi Sahay, Asawari Patil, Tanuja Shet, Heena Gupta, Devika Chauhan, Puneet Somal, Sankalp Sancheti, Sangeeta Desai
Journal of Pathology Informatics.2025; 19: 100515. CrossRef
Enhancing HER2-low breast cancer detection with quantitative transcriptomics
Maria-Anna Misiakou, Maj-Britt Jensen, Maj-Lis Talman, Bent Ejlertsen, Maria Rossing
npj Breast Cancer.2025;[Epub] CrossRef
Caracterización inmunohistoquímica del cáncer de mama correlacionado con histopatología,estudio realizado en un hospital de Ecuador
María Fernanda Calderón León, Diego Mauricio Cabrera Moyano, Jorge Daniel Cárdenas Rodríguez, Paula Andrea Vásquez Jaramillo, Andrea Alexandra Saltos Román, Maryoli González Sánchez
Journal of the Selva Andina Research Society.2025; 16(2): 116. CrossRef
Relationship of vitamin D receptor expression with hormone receptors and other clinicopathological features in primary breast carcinomas: A retrospective cross-sectional study
Yaşar Ünlü, Ethem Ömeroğlu, Abdülhalim Serden Ay, Meryem İlkay Eren Karanis, Kilinç Ayşe Nur Uğur, Esra Yilmaz
Medicine.2025; 104(35): e44222. CrossRef
Improving HER2 Diagnostics with Digital Real‐Time PCR for Ultrafast, Precise Prediction of Anti‐HER2 Therapy Response in Patients with Breast Cancer
Hee‐Joo Choi, Soo Young Park, Minsik Song, Jinhyuk Chang, YoonSik Kim, Hosub Park, Chihwan David Cha, Sohyeon Yang, Nam Hun Heo, Min Ji Song, Da Sol Kim, Hayeon Kim, Minuk Kim, Jae Eun Park, Yesung Lee, EunChae Ji, Heekyoung Chung, Ilecheon Jeong, Mineui
Small Methods.2025;[Epub] CrossRef
Unveiling Metabolic Signatures as Potential Biomarkers in Common Cancers: Insights from Lung, Breast, Colorectal, Liver, and Gastric Tumours
Kha Wai Hon, Rakesh Naidu
Biomolecules.2025; 15(10): 1376. CrossRef
Validation of ancillary procedures on formalin liquid fixed aspiration cytologic samples: from minimum to maximum
Orsolya Rideg, Tímea Dergez, Arnold Tóth, Tamás Tornóczky, Gábor Pavlovics, Endre Kálmán
American Journal of Clinical Pathology.2025; 164(6): 924. CrossRef
Challenges & recommendations for identification of human epidermal growth factor receptor -2 (HER2)-low metastatic breast cancer in India: Expert opinion statement
Neeraj Arora, Jyoti Bajpai, Amanjit Bal, Atul Batra, Anurag Gupta, Deepak Kumar Mishra, Geetashree Mukherjee, Trupti Pai, Mayur Parihar, Geeta V. Patil Okaly, Shilpa Prabhudesai, Milap Shah, Somashekhar S.P.
The Indian Journal of Medical Research.2025; 162: 279. CrossRef
Eine immunhistologische Charakterisierung des Basalzellkarzinoms bei Patienten unter 40 Jahren
Vincent Waller, Myriam Boeschen, Thomas Lingscheidt, Mathias Stiller, Lena Eickenscheidt, Thomas Wilhelm, Sonja Grunewald, Mirjana Ziemer, Jan‐Christoph Simon, Hendrik Bläker, Maximilian von Laffert
JDDG: Journal der Deutschen Dermatologischen Gesellschaft.2025; 23(11): 1414. CrossRef
Comparison of Immunohistochemical 2 (+) HER2 Gene Status with SISH in Invasive Breast Carcinoma
Alper Sayiner, Hatice Karaman, Fatma Şenel, Arzu Tasdemir, Merve Doğan, İpek Özer
Sakarya Medical Journal.2025; 15(4): 338. CrossRef
Concurrent genomic assessment of circulating tumour cells and ctDNA to guide therapy in metastatic breast cancer
Rebecca C. Allsopp, Karen Page, Evie Wren, Georgios Nteliopoulos, Kelly L. T. Gleason, Gurdeep Matharu Lall, Shradha Bhagani, Emmanuel Acheampong, Marc K. Wadsley, Raoul Charles Coombes, Jacqueline A. Shaw
BMC Cancer.2025;[Epub] CrossRef
Management Strategies and Outcomes in HR+/HER2− Metastatic Breast Cancer Receiving CDK4/6 Inhibitors and Subsequent Therapies
Katarzyna Pogoda, Hubert Pawlik, Anna Balata, Magdalena Czopowicz, Agata Bak, Iwona Twardowska, Malgorzata Meluch, Maria Wojda, Agnieszka Mlodzinska, Ewa Szombara, Renata Sienkiewicz, Aleksandra Konieczna, Elzbieta Brewczynska, Izabela Lemanska, Anna Majs
Breast Cancer: Targets and Therapy.2025; Volume 17: 1307. CrossRef
Identification of novel chemical scaffolds against kinase domain of cancer causing human epidermal growth factor receptor 2: a systemic chemoinformatic approach
Faris Alrumaihi
Journal of Biomolecular Structure and Dynamics.2024; 42(12): 6269. CrossRef
Standardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer
Mariia Ivanova, Francesca Maria Porta, Marianna D’Ercole, Carlo Pescia, Elham Sajjadi, Giulia Cursano, Elisa De Camilli, Oriana Pala, Giovanni Mazzarol, Konstantinos Venetis, Elena Guerini-Rocco, Giuseppe Curigliano, Giuseppe Viale, Nicola Fusco
Virchows Archiv.2024; 484(1): 3. CrossRef
Analytical Performance Evaluation of a 523-Gene Circulating Tumor DNA Assay for Next-Generation Sequencing–Based Comprehensive Tumor Profiling in Liquid Biopsy Samples
Johannes Harter, Eleonora Buth, Janina Johaenning, Florian Battke, Maria Kopp, Henning Zelba, Martin Schulze, Jiri Koedding, Saskia Biskup
The Journal of Molecular Diagnostics.2024; 26(1): 61. CrossRef
Are There More HER2 FISH in the Sea? An Institution’s Experience in Identifying HER2 Positivity Using Fluorescent In Situ Hybridization in Patients with HER2 Negative Immunohistochemistry
Camille Suydam, Fairouz Chibane, Nicole Brown, Madeleine Schlafly, Alicia H. Arnold, Intisar Ghleilib, Melissa Easley, Joseph White
Annals of Surgical Oncology.2024; 31(1): 376. CrossRef
HER2 copy number determination in breast cancer using the highly sensitive droplet digital PCR method
Beate Alinger-Scharinger, Cornelia Kronberger, Georg Hutarew, Wolfgang Hitzl, Roland Reitsamer, Klaassen-Federspiel Frederike, Martina Hager, Thorsten Fischer, Karl Sotlar, Heidi Jaksch-Bogensperger
Virchows Archiv.2024; 485(1): 53. CrossRef
Impact of HER2-low status for patients with early-stage breast cancer and non-pCR after neoadjuvant chemotherapy: a National Cancer Database Analysis
Huiyue Li, Jennifer K. Plichta, Kan Li, Yizi Jin, Samantha M. Thomas, Fei Ma, Li Tang, Qingyi Wei, You-Wen He, Qichen Chen, Yuanyuan Guo, Yueping Liu, Jian Zhang, Sheng Luo
Breast Cancer Research and Treatment.2024; 204(1): 89. CrossRef
Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer
Jennifer L. Guerriero, Jia-Ren Lin, Ricardo G. Pastorello, Ziming Du, Yu-An Chen, Madeline G. Townsend, Kenichi Shimada, Melissa E. Hughes, Siyang Ren, Nabihah Tayob, Kelly Zheng, Shaolin Mei, Alyssa Patterson, Krishan L. Taneja, Otto Metzger, Sara M. Tol
npj Breast Cancer.2024;[Epub] CrossRef
Clinical Utility and Benefits of Comprehensive Genomic Profiling in Cancer
Melissa Yuwono Tjota, Jeremy P Segal, Peng Wang
The Journal of Applied Laboratory Medicine.2024; 9(1): 76. CrossRef
High contrast breast cancer biomarker semi-quantification and immunohistochemistry imaging using upconverting nanoparticles
Sanathana Konugolu Venkata Sekar, Hui Ma, Katarzyna Komolibus, Gokhan Dumlupinar, Matthias J. Mickert, Krzysztof Krawczyk, Stefan Andersson-Engels
Biomedical Optics Express.2024; 15(2): 900. CrossRef
HER2-low breast cancer and response to neoadjuvant chemotherapy: a population-based cohort study
Ximena Baez-Navarro, Mieke R. van Bockstal, Agnes Jager, Carolien H.M. van Deurzen
Pathology.2024; 56(3): 334. CrossRef
Fast-tracking drug development with biomarkers and companion diagnostics
Noreen McBrearty, Devika Bahal, Suso Platero
Journal of Cancer Metastasis and Treatment.2024;[Epub] CrossRef
Emerging Landscape of Targeted Therapy of Breast Cancers With Low Human Epidermal Growth Factor Receptor 2 Protein Expression
Gary Tozbikian, Savitri Krishnamurthy, Marilyn M. Bui, Michael Feldman, David G. Hicks, Shabnam Jaffer, Thaer Khoury, Shi Wei, Hannah Wen, Paula Pohlmann
Archives of Pathology & Laboratory Medicine.2024; 148(2): 242. CrossRef
Treatment Patterns and Health Outcomes among Patients with HER2 IHC0/-Low Metastatic or Recurrent Breast Cancer
Eliya Farah, Chantelle Carbonell, Devon J. Boyne, Darren R. Brenner, Jan-Willem Henning, Daniel Moldaver, Simran Shokar, Winson Y. Cheung
Cancers.2024; 16(3): 518. CrossRef
Clinical Internal Dosimetry and Biodistribution of 177Lu-DOTA-Trastuzumab in HER2-Positive Metastatic and Locally Advanced Breast Carcinoma
Yoga S. Narwadkar, Rahul V. Parghane, Sudeep Sahu, Sangita Lad, Kamal Deep, Gaurav Wanage, Tejal Suralkar, Sharmila Banerjee, Sudeep Gupta, Sandip Basu, Rajendra A. Badwe
Clinical Nuclear Medicine.2024; 49(4): e149. CrossRef
Molecular Classifications in Gastric Cancer: A Call for Interdisciplinary Collaboration
Cristina Díaz del Arco, María Jesús Fernández Aceñero, Luis Ortega Medina
International Journal of Molecular Sciences.2024; 25(5): 2649. CrossRef
The combined immunohistochemical expression of AMBRA1 and SQSTM1 identifies patients with poorly differentiated cutaneous squamous cell carcinoma at risk of metastasis: A proof of concept study
Michael H. Alexander, William J. Cousins, Tom Ewen, Andrew P. South, Penny Lovat, Niki Stefanos
Journal of Cutaneous Pathology.2024; 51(6): 450. CrossRef
Concordance between pathologists and between specimen types in detection of HER2-low breast carcinoma by immunohistochemistry
Jing Wang, Esther Yoon, Savitri Krishnamurthy
Annals of Diagnostic Pathology.2024; 70: 152288. CrossRef
Detection of HER2 expression using 99mTc-NM-02 nanobody in patients with breast cancer: a non-randomized, non-blinded clinical trial
Lingzhou Zhao, Yan Xing, Changcun Liu, Shaofei Ma, Wenhua Huang, Zhen Cheng, Jinhua Zhao
Breast Cancer Research.2024;[Epub] CrossRef
Pyrotinib and Trastuzumab Plus Chemotherapy Serve as an Acceptable Neoadjuvant Regimen Exhibiting Good Efficacy and Tolerance in HER2-Positive Breast Cancer Patients
Yibo Chen, Tianyi Zhang, Rui Zhang, Xuchen Cao
Cancer Biotherapy and Radiopharmaceuticals.2024; 39(6): 435. CrossRef
Clinicopathological and prognostic significance of VEGF, PDGF-B, and HER2/neu expression in gallbladder cancer
Pooja Shukla, Kumudesh Mishra, Ratnakar Shukla, Ruchira Vishwakarma, Niraj Kumari, Narendra Krishnani, Anu Behari, Vinay K. Kapoor
Journal of Cancer Research and Therapeutics.2024; 20(1): 349. CrossRef
Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancer
G. Curigliano, R. Dent, H. Earle, S. Modi, P. Tarantino, G. Viale, S.M. Tolaney
ESMO Open.2024; 9(4): 102989. CrossRef
Concordance of HER2 status between core needle biopsy and surgical resection specimens of breast cancer: an analysis focusing on the HER2-low status
Sei Na, Milim Kim, Yujun Park, Hyun Jung Kwon, Hee-Chul Shin, Eun-Kyu Kim, Mijung Jang, Sun Mi Kim, So Yeon Park
Breast Cancer.2024; 31(4): 705. CrossRef
Impact of Neoadjuvant Chemotherapy (NAC) on Biomarker Expression in Breast Cancer
Suji Lee, Jee Yeon Kim, So Jeong Lee, Chung Su Hwang, Hyun Jung Lee, Kyung Bin Kim, Jung Hee Lee, Dong Hoon Shin, Kyung Un Choi, Chang Hun Lee, Gi Yeong Huh, Ahrong Kim
Medicina.2024; 60(5): 737. CrossRef
Clinical Use of Molecular Biomarkers in Canine and Feline Oncology: Current and Future
Heike Aupperle-Lellbach, Alexandra Kehl, Simone de Brot, Louise van der Weyden
Veterinary Sciences.2024; 11(5): 199. CrossRef
Clinical Validation of Artificial Intelligence–Powered PD-L1 Tumor Proportion Score Interpretation for Immune Checkpoint Inhibitor Response Prediction in Non–Small Cell Lung Cancer
Hyojin Kim, Seokhwi Kim, Sangjoon Choi, Changhee Park, Seonwook Park, Sergio Pereira, Minuk Ma, Donggeun Yoo, Kyunghyun Paeng, Wonkyung Jung, Sehhoon Park, Chan-Young Ock, Se-Hoon Lee, Yoon-La Choi, Jin-Haeng Chung
JCO Precision Oncology.2024;[Epub] CrossRef
Mesenchymal-epithelial transition factor amplification correlates with adverse pathological features and poor clinical outcome in colorectal cancer
Qiu-Xiao Yu, Ping-Ying Fu, Chi Zhang, Li Li, Wen-Ting Huang
World Journal of Gastrointestinal Surgery.2024; 16(5): 1395. CrossRef
Lipid nanoparticles-based RNA therapies for breast cancer treatment
Luigia Serpico, Yuewen Zhu, Renata Faria Maia, Sumedha Sumedha, Mohammad-Ali Shahbazi, Hélder A. Santos
Drug Delivery and Translational Research.2024; 14(10): 2823. CrossRef
Human epidermal growth factor receptor 2 (HER2) status in breast cancer: practice points and challenges
Natthawadee Laokulrath, Mihir Gudi, Syed Ahmed Salahuddin, Angela Phek Yoon Chong, Cristine Ding, Jabed Iqbal, Wei Qiang Leow, Benjamin Yongcheng Tan, Gary Tse, Emad Rakha, Puay Hoon Tan
Histopathology.2024; 85(3): 371. CrossRef
Comprehensive Immunohistochemical Analysis of Epithelial–Mesenchymal Transition Biomarkers in the Invasive Micropapillary Cancer of the Breast
Ozden Oz, Funda Alkan Tasli, Resmiye Irmak Yuzuguldu, Baha Zengel, Demet Kocatepe Cavdar, Merih Guray Durak, Raika Durusoy, Pranshu Sahgal
International Journal of Breast Cancer.2024;[Epub] CrossRef
Advancing HER2-low breast cancer management: enhancing diagnosis and treatment strategies
Simona Borstnar, Ivana Bozovic-Spasojevic, Ana Cvetanovic, Natalija Dedic Plavetic, Assia Konsoulova, Erika Matos, Lazar Popovic, Savelina Popovska, Snjezana Tomic, Eduard Vrdoljak
Radiology and Oncology.2024; 58(2): 258. CrossRef
Peer‐to‐peer validation of Ki‐67 scoring in a pathology quality circle as a tool to assess interobserver variability: are we better than we thought?
Marit Bernhardt, Leonie Weinhold, Christine Sanders, Oliver Hommerding, Jan‐Frederic Lau, Marieta Toma, Verena Tischler, Matthias Schmid, Tomasz Zienkiewicz, Ralf Hildenbrand, Peter Gerlach, Hui Zhou, Martin Braun, Gunnar Müller, Erich Sieber, Christian M
APMIS.2024; 132(10): 718. CrossRef
Immunohistochemical Expression of Cyclin D1 and p16 in Invasive Breast Carcinoma and Its Association with Clinicopathological Parameters
Shaivy Malik, Shakthivel V., Sana Ahuja, Charanjeet Ahluwalia
Indian Journal of Surgical Oncology.2024; 15(4): 864. CrossRef
Novel engineered HER2 specific recombinant protein nanocages for targeted drug delivery
Javad Kheshti, Mohammad Ahmadyousefi, Meysam Soleimani
Molecular Biology Reports.2024;[Epub] CrossRef
Circulating C-reactive protein levels as a prognostic biomarker in breast cancer across body mass index groups
J. B. Holm, E. Baggesen, D. Cronin-Fenton, J. Frystyk, J. M. Bruun, P. Christiansen, S. Borgquist
Scientific Reports.2024;[Epub] CrossRef
Standardized molecular pathology workflow for ctDNA-based ESR1 testing in HR+/HER2- metastatic breast cancer
Elena Guerini-Rocco, Konstantinos Venetis, Giulia Cursano, Eltjona Mane, Chiara Frascarelli, Francesco Pepe, Mariachiara Negrelli, Edoardo Olmeda, Davide Vacirca, Alberto Ranghiero, Dario Trapani, Carmen Criscitiello, Giuseppe Curigliano, Christian Rolfo,
Critical Reviews in Oncology/Hematology.2024; 201: 104427. CrossRef
The differences between pure and mixed invasive micropapillary breast cancer: the epithelial–mesenchymal transition molecules and prognosis
Ozden Oz, Resmiye Irmak Yuzuguldu, Ayse Yazici, Demet Kocatepe Cavdar, Cengiz Yilmaz, Mucteba Ozturk, Hilal Duzel, Duygu Gurel
Breast Cancer Research and Treatment.2024; 208(1): 41. CrossRef
Best practices for achieving consensus in HER2‐low expression in breast cancer: current perspectives from practising pathologists
Gary Tozbikian, Marilyn M. Bui, David G Hicks, Shabnam Jaffer, Thaer Khoury, Hannah Y Wen, Savitri Krishnamurthy, Shi Wei
Histopathology.2024; 85(3): 489. CrossRef
Consensus Guidelines on Human Epidermal Growth Factor Receptor 2 (HER2)-Low Testing in Breast Cancer in Malaysia
Pathmanathan Rajadurai, Sarala Ravindran, Bang Rom Lee, Suria Hayati Md Pauzi, Seow Fan Chiew, Kean Hooi Teoh, Navarasi S. Raja Gopal, Mastura Md Yusof, Cheng Har Yip
Cancers.2024; 16(13): 2325. CrossRef
Revolutionizing Pathology with Artificial Intelligence: Innovations in Immunohistochemistry
Diana Gina Poalelungi, Anca Iulia Neagu, Ana Fulga, Marius Neagu, Dana Tutunaru, Aurel Nechita, Iuliu Fulga
Journal of Personalized Medicine.2024; 14(7): 693. CrossRef
Interobserver Variability in HER‐2 Immunostaining Interpretation of Metastatic HER2 Low Breast Cancers in Cytology Specimens
Niyati Desai, Courtney F. Connelly, Simon Sung, Adela Cimic, Swikrity U. Baskota
Diagnostic Cytopathology.2024; 52(12): 722. CrossRef
Weakly-supervised deep learning models enable HER2-low prediction from H &E stained slides
Renan Valieris, Luan Martins, Alexandre Defelicibus, Adriana Passos Bueno, Cynthia Aparecida Bueno de Toledo Osorio, Dirce Carraro, Emmanuel Dias-Neto, Rafael A. Rosales, Jose Marcio Barros de Figueiredo, Israel Tojal da Silva
Breast Cancer Research.2024;[Epub] CrossRef
Understanding the spectrum of HER2 status in breast cancer: From HER2-positive to ultra-low HER2
Sana Ahuja, Adil Aziz Khan, Sufian Zaheer
Pathology - Research and Practice.2024; 262: 155550. CrossRef
Systematic review of added immunotherapy in traditional treatment for HER2 positive breast cancer patients
Rohan Choudhari
Innovative Practice in Breast Health.2024; 3-4: 100013. CrossRef
Detecting early-stage breast cancer with GATA3-positive circulating tumor cells
Chun-Hsin Hsieh, Ya-Herng Chang, Pei-Ying Ling, Ying-Tai Jin, Pei-Hsuan Lo, Hei-Jen Jou
Taiwanese Journal of Obstetrics and Gynecology.2024; 63(5): 745. CrossRef
First-in-human study of DP303c, a HER2-targeted antibody-drug conjugate in patients with HER2 positive solid tumors
Jian Zhang, Yiqun Du, Yanchun Meng, Xiaojun Liu, Yuxin Mu, Yunpeng Liu, Yehui Shi, Jufeng Wang, Aimin Zang, Shanzhi Gu, Tianshu Liu, Huan Zhou, Hongqian Guo, Silong Xiang, Xialu Zhang, Suqiong Wu, Huanhuan Qi, Mengke Li, Xichun Hu
npj Precision Oncology.2024;[Epub] CrossRef
Targeting CD276 for T cell-based immunotherapy of breast cancer
Ilona Hagelstein, Laura Wessling, Alexander Rochwarger, Latifa Zekri, Boris Klimovich, Christian M. Tegeler, Gundram Jung, Christian M. Schürch, Helmut R. Salih, Martina S. Lutz
Journal of Translational Medicine.2024;[Epub] CrossRef
Correlation of Androgen Receptor Expression With Ki67 Proliferative Index and Other Clinicopathological Characteristics in Invasive Mammary Carcinomas
D Keerthana Devi, V Pavithra, Leena D Joseph, Chithra Bhanu Challa
Cureus.2024;[Epub] CrossRef
CD81-guided heterologous EVs present heterogeneous interactions with breast cancer cells
Elena Gurrieri, Giulia Carradori, Michela Roccuzzo, Michael Pancher, Daniele Peroni, Romina Belli, Caterina Trevisan, Michela Notarangelo, Wen-Qiu Huang, Agata S. A. Carreira, Alessandro Quattrone, Guido Jenster, Timo L. M. Ten Hagen, Vito Giuseppe D’Agos
Journal of Biomedical Science.2024;[Epub] CrossRef
Deciphering HER2-low breast cancer (BC): insights from real-world data in early stage breast cancer
Anna Pous, Adrià Bernat-Peguera, Assumpció López-Paradís, Beatriz Cirauqui, Vanesa Quiroga, Iris Teruel, Eudald Felip, Angelica Ferrando-Díez, Milana Bergamino, Laia Boronat, Margarita Romeo, Gemma Soler, Christian Mariño, Paula Rodríguez-Martínez, Laura
Therapeutic Advances in Medical Oncology.2024;[Epub] CrossRef
Liquid biopsy-based technologies: a promising tool for biomarker identification in her2-low breast cancer patients for improved therapeutic outcomes
Aldo D’Alessandro, Anca Florentina Deaconu, Sandro Mandolesi, Federico Pio Fabrizio, Massimo Lombardi, Giovanna Liguori, Giovanni Pepe, Nicola Marino, Aureliano Stingi, Alessandro D’Alessandro, Antonio Giordano
Journal of Cancer Metastasis and Treatment.2024;[Epub] CrossRef
SPP1 mRNA Expression Is Associated with M2 Macrophage Infiltration and Poor Prognosis in Triple-Negative Breast Cancer
Yu-Chia Chen, Chia-Ching Chen, Rong-Fu Chen, Hsin-Hung Chen, Po-Ming Chen
Current Issues in Molecular Biology.2024; 46(12): 13499. CrossRef
MicroRNAs and their role in breast cancer metabolism (Review)
Wen Lee, Bann Yeo, Rozi Mahmud, Geok Tan, Mohamed Wahid, Yoke Cheah
International Journal of Oncology.2024;[Epub] CrossRef
CDH1 methylation and expression of E-cadherin and other markers in breast cancer
Luiz Fernando de Queiroz, Marcelo Soares da Mota e Silva, Fernando Colonna Rosman, Siane Lopes Bittencourt Rosas, Heitor Siffert Pereira de Souza, Maria da Glória da Costa Carvalho
Mastology.2024;[Epub] CrossRef
Surgical Management of the Axilla in HR+/HER2– Breast Cancer in the Z1071 Era: A Propensity Score-Matched Analysis of the National Cancer Database
Vayda R. Barker, Samer A. Naffouje, Melissa A. Mallory, Susan A. Hoover, Christine Laronga
Annals of Surgical Oncology.2023; 30(13): 8371. CrossRef
Noninvasive identification of HER2-low-positive status by MRI-based deep learning radiomics predicts the disease-free survival of patients with breast cancer
Yuan Guo, Xiaotong Xie, Wenjie Tang, Siyi Chen, Mingyu Wang, Yaheng Fan, Chuxuan Lin, Wenke Hu, Jing Yang, Jialin Xiang, Kuiming Jiang, Xinhua Wei, Bingsheng Huang, Xinqing Jiang
European Radiology.2023; 34(2): 899. CrossRef
Systemic investigation of inetetamab in combination with small molecules to treat HER2-overexpressing breast and gastric cancers
Lan Deng, Le Zhao, Lifen Liu, Haomin Huang
Open Life Sciences.2023;[Epub] CrossRef
HER2-low expression in patients with advanced or metastatic solid tumors
B. Uzunparmak, C. Haymaker, G. Raso, S. Masciari, L. Wang, H. Lin, A. Gorur, B. Kirby, A.-M. Cimo, A. Kennon, Q. Ding, G. Urschel, Y. Yuan, G. Feng, Y. Rizvi, A. Hussain, C. Zhu, P. Kim, G. Abbadessa, V. Subbiah, T.A. Yap, J. Rodon, S.A. Piha-Paul, F. Mer
Annals of Oncology.2023; 34(11): 1035. CrossRef
Data on 2D culture characterisation of potential markers in human HER2-positive breast cancer cell lines
Son H. Pham, Lyn R. Griffiths, Rachel K. Okolicsanyi, Larisa M. Haupt
Data in Brief.2023; 46: 108880. CrossRef
Determining HER2 Status by Artificial Intelligence: An Investigation of Primary, Metastatic, and HER2 Low Breast Tumors
Christiane Palm, Catherine E. Connolly, Regina Masser, Barbara Padberg Sgier, Eva Karamitopoulou, Quentin Simon, Beata Bode, Marianne Tinguely
Diagnostics.2023; 13(1): 168. CrossRef
Gene amplification mutations originate prior to selective stress in Acinetobacter baylyi
Jennifer A Herrmann, Agata Koprowska, Tesa J Winters, Nancy Villanueva, Victoria D Nikityuk, Feini Pek, Elizabeth M Reis, Constancia Z Dominguez, Daniel Davis, Eric McPherson, Staci R Rocco, Cynthia Recendez, Shyla M Difuntorum, Kelly Faeth, Mario D Lopez
G3.2023;[Epub] CrossRef
Flow Rate-Independent Multiscale Liquid Biopsy for Precision Oncology
Jie Wang, Robert Dallmann, Renquan Lu, Jing Yan, Jérôme Charmet
ACS Sensors.2023; 8(3): 1200. CrossRef
Single-cell HER2 quantification via instant signal amplification in microdroplets
Xiaoxian Liu, Yifan Zhu, Caoxin Li, Yanyun Fang, Jinna Chen, Fei Xu, Yanqing Lu, Perry Ping Shum, Ying Liu, Guanghui Wang
Analytica Chimica Acta.2023; 1251: 340976. CrossRef
Molecular imaging of HER2 receptor: Targeting HER2 for imaging and therapy in nuclear medicine
Daniela Miladinova
Frontiers in Molecular Biosciences.2023;[Epub] CrossRef
CORRELATION BETWEEN DIFFERENT CLINICOPATHOLOGICAL PARAMETERS AND MOLECULAR SUBTYPES OF FEMALE BREAST CARCINOMA IN SOUTH REGION OF IRAQ
Yassir Alaa Muhammed Hassan Shubbar
Wiadomości Lekarskie.2023; 76(1): 97. CrossRef
Pathological identification of HER2-low breast cancer: Tips, tricks, and troubleshooting for the optimal test
Elham Sajjadi, Elena Guerini-Rocco, Elisa De Camilli, Oriana Pala, Giovanni Mazzarol, Konstantinos Venetis, Mariia Ivanova, Nicola Fusco
Frontiers in Molecular Biosciences.2023;[Epub] CrossRef
Protective Effect of HER2 Gene Polymorphism rs24537331 in the Outcome of Canine Mammary Tumors
Ana Canadas-Sousa, Marta Santos, Patrícia Dias-Pereira
Animals.2023; 13(8): 1384. CrossRef
Can Patients with HER2-Low Breast Cancer Benefit from Anti-HER2 Therapies? A Review
Jin Wang, Dongying Liao, Xuemin Zhang, Changhong Miao, Kuang Chen
Breast Cancer: Targets and Therapy.2023; Volume 15: 281. CrossRef
HER2 Low Breast Cancer: A New Subtype or a Trojan for Cytotoxic Drug Delivery?
Marina Popović, Tajana Silovski, Marija Križić, Natalija Dedić Plavetić
International Journal of Molecular Sciences.2023; 24(9): 8206. CrossRef
HER2-Low Breast Cancer—Diagnostic Challenges and Opportunities for Insights from Ongoing Studies: A Podcast
Aditya Bardia, Giuseppe Viale
Targeted Oncology.2023; 18(3): 313. CrossRef
Histopathological and immunohistochemical analysis of predictive and prognostic markers in spontaneous canine mammary cancer
Vladimír Tancoš, Marcel Kovalik, Martin Levkut, Martina Bobrovská, Petra Kolenčíková, Ľubomír Straka, Zuzana Ševčíková, Ondřej Škor, Martina Antošová, Lukáš Plank, Keith L. Thoday
Acta Veterinaria Brno.2023; 92(2): 143. CrossRef
Dissecting sources of variability in patient response to targeted therapy: anti-HER2 therapies as a case study
Timothy Qi, Yanguang Cao
European Journal of Pharmaceutical Sciences.2023; 186: 106467. CrossRef
The Effect of HER2-Low Status on Pathological Complete Response and Survival in Triple-Negative Breast Cancer: A Systemic Review and Meta-Analysis
Yakup Ergun, Baran Akagunduz, Cengiz Karacin, Sema Turker, Gokhan Ucar
Clinical Breast Cancer.2023; 23(6): 567. CrossRef
Efficacy, toxicity and prognostic factors of pyrotinib‑involved neoadjuvant therapy in HER2‑positive breast cancer: A retrospective study
Hao Wang, Hailing Cao, Zhiyun Guo
Oncology Letters.2023;[Epub] CrossRef
Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer
Feng Ye, Saikat Dewanjee, Yuehua Li, Niraj Kumar Jha, Zhe-Sheng Chen, Ankush Kumar, Vishakha, Tapan Behl, Saurabh Kumar Jha, Hailin Tang
Molecular Cancer.2023;[Epub] CrossRef
Weakly supervised bilayer convolutional network in segmentation of HER2 related cells to guide HER2 targeted therapies
Ching-Wei Wang, Kun-Lin Lin, Hikam Muzakky, Yi-Jia Lin, Tai-Kuang Chao
Computerized Medical Imaging and Graphics.2023; 108: 102270. CrossRef
Immune Biomarkers in Triple-Negative Breast Cancer: Improving the Predictivity of Current Testing Methods
Francesca Maria Porta, Elham Sajjadi, Konstantinos Venetis, Chiara Frascarelli, Giulia Cursano, Elena Guerini-Rocco, Nicola Fusco, Mariia Ivanova
Journal of Personalized Medicine.2023; 13(7): 1176. CrossRef
HER2 Equivocal (Score = 2+) Breast Carcinoma Cases Identified by Immunohistochemistry at a South African Hospital. What is the Impact of Fluorescent In Situ Hybridization Testing?
Reena Dhansukh Mohanlal, Nikki Bouwer, Pascale Willem
Applied Immunohistochemistry & Molecular Morphology.2023; 31(8): 555. CrossRef
Discordance of HER2 Expression and/or Amplification on Repeat Testing
Timothy P. DiPeri, Kathleen Kong, Kaushik Varadarajan, Daniel D. Karp, Jaffer A. Ajani, Shubham Pant, Michael F. Press, Sarina A. Piha-Paul, Ecaterina E. Dumbrava, Funda Meric-Bernstam
Molecular Cancer Therapeutics.2023; 22(8): 976. CrossRef
Low and Ultra-Low HER2 in Human Breast Cancer: An Effort to Define New Neoplastic Subtypes
Mariausilia Franchina, Cristina Pizzimenti, Vincenzo Fiorentino, Maurizio Martini, Giuseppina Rosaria Rita Ricciardi, Nicola Silvestris, Antonio Ieni, Giovanni Tuccari
International Journal of Molecular Sciences.2023; 24(16): 12795. CrossRef
Genetic analysis of oligo-recurrence breast cancer: correlation with clinical outcomes
Kuikui Jiang, Danyang Zhou, Fei Xu, Wen Xia, Qiufan Zheng, Qianyi Lu, Rongzhen Luo, Ruoxi Hong, Shusen Wang
BMC Cancer.2023;[Epub] CrossRef
Single domain antibodies specific for HER2 dimerization domain effectively disrupts HER2 dimerization
Ahmad Najafi, Reza Valadan, Hossein Asgarian-Omran, Alireza Rafiei, Mohsen Tehrani
International Immunopharmacology.2023; 124: 110999. CrossRef
Récepteur du facteur de croissance épidermique HER2, tests utilisés pour rechercher son amplification dans le cancer du sein : principes et limites
Imane Eliahiai, Mohammed Eljiar, Sanae Chaib, Jinane KHarmoum, Mariame Chraïbi
Bulletin du Cancer.2023; 110(12): 1301. CrossRef
Integrated Molecular Characterization of HER2-Low Breast Cancer Using Next Generation Sequencing (NGS)
Jean-Louis Merlin, Marie Husson, Nassim Sahki, Pauline Gilson, Vincent Massard, Alexandre Harlé, Agnès Leroux
Biomedicines.2023; 11(12): 3164. CrossRef
GLUCOSE LEVELS OF PLEURAL EFFUSION FLUID AND HER2 STATUS IN PLEURAL-METASTATIC BREAST CANCER
Muhammad Dhanny Irawan, Desak Gede Agung Suprabawati, Heru Purwanto
Majalah Biomorfologi.2023; 33(2): 75. CrossRef
Design of a Ratiometric Plasmonic Biosensor for Herceptin Detection in HER2-Positive Breast Cancer
Neda Shahbazi, Rouholah Zare-Dorabei, Seyed Morteza Naghib
ACS Biomaterials Science & Engineering.2022; 8(2): 871. CrossRef
A highly sensitive nanobiosensor based on aptamer-conjugated graphene-decorated rhodium nanoparticles for detection of HER2-positive circulating tumor cells
Mahdi Sadeghi, Soheila Kashanian, Seyed Morteza Naghib, Esfandyar Askari, Fateme Haghiralsadat, Davood Tofighi
Nanotechnology Reviews.2022; 11(1): 793. CrossRef
Anti-HER2 therapy in metastatic breast cancer: many choices and future directions
Carrie S. Wynn, Shou-Ching Tang
Cancer and Metastasis Reviews.2022; 41(1): 193. CrossRef
Electroanalytical overview: screen-printed electrochemical sensing platforms for the detection of vital cardiac, cancer and inflammatory biomarkers
Robert D. Crapnell, Alejandro Garcia-Miranda Ferrari, Nina C. Dempsey, Craig E. Banks
Sensors & Diagnostics.2022; 1(3): 405. CrossRef
FTO genotype was associated with breast cancer in HER2 negative patients
Fateme Montazeri, Hossein Hatami, Soroor Fathi, Naeemeh Hasanpour Ardekanizadeh, Fatemeh Bourbour, Samira Rastgoo, Fatemeh Shafiee, Mohammad Esmail Akbari, Maryam Gholamalizadeh, Seyed Alireza Mosavi Jarrahi, Saeid Doaei
Clinical Nutrition ESPEN.2022; 49: 495. CrossRef
Breast Cancer Human Epidermal Growth Factor Receptor 2 mRNA Molecular Testing Compared to Immunohistochemistry with Correlation to Neoadjuvant Therapy Response
Mahmoud Behairy, Samia Mohamed Gabal, Mohamed Sherif Negm
Open Access Macedonian Journal of Medical Sciences.2022; 10(A): 352. CrossRef
Validity and utility of HER2/ERBB2 copy number variation assessed in liquid biopsies from breast cancer patients: A systematic review
Noortje Verschoor, Teoman Deger, Agnes Jager, Stefan Sleijfer, Saskia M. Wilting, John W.M. Martens
Cancer Treatment Reviews.2022; 106: 102384. CrossRef
RETRACTED: Longitude Variation of the microRNA-497/FGF-23 Axis during Treatment and Its Linkage with Neoadjuvant/Adjuvant Trastuzumab-Induced Cardiotoxicity in HER2-Positive Breast Cancer Patients
Hui Liu, Xiaoyan Hu, Lingyun Wang, Tao Du, Jing Feng, Ming Li, Lei Liu, Xiaofang Liu
Frontiers in Surgery.2022;[Epub] CrossRef
Use of Radionuclide-Based Imaging Methods in Breast Cancer
Betül Altunay, Agnieszka Morgenroth, Felix M. Mottaghy
Seminars in Nuclear Medicine.2022; 52(5): 561. CrossRef
Functional regulations between genetic alteration-driven genes and drug target genes acting as prognostic biomarkers in breast cancer
Li Wang, Lei Yu, Jian Shi, Feng Li, Caiyu Zhang, Haotian Xu, Xiangzhe Yin, Lixia Wang, Shihua Lin, Anastasiia Litvinova, Yanyan Ping, Shangwei Ning, Hongying Zhao
Scientific Reports.2022;[Epub] CrossRef
Human epidermal growth factor receptor-2 and endocrine resistance in hormone-dependent breast cancer
Anastasia Alataki, Mitch Dowsett
Endocrine-Related Cancer.2022; 29(8): R105. CrossRef
The Evolution of Targeted Radionuclide Diagnosis of HER2-Positive Breast Cancer
Olga D. Bragina, Sergei M. Deyev, Vladimir I. Chernov, Vladimir M. Tolmachev
Acta Naturae.2022; 14(2): 4. CrossRef
Deriving tumor purity from cancer next generation sequencing data: applications for quantitative ERBB2 (HER2) copy number analysis and germline inference of BRCA1 and BRCA2 mutations
Stephanie E. Siegmund, Danielle K. Manning, Phani K. Davineni, Fei Dong
Modern Pathology.2022; 35(10): 1458. CrossRef
Current challenges and unmet needs in treating patients with human epidermal growth factor receptor 2-positive advanced breast cancer
Matti Aapro, Fatima Cardoso, Giuseppe Curigliano, Alexandru Eniu, Joseph Gligorov, Nadia Harbeck, Andreas Mueller, Olivia Pagani, Shani Paluch-Shimon, Elzbieta Senkus, Beat Thürlimann, Khalil Zaman
The Breast.2022; 66: 145. CrossRef
[Retracted] Application of Fluorescence In Situ Hybridization Assisted by Fluorescence Microscope in Detection of Her2 Gene in Breast Cancer Patients
Fang Lu, Tingting Zhou, Yan Liu, Liying Song, Bin Zhang, Yuyan Li, Sorayouth Chumnanvej
Contrast Media & Molecular Imaging.2022;[Epub] CrossRef
High sensitivity label-free detection of HER2 using an Al–GaN/GaN high electron mobility transistor-based biosensor
Shivanshu Mishra, Pharyanshu Kachhawa, Amber Kumar Jain, Rajiv Ranjan Thakur, Nidhi Chaturvedi
Lab on a Chip.2022; 22(21): 4129. CrossRef
Indian Data on HER2 Fluorescence In Situ Hybridization in Invasive Breast Cancer with Immunohistochemically Equivocal Results As Per 2018 ASCO/CAP Guidelines
B. R. Nagarjun, Biren Parikh, Manaswi Nareshkumar Patel, Pina J. Trivedi, Dharmesh M. Patel
South Asian Journal of Cancer.2022; 11(04): 281. CrossRef
S‑phase fraction, lymph node status and disease staging as the main prognostic factors to differentiate between young and older patients with invasive breast carcinoma
António Pinto, João Matos, Teresa Pereira, Giovani Silva, Saudade André
Oncology Letters.2022;[Epub] CrossRef
Inferring tumor-specific cancer dependencies through integrating ex vivo drug response assays and drug-protein profiling
Alina Batzilla, Junyan Lu, Jarno Kivioja, Kerstin Putzker, Joe Lewis, Thorsten Zenz, Wolfgang Huber, James Gallo
PLOS Computational Biology.2022; 18(8): e1010438. CrossRef
Clinical possibilities of HER2-positive breast cancer diagnosis using alternative scaffold proteins
O. D. Bragina, V. I. Chernov, S. M. Deyev, V. M. Tolmachev
Bulletin of Siberian Medicine.2022; 21(3): 132. CrossRef
Molecular Pathology of Gastric Cancer
Moonsik Kim, An Na Seo
Journal of Gastric Cancer.2022; 22(4): 264. CrossRef
Loss of NECTIN1 triggers melanoma dissemination upon local IGF1 depletion
Julien Ablain, Amira Al Mahi, Harriet Rothschild, Meera Prasad, Sophie Aires, Song Yang, Maxim E. Dokukin, Shuyun Xu, Michelle Dang, Igor Sokolov, Christine G. Lian, Leonard I. Zon
Nature Genetics.2022; 54(12): 1839. CrossRef
Advanced diagnosis technologies for HER2 breast cancer markers
Mengxue Zhang
Highlights in Science, Engineering and Technology.2022; 14: 44. CrossRef
An Overview of Clinical Development of Agents for Metastatic or Advanced Breast Cancer Without ERBB2 Amplification (HER2-Low)
Aleix Prat, Aditya Bardia, Giuseppe Curigliano, M. Elizabeth H. Hammond, Sibylle Loibl, Sara M. Tolaney, Giuseppe Viale
JAMA Oncology.2022; 8(11): 1676. CrossRef
Development of T-cell engagers selective for cells co-expressing two antigens
Danielle M. Dicara, Sunil Bhakta, Mary Ann Go, James Ziai, Ron Firestein, Bill Forrest, Chen Gu, Steven R. Leong, Genee Lee, Shang-Fan Yu, Andrew G. Polson, Nicholas J. Agard
mAbs.2022;[Epub] CrossRef
The clinical significance of HER2 expression in DCIS
Ioanna Akrida, Francesk Mulita
Medical Oncology.2022;[Epub] CrossRef
Antibody-Drug Conjugates in Breast Cancer: Spotlight on HER2
Rachel Occhiogrosso Abelman, Arielle Medford, Laura Spring, Aditya Bardia
The Cancer Journal.2022; 28(6): 423. CrossRef
The Clinical Utility of Droplet Digital PCR for Profiling Circulating Tumor DNA in Breast Cancer Patients
Ugur Gezer, Abel J. Bronkhorst, Stefan Holdenrieder
Diagnostics.2022; 12(12): 3042. CrossRef
Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis
Ye Yuan, Xumei Liu, Yi Cai, Wenyuan Li
Systematic Reviews.2022;[Epub] CrossRef
Interactions dietary components with expression level of breast cancer-related genes
Fatemeh Bourbour, Azam Pourtaheri, Khadijeh Abbasi, Naeemeh Hasanpour Ardekanizadeh, Maryam Gholamalizadeh, Azadeh Hajipour, Sepideh Abdollahi, Seyedeh Elaheh Bagheri, Mina Ahmadzadeh, Saeid Doaei, Arezoo Haghighian
Egyptian Journal of Medical Human Genetics.2022;[Epub] CrossRef
HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging
Betül Altunay, Agnieszka Morgenroth, Mohsen Beheshti, Andreas Vogg, Nicholas C. L. Wong, Hong Hoi Ting, Hans-Jürgen Biersack, Elmar Stickeler, Felix M. Mottaghy
European Journal of Nuclear Medicine and Molecular Imaging.2021; 48(5): 1371. CrossRef
Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge
Christian Jackisch, Patricia Cortazar, Charles E. Geyer, Luca Gianni, Joseph Gligorov, Zuzana Machackova, Edith A. Perez, Andreas Schneeweiss, Sara M. Tolaney, Michael Untch, Andrew Wardley, Martine Piccart
Cancer Treatment Reviews.2021; 99: 102229. CrossRef
Histologic Patterns of Cutaneous Metastases of Breast Carcinoma: A Clinicopathologic Study of 232 Cases
Shira Ronen, David Suster, Wei-Shen Chen, Natali Ronen, Sri Krishna C. Arudra, Celestine Trinidad, Doina Ivan, Victor G. Prieto, Saul Suster
The American Journal of Dermatopathology.2021; 43(6): 401. CrossRef
Standardized pathology report for breast cancer
Soo Youn Cho, So Yeon Park, Young Kyung Bae, Jee Yeon Kim, Eun Kyung Kim, Woo Gyeong Kim, Youngmee Kwon, Ahwon Lee, Hee Jin Lee, Ji Shin Lee, Jee Young Park, Gyungyub Gong, Hye Kyoung Yoon
Journal of Pathology and Translational Medicine.2021; 55(1): 1. CrossRef
The impact of oral contraceptive use on breast cancer risk: State of the art and future perspectives in the era of 4P medicine
R. Bonfiglio, M.L. Di Pietro
Seminars in Cancer Biology.2021; 72: 11. CrossRef
The Co-Expression of Melanoma-Antigen Family a Proteins and New York Esophageal Squamous Cell Carcinoma-1 in Breast Cancer: A Pilot Study
Yu-Xin Wang, Feng-Lian Li, Li-Xin Du, Jun-Fang Liu, Li-Gang Huo, Shu-Qing Li, Bin Tian
Cancer Management and Research.2021; Volume 13: 6123. CrossRef
Targeting HER2 protein in individual cells using ICP-MS detection and its potential as prognostic and predictive breast cancer biomarker
A. Fernández Asensio, M. Corte-Rodríguez, J. Bettmer, L.M. Sierra, M. Montes-Bayón, E. Blanco- González
Talanta.2021; 235: 122773. CrossRef
Development of a 99mTc-Labeled Single-Domain Antibody for SPECT/CT Assessment of HER2 Expression in Breast Cancer
Lingzhou Zhao, Changcun Liu, Yan Xing, Jin He, Jim O’Doherty, Wenhua Huang, Jinhua Zhao
Molecular Pharmaceutics.2021; 18(9): 3616. CrossRef
WITHDRAWN: Nouvelles stratégies thérapeutiques dans les cancers du sein HER2-surexprimé
Benoîte Mery, Philippe Toussaint, Pierre-Etienne Heudel, Armelle Dufresne, Mélodie Carbonnaux, Hélène Vanacker, Thomas Bachelot, Olivier Trédan
Bulletin du Cancer.2021;[Epub] CrossRef
Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio ≥2.0, HER2 copy number <4.0 signals/cell) cases
Emad A. Rakha, Islam M. Miligy, Cecily M. Quinn, Elena Provenzano, Abeer M. Shaaban, Caterina Marchiò, Michael S. Toss, Grace Gallagy, Ciara Murray, Janice Walshe, Ayaka Katayama, Karim Eldib, Nahla Badr, Bruce Tanchel, Rebecca Millican-Slater, Colin Purd
British Journal of Cancer.2021; 124(11): 1836. CrossRef
Loss of HER2‐positivity following neoadjuvant targeted therapy for breast cancer is not associated with inferior oncologic outcomes
Catherine L. Wetzel, Thomas L. Sutton, Stuart Gardiner, Maryam Farinola, Nathalie Johnson, Jennifer R. Garreau
Journal of Surgical Oncology.2021; 124(8): 1224. CrossRef
Clinical and Genetic Predictive Models for the Prediction of Pathological Complete Response to Optimize the Effectiveness for Trastuzumab Based Chemotherapy
Lun Li, Min Chen, Shuyue Zheng, Hanlu Li, Weiru Chi, Bingqiu Xiu, Qi Zhang, Jianjing Hou, Jia Wang, Jiong Wu
Frontiers in Oncology.2021;[Epub] CrossRef
tRNA‐derived fragments: tRF‐Gly‐CCC‐046, tRF‐Tyr‐GTA‐010 and tRF‐Pro‐TGG‐001 as novel diagnostic biomarkers for breast cancer
Yue Zhang, Zhao Bi, Xiaohan Dong, Miao Yu, Kangyu Wang, Xingguo Song, Li Xie, Xianrang Song
Thoracic Cancer.2021; 12(17): 2314. CrossRef
Detection of secondary metastatic breast cancer by measurement of plasma CA 15.3
L. De Cock, J. Heylen, A. Wildiers, K. Punie, A. Smeets, C. Weltens, P. Neven, J. Billen, A. Laenen, H. Wildiers
ESMO Open.2021; 6(4): 100203. CrossRef
Standardized Pathology Report for Breast Cancer
Soo Youn Cho, So Yeon Park, Young Kyung Bae, Jee Yeon Kim, Eun Kyung Kim, Woo Gyeong Kim, Youngmee Kwon, Ahwon Lee, Hee Jin Lee, Ji Shin Lee, Jee Young Park, Gyungyub Gong, Hye Kyoung Yoon
Journal of Breast Cancer.2021; 24(1): 1. CrossRef
Circular RNA circ-ERBB2 promotes HER2-positive breast cancer progression and metastasis via sponging miR-136-5p and miR-198
Jin-xiu Zhong, Yun-yuan Kong, Rong-guang Luo, Guo-jin Xia, Wen-xing He, Xue-zhong Chen, Wei-wei Tan, Qing-jie Chen, Yu-yin Huang, Yan-xing Guan
Journal of Translational Medicine.2021;[Epub] CrossRef
Nouvelles stratégies thérapeutiques dans les cancers du sein HER2-surexprimé
Benoîte Mery, Philippe Toussaint, Pierre-Etienne Heudel, Armelle Dufresne, Mélodie Carbonnaux, Hélène Vanacker, Thomas Bachelot, Olivier Trédan
Bulletin du Cancer.2021; 108(11): 11S8. CrossRef
Association of Estrogen and Progesterone Receptors with Clinicopathological Prognostic Factors in Breast Cancer
Ali Abdul Hadi Abdul-Kareem, Qahtan A. Mahdi
Medical Journal of Babylon.2021; 18(2): 111. CrossRef
HER2 alterations in non-small-cell lung cancer – Druggable or undruggable?
Suresh Kumar Bondili, Ravindra Nandhana, Vanita Noronha, Swayamprabha Pawar, Nandini Menon, Omshree Shetty, Anuradha Chougule, Abhishek Mahajan, Rajiv Kumar, Vijay M. Patil, Amit Joshi, Kumar Prabhash
Cancer Research, Statistics, and Treatment.2021; 4(2): 374. CrossRef
UCNP-based Photoluminescent Nanomedicines for Targeted Imaging and Theranostics of Cancer
Evgenii L. Guryev, Anita S. Smyshlyaeva, Natalia Y. Shilyagina, Evgeniya A. Sokolova, Samah Shanwar, Alexey B. Kostyuk, Alexander V. Lyubeshkin, Alexey A. Schulga, Elena V. Konovalova, Quan Lin, Indrajit Roy, Irina V. Balalaeva, Sergey M. Deyev, Andrei V.
Molecules.2020; 25(18): 4302. CrossRef
Impact of the Updated Guidelines on Human Epidermal Growth Factor Receptor 2 (HER2) Testing in Breast Cancer
Min Chong Kim, Su Hwan Kang, Jung Eun Choi, Young Kyung Bae
Journal of Breast Cancer.2020; 23(5): 484. CrossRef

Original Articles

Preoperative Cytologic Diagnosis of Warthin-like Variant of Papillary Thyroid Carcinoma: Jisup Kim, Beom Jin Lim, Soon Won Hong, Ju Yeon Pyo; J Pathol Transl Med. 2018;52(2):105-109. Published online February 12, 2018; DOI: https://doi.org/10.4132/jptm.2017.12.26

9,170 View
154 Download
10 Web of Science
9 Crossref

Abstract PDF

Background
Warthin-like variant of papillary thyroid carcinoma (WLV-PTC) is a relatively rare variant of papillary thyroid carcinoma with favorable prognosis. However, preoperative diagnosis using fine-needle aspiration (FNA) specimens is challenging especially with lymphocytic thyroiditis characterized by Hürthle cells and lymphocytic background. To determine a helpful cytological differential point, we compared WLV-PTC FNA findings with conventional papillary thyroid carcinoma with lymphocytic thyroiditis (PTC-LT) and conventional papillary thyroid carcinoma without lymphocytic thyroiditis (PTC) regarding infiltrating inflammatory cells and their distribution. Preoperative diagnosis or potential for WLV-PTC will be helpful for surgeons to decide the scope of operation.
Methods
Of the 8,179 patients treated for papillary thyroid carcinoma between January 2007 and December 2012, 16 patients (0.2%) were pathologically confirmed as WLV-PTC and four cases were available for cytologic review. For comparison, we randomly selected six PTC-LT cases and five PTC cases during the same period. The number of intratumoral and background lymphocytes, histiocytes, neutrophils, and the presence of giant cells were evaluated and compared using conventional smear and ThinPrep preparations.
Results
WLV-PTC showed extensive lymphocytic smear with incorporation of thyroid follicular tumor cell clusters and frequent histiocytes. WLV-PTC was associated with higher intratumoral and background lymphocytes and histiocytes compared with PTC-LT or PTC. The difference was more distinct in liquid-based cytology.
Conclusions
The lymphocytic smear pattern and the number of inflammatory cells of WLV-PTC are different from those of PTC-LT or PTC and will be helpful for the differential diagnosis of WLV-PTC in preoperative FNA.

Citations

Citations to this article as recorded by

An Algorithmic Approach to Defining Variants of Papillary Thyroid Carcinoma: Accuracy of Fine Needle Aspiration Cytology
Neha Nigam, Neha Kumari, Rishabh Sahai, Nandita Chaudhary, Sabaretnam Mayilvaganan, Pallavi Prasad, Prabhakar Mishra
Journal of Cytology.2025; 42(1): 27. CrossRef
A Case of Warthin-Like Variant of Papillary Thyroid Cancer
Amy Chow, Israa Laklouk
Cureus.2025;[Epub] CrossRef
Warthin-like variant of papillary thyroid carcinoma: a rare case report
Rafif E Mattar, Osama Almubadel, Areej Bokhari
Journal of Surgical Case Reports.2025;[Epub] CrossRef
Warthin-like variant of papillary thyroid carcinoma with lymph node metastases: a case report and review of the literature
Andrii Hryshchyshyn, Andrii Bahrii, Pavlina Botsun, Volodymyr Chuba
Journal of Medical Case Reports.2024;[Epub] CrossRef
Cytologic hallmarks and differential diagnosis of papillary thyroid carcinoma subtypes
Agnes Stephanie Harahap, Chan Kwon Jung
Journal of Pathology and Translational Medicine.2024; 58(6): 265. CrossRef
Warthin-like papillary thyroid carcinoma: a case report and comprehensive review of the literature
Abdel Mouhaymen Missaoui, Fatma Hamza, Wafa Belabed, Manel Mellouli, Mohamed Maaloul, Slim Charfi, Issam Jardak, Tahya Sellami-Boudawara, Nabila Rekik, Mohamed Abid
Frontiers in Endocrinology.2023;[Epub] CrossRef
The Warthin-like variant of papillary thyroid carcinomas: a clinicopathologic analysis report of two cases
Xing Zhao, Yijia Zhang, Pengyu Hao, Mingzhen Zhao, Xingbin Shen
Oncologie.2023; 25(5): 581. CrossRef
Challenges in Cytology Specimens With Hürthle Cells
Eleni Thodou, Sule Canberk, Fernando Schmitt
Frontiers in Endocrinology.2021;[Epub] CrossRef
Warthin-like variant of Papillary thyroid carcinoma—Case report of an uncommon tumour with review of literature
Pradyumna Kumar Sahoo, Rashmi Patnayak, Perwez Alam Khan, Amitabh Jena
International Journal of Surgery Case Reports.2020; 77(C): 9. CrossRef

Increased Expression of Thymosin β4 Is Independently Correlated with Hypoxia Inducible Factor-1α (HIF-1α) and Worse Clinical Outcome in Human Colorectal Cancer: Seung Yun Lee, Mee Ja Park, Hye Kyung Lee, Hyun Jin Son, Chang Nam Kim, Joo Heon Kim, Dong Wook Kang; J Pathol Transl Med. 2017;51(1):9-16. Published online October 16, 2016; DOI: https://doi.org/10.4132/jptm.2016.08.23

11,998 View
163 Download
5 Web of Science
6 Crossref

Abstract PDF

Background
Thymosin β₄ is a multi-functional hormone-like polypeptide, being involved in cell migration, angiogenesis, and tumor metastasis. This study was undertaken to clarify the clinicopathologic implications of thymosin β₄ expression in human colorectal cancers (CRCs).
Methods
We investigated tissue sections from 143 patients with CRC by immunohistochemistry. In addition, we evaluated the expression patterns and the clinico-pathological significance of thymosin β₄ expression in association with hypoxia inducible factor-1α (HIF-1α) expression in the CRC series.
Results
High expression of thymosin β₄ was significantly correlated with lymphovascular invasion, invasion depth, regional lymph node metastasis, distant metastasis, and TNM stage. Patients with high expression of thymosin β₄ showed poor recurrence-free survival (p = .001) and poor overall survival (p = .005) on multivariate analysis. We also found that thymosin β₄ and HIF-1α were overexpressed and that thymosin β₄ expression increased in parallel with HIF-1α expression in CRC.
Conclusions
A high expression level of thymosin β₄ indicates poor clinical outcomes and may be a useful prognostic factor in CRC. Thymosin β₄ is functionally related with HIF-1α and may be a potentially valuable biomarker and possible therapeutic target for CRC.

Citations

Citations to this article as recorded by

Predicting the risk of lymph node metastasis in colon cancer: development and validation of an online dynamic nomogram based on multiple preoperative data
Longlian Deng, Lemuge Che, Haibin Sun, Riletu En, Bowen Ha, Tao Liu, Tengqi Wang, Qiang Xu
BMC Gastroenterology.2025;[Epub] CrossRef
Thymosin β4 Is an Endogenous Iron Chelator and Molecular Switcher of Ferroptosis
Joanna I. Lachowicz, Giusi Pichiri, Marco Piludu, Sara Fais, Germano Orrù, Terenzio Congiu, Monica Piras, Gavino Faa, Daniela Fanni, Gabriele Dalla Torre, Xabier Lopez, Kousik Chandra, Kacper Szczepski, Lukasz Jaremko, Mitra Ghosh, Abdul-Hamid Emwas, Mass
International Journal of Molecular Sciences.2022; 23(1): 551. CrossRef
Metal coordination of thymosin β4: Chemistry and possible implications
Joanna Izabela Lachowicz, Mariusz Jaremko, Lukasz Jaremko, Giuseppina Pichiri, Pierpaolo Coni, Marco Piludu
Coordination Chemistry Reviews.2019; 396: 117. CrossRef
Adipose-Derived Mesenchymal Stem Cells Enhance Ovarian Cancer Growth and Metastasis by Increasing Thymosin Beta 4X-Linked Expression
Yijing Chu, Min You, Jingjing Zhang, Guoqiang Gao, Rendong Han, Wenqiang Luo, Tingting Liu, Jianxin Zuo, Fuling Wang
Stem Cells International.2019; 2019: 1. CrossRef
An Investigation on the Therapeutic Effect of Thymosinβ4 and Its Expression Levels in Streptozotocin-Induced Diabetic Mice
Kyung Sook Cho, Dong-Jin Kim, Bomee Shim, Jung Yeon Kim, Jun Mo Kang, Seon Hwa Park, Sang-Ho Lee, Hyung-In Yang, Kyoung Soo Kim
BioMed Research International.2018; 2018: 1. CrossRef
Hypoxia-inducible factor-1α expression in colorectal carcinoma
Ahmed M. Abd ElAziz, Hanan S. Abd ElHamid, Rasha R. Mostafa, Yousra R.A. Shalaby
Egyptian Journal of Pathology.2018; 38(1): 18. CrossRef

Do Helper T Cell Subtypes in Lymphocytic Thyroiditis Play a Role in the Antitumor Effect?: Seok Woo Yang, Seong-Ho Kang, Kyung Rae Kim, In Hong Choi, Hang Seok Chang, Young Lyun Oh, Soon Won Hong; J Pathol Transl Med. 2016;50(5):377-384. Published online September 15, 2016; DOI: https://doi.org/10.4132/jptm.2016.07.25

10,011 View
108 Download
3 Web of Science
4 Crossref

Abstract PDF

Background
Papillary thyroid carcinoma (PTC) is frequently accompanied by lymphocytic thyroiditis (LT). Some reports claim that Hashimoto’s thyroiditis (the clinical form of LT) enhances the likelihood of PTC; however, others suggest that LT has antitumor activity. This study was aimed to find out the relationship between the patterns of helper T cell (Th) cytokines in thyroid tissue of PTC with or without LT and the clinicopathological manifestation of PTC.
Methods
Fresh surgical samples of PTC with (13 cases) or without (10 cases) LT were used. The prognostic parameters (tumor size, extra-thyroidal extension of PTC, and lymph node metastasis) were analyzed. The mRNA levels of two subtypes of Th cytokines, Th1 (tumor necrosis factor α [TNF-α], interferon γ [IFN-γ ], and interleukin [IL] 2) and Th2 (IL-4 and IL-10), were analyzed. Because most PTC cases were microcarcinomas and recent cases without clinical follow-up, negative or faint p27 immunoreactivity was used as a surrogate marker for lymph node metastasis.
Results
PTC with LT cases showed significantly higher expression of TNF-α (p = .043), IFN-γ (p < .010), IL-4 (p = .015) than those without LT cases. Although the data were not statistically significant, all analyzed cytokines (except for IL-4) were highly expressed in the cases with higher expression of p27 surrogate marker.
Conclusions
These results indicate that mixed Th1 (TNF-α, IFN-γ , and IL-2) and Th2 (IL-10) immunity might play a role in the antitumor effect in terms of lymph node metastasis.

Citations

Citations to this article as recorded by

Papillary thyroid carcinoma with Hashimoto’s thyroiditis: impact and correlation
Shengpeng Yao, Hong Zhang
Frontiers in Endocrinology.2025;[Epub] CrossRef
Obesity and Thyroid Cancer Risk: An Update
Fabiana Franchini, Giuseppe Palatucci, Annamaria Colao, Paola Ungaro, Paolo Emidio Macchia, Immacolata Cristina Nettore
International Journal of Environmental Research and Public Health.2022; 19(3): 1116. CrossRef
Association between Hashimoto thyroiditis and clinical outcomes of papillary thyroid carcinoma: A meta-analysis
Qizhi Tang, Weiyu Pan, Liangyue Peng, Francis Moore
PLOS ONE.2022; 17(6): e0269995. CrossRef
The Heat Shock Protein Story—From Taking mTORC1,2 and Heat Shock Protein Inhibitors as Therapeutic Measures for Treating Cancers to Development of Cancer Vaccines
Peter Chin Wan Fung, Regina Kit Chee Kong
Journal of Cancer Therapy.2017; 08(11): 962. CrossRef

Difference of the Nuclear Green Light Intensity between Papillary Carcinoma Cells Showing Clear Nuclei and Non-neoplastic Follicular Epithelia in Papillary Thyroid Carcinoma: Hyekyung Lee, Tae Hwa Baek, Meeja Park, Seung Yun Lee, Hyun Jin Son, Dong Wook Kang, Joo Heon Kim, Soo Young Kim; J Pathol Transl Med. 2016;50(5):355-360. Published online August 22, 2016; DOI: https://doi.org/10.4132/jptm.2016.05.19

8,287 View
90 Download

Abstract PDF: Background
There is subjective disagreement regarding nuclear clearing in papillary thyroid carcinoma. In this study, using digital instruments, we were able to quantify many ambiguous pathologic features and use numeric data to express our findings.
Methods
We examined 30 papillary thyroid carcinomas. For each case, we selected representative cancer cells showing clear nuclei and surrounding non-neoplastic follicular epithelial cells and evaluated objective values of green light intensity (GLI) for quantitative analysis of nuclear clearing in papillary thyroid carcinoma.
Results
From 16,274 GLI values from 600 cancer cell nuclei and 13,752 GLI values from 596 non-neoplastic follicular epithelial nuclei, we found a high correlation of 94.9% between GLI and clear nuclei. GLI between the cancer group showing clear nuclei and non-neoplastic follicular epithelia was statistically significant. The overall average level of GLI in the cancer group was over two times higher than the non-neoplastic group despite a wide range of GLI. On a polygonal line graph, there was a fluctuating unique difference between both the cancer and non-neoplastic groups in each patient, which was comparable to the microscopic findings.
Conclusions
Nuclear GLI could be a useful factor for discriminating between carcinoma cells showing clear nuclei and non-neoplastic follicular epithelia in papillary thyroid carcinoma.

Immunohistochemical Expression and Clinical Significance of Suggested Stem Cell Markers in Hepatocellular Carcinoma: Jong Jin Sung, Sang Jae Noh, Jun Sang Bae, Ho Sung Park, Kyu Yun Jang, Myoung Ja Chung, Woo Sung Moon; J Pathol Transl Med. 2016;50(1):52-57. Published online November 18, 2015; DOI: https://doi.org/10.4132/jptm.2015.10.09

11,714 View
78 Download
21 Web of Science
18 Crossref

Abstract PDF

Background
Increasing evidence has shown that tumor initiation and growth are nourished by a small subpopulation of cancer stem cells (CSCs) within the tumor mass. CSCs are posited to be responsible for tumor maintenance, growth, distant metastasis, and relapse after curative operation. We examined the expression of CSC markers in paraffin-embedded tissue sections of hepatocellular carcinoma (HCC) and correlated the results with clinicopathologic characteristics. Methods: Immunohistochemical staining for the markers believed to be expressed in the CSCs, including epithelial cell adhesion molecule (EpCAM), keratin 19 (K19), CD133, and CD56, was performed in 82 HCC specimens. Results: EpCAM expression was observed in 56% of the HCCs (46/82) and K19 in 6% (5/82). EpCAM expression in HCC significantly correlated with elevated α-fetoprotein level, microvessel invasion of tumor cells, and high histologic grade. In addition, Ep- CAM expression significantly correlated with K19 expression. The overall survival and relapsefree survival rates in patients with EpCAM-expressing HCC were relatively lower than those in patients with EpCAM-negative HCC. All but two of the 82 HCCs were negative for CD133 and CD56, respectively. Conclusions: Our results suggest that HCCs expressing EpCAM are associated with unfavorable prognostic factors and have a more aggressive clinical course than those not expressing EpCAM. Further, the expression of either CD133 or CD56 in paraffin-embedded HCC tissues appears to be rare.

Citations

Citations to this article as recorded by

Spatial immune scoring system predicts hepatocellular carcinoma recurrence
Gengjie Jia, Peiqi He, Tianli Dai, Denise Goh, Jiabei Wang, Mengyuan Sun, Felicia Wee, Fuling Li, Jeffrey Chun Tatt Lim, Shuxia Hao, Yao Liu, Tony Kiat Hon Lim, Nye-Thane Ngo, Qingping Tao, Wei Wang, Ahitsham Umar, Björn Nashan, Yongchang Zhang, Chen Ding
Nature.2025; 640(8060): 1031. CrossRef
Evolving Landscape of Systemic Therapy for Hepatocellular Carcinoma in 2025
Karan Kumar, Vivek A. Saraswat
Journal of Clinical and Experimental Hepatology.2025; 15(5): 102547. CrossRef
Recent Progress in Systemic Therapy for Advanced Hepatocellular Carcinoma
Narayanan Sadagopan, Aiwu Ruth He
International Journal of Molecular Sciences.2024; 25(2): 1259. CrossRef
Diagnostic value of expressions of cancer stem cell markers for adverse outcomes of hepatocellular carcinoma and their associations with prognosis: A Bayesian network meta‑analysis
Zhengrong Ou, Shoushuo Fu, Jian Yi, Jingxuan Huang, Weidong Zhu
Oncology Letters.2024;[Epub] CrossRef
Clinicopathological and prognostic value of epithelial cell adhesion molecule in solid tumours: a meta-analysis
Peiwen Ding, Panyu Chen, Jiqi Ouyang, Qiang Li, Shijie Li
Frontiers in Oncology.2023;[Epub] CrossRef
PD-L1 Downregulation and DNA Methylation Inhibition for Molecular Therapy against Cancer Stem Cells in Hepatocellular Carcinoma
Caecilia Sukowati, Loraine Kay D. Cabral, Beatrice Anfuso, Francesco Dituri, Roberto Negro, Gianluigi Giannelli, Claudio Tiribelli
International Journal of Molecular Sciences.2023; 24(17): 13357. CrossRef
EpCAM, Ki67, and ESM1 Predict Hepatocellular Carcinoma Recurrence After Liver Transplantation
Aiat Shaban Hemida, Doha Maher Taie, Moshira Mohamed Abd El-Wahed, Mohammed Ibrahim Shabaan, Mona Saeed Tantawy, Nermine Ahmed Ehsan
Applied Immunohistochemistry & Molecular Morphology.2023; 31(9): 596. CrossRef
The clinical, prognostic and therapeutic significance of liver cancer stem cells and their markers
Izabela Zarębska, Arkadiusz Gzil, Justyna Durślewicz, Damian Jaworski, Paulina Antosik, Navid Ahmadi, Marta Smolińska-Świtała, Dariusz Grzanka, Łukasz Szylberg
Clinics and Research in Hepatology and Gastroenterology.2021; 45(3): 101664. CrossRef
Detection of oncogenic mutations in paired circulating tumor DNA and circulating tumor cells in patients with hepatocellular carcinoma
Zhouhong Ge, Jean C.A. Helmijr, Maurice P.H.M. Jansen, Patrick P.C. Boor, Lisanne Noordam, Maikel Peppelenbosch, Jaap Kwekkeboom, Jaco Kraan, Dave Sprengers
Translational Oncology.2021; 14(7): 101073. CrossRef
Hepatocellular Carcinoma Score and Subclassification Into Aggressive Subtypes Using Immunohistochemical Expression of p53, β-Catenin, CD133, and Ki-67
Asmaa G. Abdou, Nanis S. Holah, Dina S. Elazab, Walaa G. El-Gendy, Mohammed T. Badr, Dalia R. Al-Sharaky
Applied Immunohistochemistry & Molecular Morphology.2021; 29(1): 20. CrossRef
The prognostic significance of neuroendocrine markers and somatostatin receptor 2 in hepatocellular carcinoma
Keigo Murakami, Hiroyuki Kumata, Shigehito Miyagi, Takashi Kamei, Hironobu Sasano
Pathology International.2021; 71(10): 682. CrossRef
Predictors of recurrence and survival of hepatocellular carcinoma: A prospective study including transient elastography and cancer stem cell markers
Hend Ibrahim Shousha, Rabab Fouad, Tamer Mahmoud Elbaz, Dina Sabry, Mohamed Mahmoud Nabeel, Ahmed Hosni Abdelmaksoud, Aisha Mahmoud Elsharkawy, Zeinab Abdellatif Soliman, Ghada Habib, Ashraf Omar Abdelaziz
Arab Journal of Gastroenterology.2020; 21(2): 95. CrossRef
Napabucasin Reduces Cancer Stem Cell Characteristics in Hepatocellular Carcinoma
Ya Li, Qiuju Han, Huajun Zhao, Quanjuan Guo, Jian Zhang
Frontiers in Pharmacology.2020;[Epub] CrossRef
The mRNA Distribution of Cancer Stem Cell Marker CD90/Thy-1 Is Comparable in Hepatocellular Carcinoma of Eastern and Western Populations
An B. Luong, Huy Q. Do, Paola Tarchi, Deborah Bonazza, Cristina Bottin, Loraine Kay D. Cabral, Long D. C. Tran, Thao P. T. Doan, Lory S. Crocè, Hoa L. T. Pham, Claudio Tiribelli, Caecilia H. C. Sukowati
Cells.2020; 9(12): 2672. CrossRef
Histological architectural classification determines recurrence pattern and prognosis after curative hepatectomy in patients with hepatocellular carcinoma
Hirohisa Okabe, Tomoharu Yoshizumi, Yo-ichi Yamashita, Katsunori Imai, Hiromitsu Hayashi, Shigeki Nakagawa, Shinji Itoh, Norifumi Harimoto, Toru Ikegami, Hideaki Uchiyama, Toru Beppu, Shinichi Aishima, Ken Shirabe, Hideo Baba, Yoshihiko Maehara, Motoyuki
PLOS ONE.2018; 13(9): e0203856. CrossRef
Overexpression of epithelial cell adhesion molecule as a predictor of poor outcome in patients with hepatocellular carcinoma
Chih‑Jan Ko, Chia‑Jung Li, Meng‑Yu Wu, Pei‑Yi Chu
Experimental and Therapeutic Medicine.2018;[Epub] CrossRef
Clinicopathologic Significance of Survivin Expression in Relation to CD133 Expression in Surgically Resected Stage II or III Colorectal Cancer
Wanlu Li, Mi-Ra Lee, EunHee Choi, Mee-Yon Cho
Journal of Pathology and Translational Medicine.2017; 51(1): 17. CrossRef
PIN1 in hepatocellular carcinoma is associated with TP53 gene status
Jun Sang Bae, Sang Jae Noh, Kyoung Min Kim, Kyu Yun Jang, Ho Sung Park, Myoung Ja Chung, Byung-Hyun Park, Woo Sung Moon
Oncology Reports.2016; 36(4): 2405. CrossRef

Reviews

Molecular Dimensions of Gastric Cancer: Translational and Clinical Perspectives: Yoon Young Choi, Sung Hoon Noh, Jae-Ho Cheong; J Pathol Transl Med. 2016;50(1):1-9. Published online October 26, 2015; DOI: https://doi.org/10.4132/jptm.2015.09.10

15,191 View
157 Download
21 Web of Science
22 Crossref

Abstract PDF

Gastric cancer is a global health burden and has the highest incidence in East Asia. This disease is complex in nature because it arises from multiple interactions of genetic, local environmental, and host factors, resulting in biological heterogeneity. This genetic intricacy converges on molecular characteristics reflecting the pathophysiology, tumor biology, and clinical outcome. Therefore, understanding the molecular characteristics at a genomic level is pivotal to improving the clinical care of patients with gastric cancer. A recent landmark study, The Cancer Genome Atlas (TCGA) project, showed the molecular landscape of gastric cancer through a comprehensive molecular evaluation of 295 primary gastric cancers. The proposed molecular classification divided gastric cancer into four subtypes: Epstein-Barr virus–positive, microsatellite unstable, genomic stable, and chromosomal instability. This information will be taken into account in future clinical trials and will be translated into clinical therapeutic decisions. To fully realize the clinical benefit, many challenges must be overcome. Rapid growth of high-throughput biology and functional validation of molecular targets will further deepen our knowledge of molecular dimensions of this cancer, allowing for personalized precision medicine.

Citations

Citations to this article as recorded by

Establishment and characterization of a new mouse gastric carcinoma cell line, MCC
Yushen Wang, Xianju Li, Yi Wang, Jun Qin
Cancer Cell International.2025;[Epub] CrossRef
Advancements and challenges in gastric cancer: epidemiology, biomarkers, and therapeutic strategies
Marina Nishimuni, Laura Carolina Lopez Claro, Maria Ignez Freitas Melro Braghiroli
Surgical and Experimental Pathology.2024;[Epub] CrossRef
Tissue Biomarkers in Gastric Cancer Treatment: Present and Future
Giulia Airò, Virginia Agnetti, Fabiana Pratticò, Marianna Peroni, Simona Bui, Giovanni Mura, Maria Urbanowicz-Nijaki, Eleonora Lai, Marco Puzzoni, Fabiana Contu, Nerina Denaro, Mario Scartozzi, Cinzia Solinas, Chiara Tommasi
International Journal of Translational Medicine.2024; 4(4): 640. CrossRef
Research Progress of MSI Gastric Cancer Subtypes
成菊马
Advances in Clinical Medicine.2022; 12(07): 6719. CrossRef
OCT4-mediated transcription confers oncogenic advantage for a subset of gastric tumors with poor clinical outcome
Jaishree Pandian, Ponmathi Panneerpandian, Balaji T. Sekar, Karthikeyan Selvarasu, Kumaresan Ganesan
Functional & Integrative Genomics.2022; 22(6): 1345. CrossRef
Secondary Primary Cancer after Primary Gastric Cancer: Literature Review and Big Data Analysis Using the Health Insurance Review and Assessment Service (HIRA) Database of Republic of Korea
Jeong Ho Song, Yeonkyoung Lee, Jaesung Heo, Sang-Yong Son, Hoon Hur, Sang-Uk Han
Cancers.2022; 14(24): 6165. CrossRef
Microsatellite instability: a review of what the oncologist should know
Kai Li, Haiqing Luo, Lianfang Huang, Hui Luo, Xiao Zhu
Cancer Cell International.2020;[Epub] CrossRef
Single Patient Classifier Assay, Microsatellite Instability, and Epstein-Barr Virus Status Predict Clinical Outcomes in Stage II/III Gastric Cancer: Results from CLASSIC Trial
Chul Kyu Roh, Yoon Young Choi, Seohee Choi, Won Jun Seo, Minah Cho, Eunji Jang, Taeil Son, Hyoung-Il Kim, Hyeseon Kim, Woo Jin Hyung, Yong-Min Huh, Sung Hoon Noh, Jae-Ho Cheong
Yonsei Medical Journal.2019; 60(2): 132. CrossRef
Ten Thousand Consecutive Gastrectomies for Gastric Cancer: Perspectives of a Master Surgeon
Yoon Young Choi, Minah Cho, In Gyu Kwon, Taeil Son, Hyoung-Il Kim, Seung Ho Choi, Jae-Ho Cheong, Woo Jin Hyung
Yonsei Medical Journal.2019; 60(3): 235. CrossRef
Clinicopathologic significance of human leukocyte antigen class I expression in patients with stage II and III gastric cancer
Yujun Park, Jiwon Koh, Yoonjin Kwak, Sang-Hoon Ahn, Do Joong Park, Hyung-Ho Kim, Woo Ho Kim, Hye Seung Lee
Cancer Immunology, Immunotherapy.2019; 68(11): 1779. CrossRef
Phosphoproteomics Enables Molecular Subtyping and Nomination of Kinase Candidates for Individual Patients of Diffuse-Type Gastric Cancer
Mengsha Tong, Chunyu Yu, Jinwen Shi, Wenwen Huang, Sai Ge, Mingwei Liu, Lei Song, Dongdong Zhan, Xia Xia, Wanlin Liu, Jinwen Feng, Wenhao Shi, Jiafu Ji, Jing Gao, Tieliu Shi, Weimin Zhu, Chen Ding, Yi Wang, Fuchu He, Lin Shen, Tingting Li, Jun Qin
iScience.2019; 22: 44. CrossRef
Trastuzumab Specific Epitope Evaluation as a Predictive and Prognostic Biomarker in Gastric Cancer Patients
Jiwon Koh, Soo Kyung Nam, Youn Woo Lee, Jin Won Kim, Keun-Wook Lee, Chan-Young Ock, Do-Youn Oh, Sang-Hoon Ahn, Hyung-Ho Kim, Keon-Wook Kang, Woo Ho Kim, Ho-Young Lee, Hye Seung Lee
Biomolecules.2019; 9(12): 782. CrossRef
Targeted drug delivery of capecitabine to mice xenograft gastric cancer by PAMAM dendrimer nanocarrier
Sharareh Jafari, Fatemeh Nabavizadeh, Jalal Vahedian, Mehdi Shafie Ardestani, Hedayat Samandari, Ali Zare Mehrjerdi
african journal of gastroenterology and hepatology.2019; 2(1): 28. CrossRef
New therapeutic options opened by the molecular classification of gastric cancer
Mihaela Chivu-Economescu, Lilia Matei, Laura G Necula, Denisa L Dragu, Coralia Bleotu, Carmen C Diaconu
World Journal of Gastroenterology.2018; 24(18): 1942. CrossRef
Proposed Molecular and miRNA Classification of Gastric Cancer
Lara Alessandrini, Melissa Manchi, Valli De Re, Riccardo Dolcetti, Vincenzo Canzonieri
International Journal of Molecular Sciences.2018; 19(6): 1683. CrossRef
High serum MMP-14 predicts worse survival in gastric cancer
Aaro Kasurinen, Taina Tervahartiala, Alli Laitinen, Arto Kokkola, Timo Sorsa, Camilla Böckelman, Caj Haglund, Dajun Deng
PLOS ONE.2018; 13(12): e0208800. CrossRef
miR-30 functions as an oncomiR in gastric cancer cells through regulation of P53-mediated mitochondrial apoptotic pathway
Jianjun Wang, Yang Jiao, Lunmeng Cui, Lili Jiang
Bioscience, Biotechnology, and Biochemistry.2017; 81(1): 119. CrossRef
Clinicopathologic implication of meticulous pathologic examination of regional lymph nodes in gastric cancer patients
Jiwon Koh, Hee Eun Lee, Woo Ho Kim, Hye Seung Lee, Ju-Seog Lee
PLOS ONE.2017; 12(3): e0174814. CrossRef
Perioperative chemotherapy for resectable gastric cancer – what is the evidence?
Erling A Bringeland, Hans H Wasmuth, Jon E Grønbech
Scandinavian Journal of Gastroenterology.2017; 52(6-7): 647. CrossRef
Molecular classifications of gastric cancers: Novel insights and possible future applications
Silvio Ken Garattini, Debora Basile, Monica Cattaneo, Valentina Fanotto, Elena Ongaro, Marta Bonotto, Francesca V Negri, Rosa Berenato, Paola Ermacora, Giovanni Gerardo Cardellino, Mariella Giovannoni, Nicoletta Pella, Mario Scartozzi, Lorenzo Antonuzzo,
World Journal of Gastrointestinal Oncology.2017; 9(5): 194. CrossRef
GRAM domain-containing protein 1B (GRAMD1B), a novel component of the JAK/STAT signaling pathway, functions in gastric carcinogenesis
Puja Khanna, Pei Jou Chua, Belinda Shu Ee Wong, Changhong Yin, Aye Aye Thike, Wei Keat Wan, Puay Hoon Tan, Gyeong Hun Baeg
Oncotarget.2017; 8(70): 115370. CrossRef
Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients
Jiwon Koh, Chan-Young Ock, Jin Won Kim, Soo Kyung Nam, Yoonjin Kwak, Sumi Yun, Sang-Hoon Ahn, Do Joong Park, Hyung-Ho Kim, Woo Ho Kim, Hye Seung Lee
Oncotarget.2017; 8(16): 26356. CrossRef

Genomic Landscapes of Pancreatic Neoplasia: Laura D. Wood, Ralph H. Hruban; J Pathol Transl Med. 2015;49(1):13-22. Published online January 15, 2015; DOI: https://doi.org/10.4132/jptm.2014.12.26

14,754 View
122 Download
19 Web of Science
16 Crossref

Abstract PDF

Pancreatic cancer is a deadly disease with a dismal prognosis. However, recent advances in sequencing and bioinformatic technology have led to the systematic characterization of the genomes of all major tumor types in the pancreas. This characterization has revealed the unique genomic landscape of each tumor type. This knowledge will pave the way for improved diagnostic and therapeutic approaches to pancreatic tumors that take advantage of the genetic alterations in these neoplasms.

Citations

Citations to this article as recorded by

c-Myc inhibition and p21 modulation contribute to unsymmetrical bisacridines-induced apoptosis and senescence in pancreatic cancer cells
Agnieszka Kurdyn, Monika Pawłowska, Ewa Paluszkiewicz, Mirosława Cichorek, Ewa Augustin
Pharmacological Reports.2025; 77(1): 182. CrossRef
Evaluation of the Value of Fine Needle Aspiration Cytology and Cell Morphology in Determining the Histogenesis of Pancreatic Lesions With Review of Literature, Overview and Cytological Experience of 25 Years: Original Research
Soudah Bisharah, Abbas Mahmoud
Health Science Reports.2025;[Epub] CrossRef
Research of immunotherapy in pancreatic cancer
Zetian Li, Y.-T. Yu, P.P. Piccaluga, S. Xie
BIO Web of Conferences.2024; 111: 02026. CrossRef
Pancreatoblastoma with a novel fusion gene ofIQSEC1‐RAF1
Hironori Goto, Yuhki Koga, Kenichi Kohashi, Hiroaki Ono, Junkichi Takemoto, Toshiharu Matsuura, Tatsuro Tajiri, Kenji Ihara, Yoshinao Oda, Shouichi Ohga
Pediatric Blood & Cancer.2023;[Epub] CrossRef
Imaging phenotype using 18F-fluorodeoxyglucose positron emission tomography–based radiomics and genetic alterations of pancreatic ductal adenocarcinoma
Chae Hong Lim, Young Seok Cho, Joon Young Choi, Kyung-Han Lee, Jong Kyun Lee, Ji Hye Min, Seung Hyup Hyun
European Journal of Nuclear Medicine and Molecular Imaging.2020; 47(9): 2113. CrossRef
NOSH-aspirin (NBS-1120) inhibits pancreatic cancer cell growth in a xenograft mouse model: Modulation of FoxM1, p53, NF-κB, iNOS, caspase-3 and ROS
Mitali Chattopadhyay, Ravinder Kodela, Gabriela Santiago, Thuy Tien C. Le, Niharika Nath, Khosrow Kashfi
Biochemical Pharmacology.2020; 176: 113857. CrossRef
Targeting Mutant KRAS in Pancreatic Cancer: Futile or Promising?
Friederike Inga Nollmann, Dietrich Alexander Ruess
Biomedicines.2020; 8(8): 281. CrossRef
Ancillary Techniques in Cytologic Specimens Obtained from Solid Lesions of the Pancreas: A Review
Jonas J. Heymann, Momin T. Siddiqui
Acta Cytologica.2020; 64(1-2): 103. CrossRef
DNA polymerase η mutational signatures are found in a variety of different types of cancer
Igor B. Rogozin, Alexander Goncearenco, Artem G. Lada, Subhajyoti De, Vyacheslav Yurchenko, German Nudelman, Anna R. Panchenko, David N. Cooper, Youri I. Pavlov
Cell Cycle.2018; 17(3): 348. CrossRef
Genetics of Pancreatic Neoplasms and Role of Screening
Venkata S. Katabathina, Omid Y. Rikhtehgar, Anil K. Dasyam, Rohan Manickam, Srinivasa R. Prasad
Magnetic Resonance Imaging Clinics of North America.2018; 26(3): 375. CrossRef
Team work and cytopathology molecular diagnosis of solid pancreatic lesions
Carlo Fabbri, Giulia Gibiino, Adele Fornelli, Vincenzo Cennamo, Daniela Grifoni, Michela Visani, Giorgia Acquaviva, Matteo Fassan, Sirio Fiorino, Silvia Giovanelli, Marco Bassi, Stefania Ghersi, Giovanni Tallini, Elio Jovine, Antonio Gasbarrini, Dario de
Digestive Endoscopy.2017; 29(6): 657. CrossRef
Mutational signatures and mutable motifs in cancer genomes
Igor B. Rogozin, Youri I. Pavlov, Alexander Goncearenco, Subhajyoti De, Artem G. Lada, Eugenia Poliakov, Anna R. Panchenko, David N. Cooper
Briefings in Bioinformatics.2017;[Epub] CrossRef
The evolving field of genomic biomarkers to characterize pancreatic cystic neoplasia by EUS-guided FNA
Ferga C. Gleeson, Michael J. Levy
Gastrointestinal Endoscopy.2016; 83(1): 149. CrossRef
MIA PaCa-2 and PANC-1 – pancreas ductal adenocarcinoma cell lines with neuroendocrine differentiation and somatostatin receptors
Rui Gradiz, Henriqueta C. Silva, Lina Carvalho, Maria Filomena Botelho, Anabela Mota-Pinto
Scientific Reports.2016;[Epub] CrossRef
p53 and p16/p19 Loss Promotes Different Pancreatic Tumor Types from PyMT-Expressing Progenitor Cells
Stephanie Azzopardi, Sharon Pang, David S. Klimstra, Yi-Chieh Nancy Du
Neoplasia.2016; 18(10): 610. CrossRef
MicroRNA-506 participates in pancreatic cancer pathogenesis by targeting PIM3
JUNDONG DU, XI ZHENG, SHOUWANG CAI, ZIMAN ZHU, JINGWANG TAN, BIN HU, ZHIQIANG HUANG, HUABO JIAO
Molecular Medicine Reports.2015; 12(4): 5121. CrossRef

Case Study

Recurrent Thyroid Papillary Carcinoma in Children Under Ten Years Old: Report of Two Cases and Literature Review: Byeong-Joo Noh, Ji-Youn Sung, Youn-Wha Kim, Yong-Koo Park; Korean J Pathol. 2014;48(4):297-301. Published online August 26, 2014; DOI: https://doi.org/10.4132/KoreanJPathol.2014.48.4.297

8,917 View
50 Download
1 Crossref

Abstract PDF

Papillary thyroid carcinoma (PTC) in children under ten years old is very rare. To date, 18 cases of PTC in children under ten years old (including our two cases) have been reported in Korea. Here, we describe two cases of recurrent PTC with follicular variant and conventional type in an 8-year-old boy and a 7-year-old boy, respectively, and discuss clinicopathologic and molecular characteristics that differ in pediatric patients from adults.

Citations

Citations to this article as recorded by

Extremely Well-Differentiated Papillary Thyroid Carcinoma Resembling Adenomatous Hyperplasia Can Metastasize to the Skull: A Case Report
Ju Yeon Pyo, Jisup Kim, Sung-eun Choi, Eunah Shin, Seok-Woo Yang, Cheong Soo Park, Seok-Mo Kim, SoonWon Hong
Yonsei Medical Journal.2017; 58(1): 255. CrossRef

Original Article

The Role of TWIST in Ovarian Epithelial Cancers: Kyungbin Kim, Eun Young Park, Man Soo Yoon, Dong Soo Suh, Ki Hyung Kim, Jeong Hee Lee, Dong Hoon Shin, Jee Yeon Kim, Mee Young Sol, Kyung Un Choi; Korean J Pathol. 2014;48(4):283-291. Published online August 26, 2014; DOI: https://doi.org/10.4132/KoreanJPathol.2014.48.4.283

9,492 View
42 Download
12 Crossref

Abstract PDF

Background

Epithelial-mesenchymal transition (EMT) is associated with tumor hypoxia. EMT is regulated, in part, by the action of TWIST, which inhibits of E-cadherin expression and may interfere with the p53 tumor-suppressor pathway.

Methods

We examined the expression of TWIST, E-cadherin, hypoxia-inducible factor 1α (HIF1α), and p53 by immunohistochemistry in 123 cases of ovarian epithelial cancers (OEC) to evaluate the role of TWIST in OEC. We assessed the association between protein expression and clinicopathologic parameters.

Results

The expression of TWIST, E-cadherin, HIF1α, and p53 proteins was found in 28.5%, 51.2%, 35.0%, and 29.3% of cases, respectively. TWIST expression was associated with higher histologic grade and unfavorable survival. TWIST expression was correlated with HIF1α expression and reduced E-cadherin expression. The altered HIF1α/TWIST/E-cadherin pathway was associated with lower overall survival (OS), while the co-expression of TWIST and p53 was correlated with lower progression-free survival. In the multivariate analyses, TWIST expression was an independent prognostic factor for OS.

Conclusions

Our data imply that TWIST expression could be a useful predictor of unfavorable prognosis for OEC. TWIST may affect the p53 tumor-suppressor pathway. Moreover, hypoxia-mediated EMT, which involves the HIF1α/TWIST/E-cadherin pathway may play an important role in the progression of OEC.

Citations

Citations to this article as recorded by

The Mechanism and Dynamic Regulation of Epithelial to Mesenchymal Transition in Ovarian Cancer
Pande Kadek Aditya Prayudi, I Gde Sastra Winata, I Nyoman Bayu Mahendra, I Nyoman Gede Budiana, Kade Yudi Saspriyana, Ketut Suwiyoga
Clinical and Experimental Obstetrics & Gynecology.2023;[Epub] CrossRef
E-Cadherin Expression in Relation to Clinicopathological Parameters and Survival of Patients with Epithelial Ovarian Cancer
Michal Kielbik, Izabela Szulc-Kielbik, Magdalena Klink
International Journal of Molecular Sciences.2022; 23(22): 14383. CrossRef
Oxygen sensing, mitochondrial biology and experimental therapeutics for pulmonary hypertension and cancer
Danchen Wu, Asish Dasgupta, Austin D. Read, Rachel E.T. Bentley, Mehras Motamed, Kuang-Hueih Chen, Ruaa Al-Qazazi, Jeffrey D. Mewburn, Kimberly J. Dunham-Snary, Elahe Alizadeh, Lian Tian, Stephen L. Archer
Free Radical Biology and Medicine.2021; 170: 150. CrossRef
Hypoxia-Induced Epithelial-Mesenchymal Transition in Cancers: HIF-1α and Beyond
Shing Yau Tam, Vincent W. C. Wu, Helen K. W. Law
Frontiers in Oncology.2020;[Epub] CrossRef
Expression of selected epithelial–mesenchymal transition transcription factors in serous borderline ovarian tumors and type I ovarian cancers
Pawel Sadlecki, Jakub Jóźwicki, Paulina Antosik, Marek Grabiec
Tumor Biology.2018; 40(6): 101042831878480. CrossRef
Expression and prognostic significance of epithelial-mesenchymal transition-related markers and phenotype in serous ovarian cancer
In Hye Song, Kyu-Rae Kim, Sehun Lim, Seok-Hyung Kim, Chang Ohk Sung
Pathology - Research and Practice.2018; 214(10): 1564. CrossRef
Transcription factors controlling E-cadherin down-regulation in ovarian cancer
Holly Russell, Md Zahidul Islam Pranjol
Bioscience Horizons: The International Journal of Student Research.2018;[Epub] CrossRef
Immunohistochemical expression of TWIST in oral squamous cell carcinoma and its correlation with clinicopathologic factors
Maryam Seyedmajidi, Safoura Seifi, Dariush Moslemi, Seyyedeh-Fatemeh Mozaffari, Hemmat Gholinia, Zahra Zolfaghari
Journal of Cancer Research and Therapeutics.2018; 14(5): 964. CrossRef
Activation of TWIST1 by COL11A1 promotes chemoresistance and inhibits apoptosis in ovarian cancer cells by modulating NF‐κB‐mediated IKKβ expression
Yi‐Hui Wu, Yu‐Fang Huang, Tzu‐Hao Chang, Cheng‐Yang Chou
International Journal of Cancer.2017; 141(11): 2305. CrossRef
MicroRNA-219-5p inhibits the proliferation, migration, and invasion of epithelial ovarian cancer cells by targeting the Twist/Wnt/β-catenin signaling pathway
Chunyan Wei, Xi Zhang, Sai He, Bianli Liu, Hongfang Han, Xuejun Sun
Gene.2017; 637: 25. CrossRef
Inhibition of proliferation and invasion of hepatocellular carcinoma cells by lncRNA-ASLNC02525 silencing and the mechanism
Zi Chen, Dongwen Xu, Tao Zhang
International Journal of Oncology.2017; 51(3): 851. CrossRef
Is overexpression of TWIST, a transcriptional factor, a prognostic biomarker of head and neck carcinoma? Evidence from fifteen studies
Xianlu Zhuo, Huanli Luo, Aoshuang Chang, Dairong Li, Houyu Zhao, Qi Zhou
Scientific Reports.2015;[Epub] CrossRef

Case Study

Anaplastic Transformation of Papillary Thyroid Carcinoma in a Young Man: A Case Study with Immunohistochemical and BRAF Analysis: Ji Hye Park, Hyeong Ju Kwon, Cheong Soo Park, SoonWon Hong; Korean J Pathol. 2014;48(3):234-240. Published online June 26, 2014; DOI: https://doi.org/10.4132/KoreanJPathol.2014.48.3.234

11,861 View
74 Download
7 Crossref

Abstract PDF

This study reports a case of anaplastic transformation from a well-differentiated thyroid carcinoma in a young patient. The first recurrent tissue contained poorly differentiated foci that revealed lower thyroglobulin, thyroid transcription factor 1 (TTF-1), and galectin-3 expression than the well-differentiated area. However there was no increased p53 or Ki-67 expression in the poorly differentiated foci, nor in the well-differentiated area. The tissue subsequently relapsed and revealed only anaplastic features, complete loss of thyroglobulin, TTF-1, and galectin-3 expression and revealed an increase in p53 and Ki-67 expression. The BRAF V600E and BRAF V600V mutation were found in the initially diagnosed papillary thyroid carcinoma and the poorly differentiated foci of the recurring papillary thyroid carcinoma; however, only the BRAF V600V mutation was found in the anaplastic carcinoma. These results suggest that overexpression of p53 and Ki-67 contributed to the anaplastic transformation. We also found that the BRAF type changed during the tumor relapse.

Citations

Citations to this article as recorded by

Regressed Papillary Thyroid Carcinoma with Anaplastic Transformation into Lymph Node Metastasis: Case Report with Review of the Literature
Bozidar Kovacevic, Bojana Rancic, Sasa Jovic, Snezana Cerovic, Vesna Skuletic, Jelena Karajovic, Milka Gardasevic, Gordana Supic, Kennichi Kakudo
Diagnostics.2025; 15(5): 523. CrossRef
Rare but Complex: Outcomes and Challenges in Managing Composite Follicular-Anaplastic Thyroid Cancer
Dilay Aykan, Hala al Asadi, Anjani Turaga, Lutske Lodewijk, Brendan M. Finnerty, Thomas J. Fahey, Inne H. M. Borel Rinkes, Menno R. Vriens, Rasa Zarnegar
Annals of Surgical Oncology.2025; 32(7): 4754. CrossRef
Immunomodulation exerted by galectins: a land of opportunity in rare cancers
Laura Díaz-Alvarez, Georgina I. López-Cortés, Erandi Pérez-Figueroa
Frontiers in Immunology.2023;[Epub] CrossRef
Coexisting well-differentiated and anaplastic thyroid carcinoma in the same primary resection specimen: immunophenotypic and genetic comparison of the two components in a consecutive series of 13 cases and a review of the literature
Moira Ragazzi, Federica Torricelli, Benedetta Donati, Alessia Ciarrocchi, Dario de Biase, Giovanni Tallini, Eleonora Zanetti, Alessandra Bisagni, Elisabetta Kuhn, Davide Giordano, Andrea Frasoldati, Simonetta Piana
Virchows Archiv.2021; 478(2): 265. CrossRef
HDAC Inhibition Induces PD-L1 Expression in a Novel Anaplastic Thyroid Cancer Cell Line
Luca Hegedűs, Dominika Rittler, Tamás Garay, Paul Stockhammer, Ildikó Kovács, Balázs Döme, Sarah Theurer, Thomas Hager, Thomas Herold, Stavros Kalbourtzis, Agnes Bankfalvi, Kurt W. Schmid, Dagmar Führer, Clemens Aigner, Balázs Hegedűs
Pathology & Oncology Research.2020; 26(4): 2523. CrossRef
EWSR1 rearrangement is a frequent event in papillary thyroid carcinoma and in carcinoma of the thyroid with Ewing family tumor elements (CEFTE)
G. Oliveira, A. Polónia, J. M. Cameselle-Teijeiro, D. Leitão, S. Sapia, M. Sobrinho-Simões, C. Eloy
Virchows Archiv.2017; 470(5): 517. CrossRef
Anaplastic carcinoma of the thyroid in a 12-year old girl
Rodrigo Mon, James Newlon
Journal of Pediatric Surgery Case Reports.2015; 3(9): 404. CrossRef

Original Articles

Mesenchymal Stromal Cells Promote Tumor Progression in Fibrosarcoma and Gastric Cancer Cells: Byunghoo Song, Bokyung Kim, Se-Ha Choi, Kyo Young Song, Yang-Guk Chung, Youn-Soo Lee, Gyeongsin Park; Korean J Pathol. 2014;48(3):217-224. Published online June 26, 2014; DOI: https://doi.org/10.4132/KoreanJPathol.2014.48.3.217

9,555 View
57 Download
8 Crossref

Abstract PDF

Background

Extensive evidence has accumulated regarding the role of mesenchymal stromal cells (MSCs) in tumor progression, but the exact effects and mechanisms underlying this role remain unclear. We investigated the effects of MSC-associated tumor progression in MSC-sarcoma models and a gastric cancer metastatic model.

Methods

We conducted an in vitro growth kinetics assay and an in vivo tumor progression assay for sarcoma cells and gastric cancer cells in the presence or absence of MSCs.

Results

MSC-cocultured human fibrosarcoma cells (HT1080) showed accelerated growth compared with HT1080 alone (79- vs 37-fold change, p<.050). For HT1080, human MSC-coinjected tumors showed significantly greater and highly infiltrative growth compared to those of HT1080 alone (p=.035). For mouse fibrosarcoma cells (WEHI164), mouse MSC-coinjected tumors had greater volume than those of WEHI164 alone (p=.141). For rat sarcoma cells (RR1022), rat MSC-coinjected tumors exhibited greater volume and infiltrative growth than those of RR1022 alone (p=.050). For human gastric cancer cells (5FU), tumors of 5FU alone were compact, nodular in shape, and expansile with good demarcation and no definite lung metastatic nodules, whereas tumors grown in the presence of human MSCs showed highly desmoplastic and infiltrative growth and multiple lung metastasis.

Conclusions

We observed morphological evidence for MSC-associated tumor progression of fibrosarcomas and gastric cancer cells.

Citations

Citations to this article as recorded by

Transition between canonical to non-canonical Wnt signaling during interactions between mesenchymal stem cells and osteosarcomas
Asulin Masha, Ghedalia-Peled Noa Ben, Erez Ifat Cohen, Ventura Yvonne, Vago Razi
Open Journal of Orthopedics and Rheumatology.2020; : 037. CrossRef
Mesenchymal stem-cell therapy for perianal fistulas in Crohn’s disease: a systematic review and meta-analysis
F. Cheng, Z. Huang, Z. Li
Techniques in Coloproctology.2019; 23(7): 613. CrossRef
Human mesenchymal stromal cells do not promote recurrence of soft tissue sarcomas in mouse xenografts after radiation and surgery
PAOLA A. FILOMENO, KYUNG-PHIL KIM, NARA YOON, IRAN RASHEDI, VICTOR DAYAN, RITA A. KANDEL, XING-HUA WANG, TANIA C. FELIZARDO, ELLIOT BERINSTEIN, SALOMEH JELVEH, ANDREA FILOMENO, JEFFREY A. MEDIN, PETER C. FERGUSON, ARMAND KEATING
Cytotherapy.2018; 20(8): 1001. CrossRef
Review article: mesenchymal stromal cell therapy for inflammatory bowel diseases
C. Grégoire, C. Lechanteur, A. Briquet, É. Baudoux, F. Baron, E. Louis, Y. Beguin
Alimentary Pharmacology & Therapeutics.2017; 45(2): 205. CrossRef
Effect of hGC-MSCs from human gastric cancer tissue on cell proliferation, invasion and epithelial-mesenchymal transition in tumor tissue of gastric cancer tumor-bearing mice
Lin Song, Xin Zhou, Hong-Jun Jia, Mei Du, Jin-Ling Zhang, Liang Li
Asian Pacific Journal of Tropical Medicine.2016; 9(8): 796. CrossRef
BMP9 inhibits the growth and migration of lung adenocarcinoma A549 cells in a bone marrow stromal cell-derived microenvironment through the MAPK/ERK and NF-κB pathways
JING WANG, YAGUANG WENG, MINGHAO ZHANG, YA LI, MENGTIAN FAN, YANGLIU GUO, YANTING SUN, WANG LI, QIONG SHI
Oncology Reports.2016; 36(1): 410. CrossRef
Comparative proteomic analysis of fibrosarcoma and skin fibroblast cell lines
Ogunc Meral, Hamdi Uysal
Tumor Biology.2015; 36(2): 561. CrossRef
Involvement of Wnt/β-catenin signaling in the mesenchymal stem cells promote metastatic growth and chemoresistance of cholangiocarcinoma
Weiwei Wang, Wei Zhong, Jiahui Yuan, Congcong Yan, Shaoping Hu, Yinping Tong, Yubin Mao, Tianhui Hu, Bing Zhang, Gang Song
Oncotarget.2015; 6(39): 42276. CrossRef

Tumor Sprouting in Papillary Thyroid Carcinoma Is Correlated with Lymph Node Metastasis and Recurrence: Eunjung Lee, Wonkyung Jung, Jeong-Soo Woo, Jae Bok Lee, Bong Kyung Shin, Han Kyeom Kim, Aeree Kim, Baek-hui Kim; Korean J Pathol. 2014;48(2):117-125. Published online April 28, 2014; DOI: https://doi.org/10.4132/KoreanJPathol.2014.48.2.117

13,085 View
68 Download
8 Crossref

Abstract PDF

Background

Identification of poor prognostic factors in papillary thyroid carcinoma (PTC) patients is important for the patients' care and follow-up. We can sometimes see small tumor clusters without desmoplasia and no evidence of lymphatic emboli around the main tumor mass of PTC. We termed this form of tumor clustering, 'tumor sprouting,' and determined whether these tumors correlate with lymphovascular invasion, lymph node metastasis, and recurrence.

Methods

We analyzed a total of 204 cases of papillary thyroid macrocarcinoma. Number, size and distance from the main tumor of the tumor sprouting were observed and analyzed with clinicopathologic characteristics.

Results

Tumor sprouting was observed in 101 patients. Presence of tumor sprouting was significantly associated with positive resection margin (p=.002), lymphovascular invasion (p=.001), lymph node metastasis (p<.001), and recurrence (p=.004). Univariate analysis of recurrence-free survival revealed that tumor multiplicity (p=.037), positive resection margin (p=.007), lymphovascular invasion (p=.004), lymph node metastasis (p<.001), and tumor sprouting (p=.004) were poor prognostic factors. In multivariate analysis, positive resection margin was an independent poor prognostic factor of recurrence.

Conclusions

In conclusion, tumor sprouting is significantly correlated with lymph node metastasis and recurrence. Evaluation of tumor sprouting in PTC patients could be helpful in predicting tumor recurrence or lymph node metastasis.

Citations

Citations to this article as recorded by

The Initial Risk Stratification System for Differentiated Thyroid Cancer: Key Updates in the 2024 Korean Thyroid Association Guideline
Shinje Moon, Young Shin Song, Kyong Yeun Jung, Eun Kyung Lee, Jeongmin Lee, Dong-Jun Lim, Chan Kwon Jung, Young Joo Park
Endocrinology and Metabolism.2025; 40(3): 357. CrossRef
Korean Thyroid Association Guidelines on the Management of Differentiated Thyroid Cancers; Part I. Initial Management of Differentiated Thyroid Cancers - Chapter 5. Evaluation of Recurrence Risk Postoperatively and Initial Risk Stratification in Different
Eun Kyung Lee, Young Shin Song, Ho-Cheol Kang, Sun Wook Kim, Dong Gyu Na, Shin Je Moon, Dong-Jun Lim, Kyong Yeun Jung, Yun Jae Chung, Chan Kwon Jung, Young Joo Park
International Journal of Thyroidology.2024; 17(1): 68. CrossRef
Significance of Lymphovascular Invasion as a Prognostic Factor in Patients with Papillary Thyroid Cancer: a Systematic Review and Meta-Analysis
Ho-Ryun Won, Bon Seok Koo
International Journal of Thyroidology.2023; 16(2): 157. CrossRef
Peripheral Versus Intraparenchymal Papillary Thyroid Microcarcinoma: Different Morphologies and PD-L1 Expression
Bozidar Kovacevic, Dragana Vucevic, Snezana Cerovic, Catarina Eloy
Head and Neck Pathology.2022; 16(1): 200. CrossRef
Lymphovascular invasion and risk of recurrence in papillary thyroid carcinoma
Katy Wagner, Earl Abraham, Bryan Tran, David Roshan, James Wykes, Peter Campbell, Ardalan Ebrahimi
ANZ Journal of Surgery.2020; 90(9): 1727. CrossRef
The Predictors of Multicentricity in Well-Differentiated Thyroid Cancer
Mohamed Hegazi, Waleed El Nahas, Mohamed Elmetwally, Amr Hassan, Waleed Gado , Islam Abdou, Ahmed Senbel, Mohamed Samir Abou-Sheishaa
Journal of Analytical Oncology.2018; 7(4): 65. CrossRef
Prognostic impact of vascular invasion in differentiated thyroid carcinoma: a systematic review and meta-analysis
Huy Gia Vuong, Tetsuo Kondo, Uyen N P Duong, Thong Quang Pham, Naoki Oishi, Kunio Mochizuki, Tadao Nakazawa, Lewis Hassell, Ryohei Katoh
European Journal of Endocrinology.2017; 177(2): 207. CrossRef
Detection of Tumor Multifocality Is Important for Prediction of Tumor Recurrence in Papillary Thyroid Microcarcinoma: A Retrospective Study and Meta-Analysis
Jung-Soo Pyo, Jin Hee Sohn, Guhyun Kang
Journal of Pathology and Translational Medicine.2016; 50(4): 278. CrossRef

P2X₇ Receptor Expression in Coexistence of Papillary Thyroid Carcinoma with Hashimoto's Thyroiditis: Ji Hyun Kwon, Eun Sook Nam, Hyung Sik Shin, Seong Jin Cho, Hye Rim Park, Mi Jung Kwon; Korean J Pathol. 2014;48(1):30-35. Published online February 25, 2014; DOI: https://doi.org/10.4132/KoreanJPathol.2014.48.1.30

11,144 View
56 Download
21 Crossref

Abstract PDF

Background

This study was aimed at investigating the relation of P2X₇ receptor (P2X₇R) expression with the clinicopathological features of papillary thyroid carcinoma (PTC) coexisting with Hashimoto's thyroiditis (HT).

Methods

We examined 170 patients (84, PTC with HT; 86, PTC without HT). P2X₇R expression was examined by immunohistochemical methods. The staining intensity and patterns were evaluated and scored using a semi-quantitative method.

Results

The PTC with HT group was more likely to contain women and had less extrathyroid extension, lymph node (LN) metastasis, lymphovascular invasion, and recurrence than the PTC without HT group. Patients positive for P2X₇R had significantly higher frequencies of lymphovascular invasion, extrathyroid extension, LN metastasis, and absence of HT. As shown by multivariate analysis, the expression of P2X₇R was significantly higher if HT was absent and extrathyroid extension was present. In the PTC with HT group, the expression of P2X₇R was significantly higher in patients with tumor multifocality, lymphovascular invasion, and extrathyroid extension. In the PTC without HT group, the expression of P2X₇R was significantly higher in women and those having tumor multifocality.

Conclusions

Coexistence of PTC with HT is associated with good prognostic factors, and P2X₇R expression in PTC was correlated with poor prognostic factors and the absence of HT.

Citations

Citations to this article as recorded by

Research Progress in the Relationship Between P2X7R and Cervical Cancer
Yiqing Tang, Cuicui Qiao, Qianqian Li, Xiaodi Zhu, Ronglan Zhao, Xiaoxiang Peng
Reproductive Sciences.2023; 30(3): 823. CrossRef
Warthin-like papillary thyroid carcinoma: a case report and comprehensive review of the literature
Abdel Mouhaymen Missaoui, Fatma Hamza, Wafa Belabed, Manel Mellouli, Mohamed Maaloul, Slim Charfi, Issam Jardak, Tahya Sellami-Boudawara, Nabila Rekik, Mohamed Abid
Frontiers in Endocrinology.2023;[Epub] CrossRef
Mapping the path towards novel treatment strategies: a bibliometric analysis of Hashimoto’s thyroiditis research from 1990 to 2023
Manping Guo, Qingna Li, Xingfang Liu, Yiming Wang, Qiaoning Yang, Rui Li, Yang Zhao, Chenfei Li, Song Sheng, Hangkun Ma, Zhenghong Li, Rui Gao
Frontiers in Endocrinology.2023;[Epub] CrossRef
Association between Hashimoto thyroiditis and clinical outcomes of papillary thyroid carcinoma: A meta-analysis
Qizhi Tang, Weiyu Pan, Liangyue Peng, Francis Moore
PLOS ONE.2022; 17(6): e0269995. CrossRef
Hashimoto’s Thyroiditis Minimizes Lymph Node Metastasis in BRAF Mutant Papillary Thyroid Carcinomas
Peter P. Issa, Mahmoud Omar, Yusef Buti, Chad P. Issa, Bert Chabot, Christopher J. Carnabatu, Ruhul Munshi, Mohammad Hussein, Mohamed Aboueisha, Mohamed Shama, Ralph L. Corsetti, Eman Toraih, Emad Kandil
Biomedicines.2022; 10(8): 2051. CrossRef
Overexpression of PD-L1 in Papillary Carcinoma and Its Association with Clinicopathological Variables
Servet KOCAÖZ, Gülay TURAN
Düzce Tıp Fakültesi Dergisi.2021; 23(3): 252. CrossRef
Effect of P2X7 receptor on tumorigenesis and its pharmacological properties
Wen-jun Zhang, Ce-gui Hu, Zheng-ming Zhu, Hong-liang Luo
Biomedicine & Pharmacotherapy.2020; 125: 109844. CrossRef
P2X7 in Cancer: From Molecular Mechanisms to Therapeutics
Romain Lara, Elena Adinolfi, Catherine A. Harwood, Mike Philpott, Julian A. Barden, Francesco Di Virgilio, Shaun McNulty
Frontiers in Pharmacology.2020;[Epub] CrossRef
The P2X7 Receptor in Inflammatory Diseases: Angel or Demon?
Luiz E. B. Savio, Paola de Andrade Mello, Cleide Gonçalves da Silva, Robson Coutinho-Silva
Frontiers in Pharmacology.2018;[Epub] CrossRef
Patients with Oncocytic Variant Papillary Thyroid Carcinoma Have a Similar Prognosis to Matched Classical Papillary Thyroid Carcinoma Controls
Azadeh A. Carr, Tina W.F. Yen, Diana I. Ortiz, Bryan C. Hunt, Gilbert Fareau, Becky L. Massey, Bruce H. Campbell, Kara L. Doffek, Douglas B. Evans, Tracy S. Wang
Thyroid.2018; 28(11): 1462. CrossRef
Extracellular purines, purinergic receptors and tumor growth
F Di Virgilio, E Adinolfi
Oncogene.2017; 36(3): 293. CrossRef
Multifaceted Effects of Extracellular Adenosine Triphosphate and Adenosine in the Tumor–Host Interaction and Therapeutic Perspectives
Paola de Andrade Mello, Robson Coutinho-Silva, Luiz Eduardo Baggio Savio
Frontiers in Immunology.2017;[Epub] CrossRef
Potential role of P2X7R in esophageal squamous cell carcinoma proliferation
André A Santos, Angélica R Cappellari, Fernanda O de Marchi, Marina P Gehring, Aline Zaparte, Caroline A Brandão, Tiago Giuliani Lopes, Vinicius D da Silva, Luis Felipe Ribeiro Pinto, Luiz Eduardo Baggio Savio, Aline Cristina Abreu Moreira-Souza, Robson C
Purinergic Signalling.2017; 13(3): 279. CrossRef
Potential relationship between Hashimoto's thyroiditis and BRAFV600E mutation status in papillary thyroid cancer
Rui‐chao Zeng, Lang‐ping Jin, En‐dong Chen, Si‐yang Dong, Ye‐feng Cai, Guan‐li Huang, Quan Li, Chun Jin, Xiao‐hua Zhang, Ou‐chen Wang
Head & Neck.2016;[Epub] CrossRef
Papillary thyroid carcinoma in Hashimoto’s thyroiditis as an incidental finding
Al Mogrampi Saad, A. Krexi, N. Papoulidis, M. Verroiotou, D. Michalakis, I. Fardellas
Hellenic Journal of Surgery.2016; 88(1): 47. CrossRef
Association of Hashimoto's thyroiditis and thyroid cancer
Salem I. Noureldine, Ralph P. Tufano
Current Opinion in Oncology.2015; 27(1): 21. CrossRef
Cribriform-morular variant of papillary thyroid carcinoma: a study of 3 cases featuring the PIK3CA mutation
Mi Jung Kwon, Young-Soo Rho, Jin Cheol Jeong, Hyung Sik Shin, Jong Seok Lee, Seong Jin Cho, Eun Sook Nam
Human Pathology.2015; 46(8): 1180. CrossRef
Understanding the roles of the P2X7 receptor in solid tumour progression and therapeutic perspectives
Sébastien Roger, Bilel Jelassi, Isabelle Couillin, Pablo Pelegrin, Pierre Besson, Lin-Hua Jiang
Biochimica et Biophysica Acta (BBA) - Biomembranes.2015; 1848(10): 2584. CrossRef
Purinergic signaling pathways in endocrine system
Ivana Bjelobaba, Marija M. Janjic, Stanko S. Stojilkovic
Autonomic Neuroscience.2015; 191: 102. CrossRef
P2X7 receptor stimulates breast cancer cell invasion and migration via the AKT pathway
JIYI XIA, XIAOLAN YU, LI TANG, GANG LI, TAO HE
Oncology Reports.2015; 34(1): 103. CrossRef
Regulation of the P2X7R by microRNA-216b in human breast cancer
Luming Zheng, Xukui Zhang, Feng Yang, Jian Zhu, Peng Zhou, Fang Yu, Lei Hou, Lei Xiao, Qingqing He, Baocheng Wang
Biochemical and Biophysical Research Communications.2014; 452(1): 197. CrossRef

A Different Perspective on Macroscopic Sampling of Cholecystectomy Specimens: Asuman Argon, Ayşe Yağcı, Funda Taşlı, Tulu Kebat, Senem Deniz, Nazif Erkan, Gül Kitapçıoğlu, Enver Vardar; Korean J Pathol. 2013;47(6):519-525. Published online December 24, 2013; DOI: https://doi.org/10.4132/KoreanJPathol.2013.47.6.519

9,363 View
71 Download
8 Crossref

Abstract PDF

Background

Because there may be interdepartmental differences in macroscopic sampling of cholecystectomy specimens, we aimed to investigate differences between the longitudinal sampling technique and our classical sampling technique in cholecystectomy specimens in which there was no obvious malignancy.

Methods

Six hundred eight cholecystectomy specimens that were collected between 2011 and 2012 were included in this study. The first group included 273 specimens for which one sample was taken from each of the fundus, body, and neck regions (our classical technique). The second group included 335 specimens for which samples taken from the neck region and lengthwise from the fundus toward the neck were placed together in one cassette (longitudinal sampling). The Pearson chi-square, Fisher exact, and ANOVA tests were used and differences were considered significant at p<.05.

Results

In the statistical analysis, although gallbladders in the first group were bigger, the average length of the samples taken in the second group was greater. Inflammatory cells, pyloric metaplasia, intestinal metaplasia, low grade dysplasia, and invasive carcinoma were seen more often in the second group.

Conclusions

In our study, the use of a longitudinal sampling technique enabled us to examine a longer mucosa and to detect more mucosal lesions than did our classical technique. Thus, longitudinal sampling can be an effective technique in detecting preinvasive lesions.

Citations

Citations to this article as recorded by

Differentiating Neoplastic From Non-neoplastic Gallbladder Lesions Using MUC1 and MUC5AC: An Immunohistochemical Analysis
Umika Gupta, Vijai Singh, Sanjeev Yadav
Cureus.2025;[Epub] CrossRef
Cholecystectomy in children: indications, clinical, laboratory and histopathological findings and cost analysis
Aysel Ünlüsoy Aksu, Nebiyye Genel, Gülseren Şahin, Ferda Özbay Hoşnut, Ayşegül Tok, Ayşe Karaman
The Turkish Journal of Pediatrics.2024; 66(4): 473. CrossRef
Ultrasonographic features of gallbladder wall thickening in dogs with hypoalbuminemia
Masahiro Murakami, Hock Gan Heng, Sarah Steinbach, Mario Sola
Veterinary Quarterly.2023; 43(1): 1. CrossRef
Can the sampling method affect the detection of incidental gallbladder carcinoma? Comparative analysis of two sampling methods
Ezgi Hacihasanoglu, Esra Pasaoglu, Merve Cin, Enver Yarikkaya, Nevra Dursun, Sevim Baykal Koca
Annals of Diagnostic Pathology.2023; 67: 152187. CrossRef
Current management of incidental gallbladder cancer: A review
Claudio F. Feo, Giorgio C. Ginesu, Alessandro Fancellu, Teresa Perra, Chiara Ninniri, Giulia Deiana, Antonio M. Scanu, Alberto Porcu
International Journal of Surgery.2022; 98: 106234. CrossRef
Accuracy of Right Upper Quadrant Ultrasound in Estimating Gallbladder Wall Thickness
Lindsay Cefalu, Robert McMurray, Grant Sizemore, Gerald Bieniek, Michael Lustik, Christopher Yheulon
Surgical Laparoscopy, Endoscopy & Percutaneous Techniques.2019; 29(1): 26. CrossRef
Optimal block sampling of routine, non‐tumorous gallbladders
Newton A C S Wong
Histopathology.2017; 71(1): 162. CrossRef
The Relationship Between Intracholecystic Papillary-Tubular Neoplasms and Invasive Carcinoma of the Gallbladder
Asuman Argon, Funda Yılmaz Barbet, Deniz Nart
International Journal of Surgical Pathology.2016; 24(6): 504. CrossRef

Endogenous Gastric-Resident Mesenchymal Stem Cells Contribute to Formation of Cancer Stroma and Progression of Gastric Cancer: Eun-Kyung Kim, Hye-Jung Kim, Young-Il Yang, Jong Tae Kim, Min-Young Choi, Chang Soo Choi, Kwang-Hee Kim, Jeong-Han Lee, Won-Hee Jang, Soon-Ho Cheong; Korean J Pathol. 2013;47(6):507-518. Published online December 24, 2013; DOI: https://doi.org/10.4132/KoreanJPathol.2013.47.6.507

10,230 View
53 Download
17 Crossref

Abstract PDF

Background

Carcinoma-associated fibroblasts (CAFs) contribute to carcinogenesis and cancer progression, although their origin and role remain unclear. We recently identified and investigated the in situ identity and implications of gastric submucosa-resident mesenchymal stem cells (GS-MSCs) in the progression of gastric carcinogenesis.

Methods

We isolated GS-MSCs from gastric submucosa using hydrogel-supported organ culture and defined their identity. Isolated cells were assessed in vitro by immunophenotype and mesengenic multipotency. Reciprocal interactions between GS-MSCs and gastric cancer cells were evaluated. To determine the role of GS-MSCs, xenografts were constructed of gastric cancer cells admixed with or without GS-MSCs.

Results

Isolated cells fulfilled MSCs requirements in regard to plastic adherence, stromal cell immunophenotype, and multipotency. We demonstrated a paracrine loop that gastric cancer cells enhanced the migration, proliferation, and differentiation of GS-MSCs; additionally, GS-MSCs promoted the proliferation of gastric cancer cell in vitro. Xenograft experiments showed that GS-MSCs significantly promoted cancer growth and angiogenesis. GS-MSCs that integrated into gastric cancer became not only CAFs but also rarely endothelial cells which contributed to the formation of cellular and vascular cancer stroma.

Conclusions

Endogenous GS-MSCs play an important role in gastric cancer progression.

Citations

Citations to this article as recorded by

The therapeutic potential of mesenchymal stem cells in intestinal diseases: from mechanisms to clinical translation
Jia-Zhi Yang, Li-Yan He, Xian-Zhou Lu
Stem Cell Research & Therapy.2025;[Epub] CrossRef
Gastric cancer and mesenchymal stem cell-derived exosomes: from pro-tumorigenic effects to anti-cancer vehicles
Maryam Dolatshahi, Ahmad Reza Bahrami, Qaiser Iftikhar Sheikh, Mohsen Ghanbari, Maryam M. Matin
Archives of Pharmacal Research.2024; 47(1): 1. CrossRef
Extracellular vesicles derived from SARS-CoV-2 M-protein-induced triple negative breast cancer cells promoted the ability of tissue stem cells supporting cancer progression
Hoai-Nga Thi Nguyen, Cat-Khanh Vuong, Mizuho Fukushige, Momoko Usuda, Liora Kaho Takagi, Toshiharu Yamashita, Mana Obata-Yasuoka, Hiromi Hamada, Motoo Osaka, Toru Tsukada, Yuji Hiramatsu, Osamu Ohneda
Frontiers in Oncology.2024;[Epub] CrossRef
Revisiting the role of mesenchymal stromal cells in cancer initiation, metastasis and immunosuppression
Yanyan Zhang, Charles Wang, Jian Jian Li
Experimental Hematology & Oncology.2024;[Epub] CrossRef
Mesenchymal stem cells and their potential therapeutic benefits and challenges in the treatment and pathogenesis of gastric cancer
Asma'a H. Mohamed, Alaa Shafie, Waleed Al Abdulmonem, Hassan Swed Alzahrani, Amal Adnan Ashour, Ahmed Hjazi, Azfar Jamal, Allolo D. Aldreiwish, Mohammad Azhar Kamal, Fuzail Ahmad, Nazia Khan
Pathology - Research and Practice.2024; 260: 155422. CrossRef
Cancer-associated fibroblasts promote proliferation, angiogenesis, metastasis and immunosuppression in gastric cancer
Peiyuan Li, Huan Zhang, Tao Chen, Yajing Zhou, Jiaoyang Yang, Jin Zhou
Matrix Biology.2024; 132: 59. CrossRef
Mesenchymal Stem Cell-Derived Exosomes Modulate Angiogenesis in Gastric Cancer
Fawzy Akad, Veronica Mocanu, Sorin Nicolae Peiu, Viorel Scripcariu, Bogdan Filip, Daniel Timofte, Florin Zugun-Eloae, Magdalena Cuciureanu, Monica Hancianu, Teodor Oboroceanu, Laura Condur, Radu Florin Popa
Biomedicines.2023; 11(4): 1031. CrossRef
LRRC15 expression indicates high level of stemness regulated by TWIST1 in mesenchymal stem cells
Kensuke Toriumi, Yuta Onodera, Toshiyuki Takehara, Tatsufumi Mori, Joe Hasei, Kanae Shigi, Natsumi Iwawaki, Toshifumi Ozaki, Masao Akagi, Mahito Nakanishi, Takeshi Teramura
iScience.2023; 26(7): 106946. CrossRef
Rat Adipose-Derived Stromal Cells (ADSCs) Increases the Glioblastoma Growth and Decreases the Animal Survival
Isabele Cristiana Iser, Liziane Raquel Beckenkamp, Juliana Hofstatter Azambuja, Francine Luciano Rahmeier, Paula Andreghetto Bracco, Ana Paula Santin Bertoni, Rita de Cássia Sant’Anna Alves, Elizandra Braganhol, Léder Leal Xavier, Marilda da Cruz Fernande
Stem Cell Reviews and Reports.2022; 18(4): 1495. CrossRef
Mesenchymal/stromal stem cells: necessary factors in tumour progression
Xinyu Li, Qing Fan, Xueqiang Peng, Shuo Yang, Shibo Wei, Jingang Liu, Liang Yang, Hangyu Li
Cell Death Discovery.2022;[Epub] CrossRef
Mesenchymal stromal cells in cancer: a review of their immunomodulatory functions and dual effects on tumor progression
Sabine Galland, Ivan Stamenkovic
The Journal of Pathology.2020; 250(5): 555. CrossRef
A highly efficient non-viral process for programming mesenchymal stem cells for gene directed enzyme prodrug cancer therapy
Yoon Khei Ho, Jun Yung Woo, Geraldine Xue En Tu, Lih-Wen Deng, Heng-Phon Too
Scientific Reports.2020;[Epub] CrossRef
Fruit-Derived Polysaccharides and Terpenoids: Recent Update on the Gastroprotective Effects and Mechanisms
Mohammed Safwan Ali Khan, Syeda Umme Kulsoom Khundmiri, Syeda Rukhaiya Khundmiri, Mohammad M. Al-Sanea, Pooi Ling Mok
Frontiers in Pharmacology.2018;[Epub] CrossRef
Gastric cancer mesenchymal stem cells derived IL-8 induces PD-L1 expression in gastric cancer cells via STAT3/mTOR-c-Myc signal axis
Li Sun, Qianqian Wang, Bin Chen, Yuanyuan Zhao, Bo Shen, Hua Wang, Jing Xu, Miaolin Zhu, Xiangdong Zhao, Changgen Xu, Zhihong Chen, Mei Wang, Wenrong Xu, Wei Zhu
Cell Death & Disease.2018;[Epub] CrossRef
Mesenchymal stem cells: key players in cancer progression
Sarah M. Ridge, Francis J. Sullivan, Sharon A. Glynn
Molecular Cancer.2017;[Epub] CrossRef
Gastric cancer-derived mesenchymal stem cells prompt gastric cancer progression through secretion of interleukin-8
Wei Li, Ying Zhou, Jin Yang, Xu Zhang, Huanhuan Zhang, Ting Zhang, Shaolin Zhao, Ping Zheng, Juan Huo, Huiyi Wu
Journal of Experimental & Clinical Cancer Research.2015;[Epub] CrossRef
Mesenchymal stem cells – A new hope for radiotherapy-induced tissue damage?
Nils H. Nicolay, Ramon Lopez Perez, Juergen Debus, Peter E. Huber
Cancer Letters.2015; 366(2): 133. CrossRef

Case Study

Papillary Carcinoma of the Thyroid Gland with Nodular Fasciitis-like Stroma: Ki Yong Na, Hyun-Soo Kim, Ji-Youn Sung, Won Seo Park, Youn Wha Kim; Korean J Pathol. 2013;47(2):167-171. Published online April 24, 2013; DOI: https://doi.org/10.4132/KoreanJPathol.2013.47.2.167

10,319 View
53 Download
13 Crossref

Abstract PDF

Papillary thyroid carcinoma with nodular fasciitis-like stroma (PTC-NFS) is a rare variant of PTC. The term 'PTC with fibromatosis-like stroma' has been used as a synonym to describe this variant. It is characterized by extensive proliferation of fibroblasts and myofibroblasts in the tumor stroma, which occurs in up to 80% of the tumors. We herein describe a case of PTC-NFS which developed in a 49-year-old woman with the demonstration of findings of ultrasonography, fine needle aspiration cytology and histological examination of the lesion. To characterize the stromal components, we investigated the expression of several immunohistochemical markers which have been shown to be expressed differently in nodular fasciitis (NF) and fibromatosis (FM). The immunostaining results demonstrated nuclear and cytoplasmic accumulation of β-catenin, cytoplasmic transforming growth factor-β expression and nuclear Smad expression in the stromal cells, suggesting that the stromal cells in this case have similar molecular profiles to those of FM rather than NF.

Citations

Citations to this article as recorded by

Papillary thyroid carcinoma with nodular fasciitis-like stroma: An intriguing encounter
Pranjal Kalita, Biswajit Dey, Vandana Raphael, Gauranga Handique, Sungjemla Longkumer, Nikhil Choudhary
Thyroid Research and Practice.2025; 21(1): 41. CrossRef
Comparative Evaluation of Machine Learning Algorithms with Data Balancing Approach and Hyperparameter Tuning in Predicting Thyroid Disorder Recurrence
Darnell Ignasius, Rhyan David Levandra, Ramadhan Rakhmat Sani, Ika Novita Dewi
Jurnal Masyarakat Informatika.2025; 16(2): 284. CrossRef
Papillary thyroid carcinoma with desmoid-type fibromatosis: the clinicopathological features with characteristic imaging and molecular correlation requiring comprehensive treatment
Haining Huang, Lei Li, Xiaolong Liu, Lihua Zhao, Zhihong Cui, Renya Zhang, Shuai Chen
Human Pathology.2023; 136: 84. CrossRef
Papillary Thyroid Carcinoma with Desmoid-Type Fibromatosis: Review of Published Cases
Abdallah Roukain, Stefano La Rosa, Massimo Bongiovanni, Marie Nicod Lalonde, Valérie Cristina, Michael Montemurro, Stephane Cochet, Alexandra Luquain, Peter A. Kopp, Gerasimos P. Sykiotis
Cancers.2021; 13(17): 4482. CrossRef
Case of medullary thyroid carcinoma with desmoid‐type fibromatosis
Yoon Ah Cho, Young Lyun Oh
Pathology International.2020; 70(6): 364. CrossRef
SOX11 expression in a case of papillary thyroid carcinoma with fibromatosis/fasciitis-like stroma containing BRAF c.1799_1801delTGA and CTNNB1 c.133T>C mutations
Soon Boon Justin Wong, Min En Nga, Michal Michal, Tomas Vanecek, Ju Ee Seet, Fredrik Petersson
Virchows Archiv.2019; 475(4): 519. CrossRef
Papillary thyroid cancer with extrathyroidal extension of desmoid-type fibromatosis. A case report of an aggressive presentation of an uncommon pathologic entity
Eve M. Roth, Courtney E. Barrows, Michiya Nishino, Barry Sacks, Per-Olof Hasselgren, Benjamin C. James
International Journal of Surgery Case Reports.2019; 63(C): 5. CrossRef
Papillary thyroid carcinoma with nodular fasciitis-like stroma and β-catenin mutations should be renamed papillary thyroid carcinoma with desmoid-type fibromatosis
Caterina Rebecchini, Antoine Nobile, Simonetta Piana, Rossella Sarro, Bettina Bisig, Sykiotis P Gerasimos, Chiara Saglietti, Maurice Matter, Laura Marino, Massimo Bongiovanni
Modern Pathology.2017; 30(2): 236. CrossRef
Papillary thyroid carcinoma with desmoid-type fibromatosis: A clinical, pathological, and immunohistochemical study of 14 cases
Nami Takada, Mitsuyoshi Hirokawa, Masahiro Ito, Aki Ito, Ayana Suzuki, Miyoko Higuchi, Seiji Kuma, Toshitetsu Hayashi, Masao Kishikawa, Shuichi Horikawa, Akira Miyauchi
Endocrine Journal.2017; 64(10): 1017. CrossRef
A Case of Papillary Thyroid Carcinoma with Fasciitis-like Stroma
Toshihiko WAKU, Hiroshi SONOBE
Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association).2016; 77(12): 2892. CrossRef
Stromal Modulation and its Role in the Diagnosis of Papillary Patterned Thyroid Lesions
Sahar Aly Daoud, Reham Shehab El Nemr Esmail, Amal Ahmed Hareedy, Abdullah Khalil
Asian Pacific Journal of Cancer Prevention.2015; 16(8): 3307. CrossRef
Papillary Thyroid Carcinoma With Nodular Fasciitis–Like Stroma
Paula S. Ginter, Theresa Scognamiglio
International Journal of Surgical Pathology.2015; 23(4): 305. CrossRef
Notch and TGF-β/Smad3 pathways are involved in the interaction between cancer cells and cancer-associated fibroblasts in papillary thyroid carcinoma
Jie Zhang, Yuan Wang, Dan Li, Shanghua Jing
Tumor Biology.2014; 35(1): 379. CrossRef

Original Articles

Prognostic Relevance of the Expression of CA IX, GLUT-1, and VEGF in Ovarian Epithelial Cancers: Kyungbin Kim, Won Young Park, Jee Yeon Kim, Mee Young Sol, Dong Hun Shin, Do Youn Park, Chang Hun Lee, Jeong Hee Lee, Kyung Un Choi; Korean J Pathol. 2012;46(6):532-540. Published online December 26, 2012; DOI: https://doi.org/10.4132/KoreanJPathol.2012.46.6.532

10,384 View
42 Download
15 Crossref

Abstract PDF

Background

Tumor hypoxia is associated with malignant progression and treatment resistance. Hypoxia-related factors, such as carbonic anhydrase IX (CA IX), glucose transporter-1 (GLUT-1), and vascular endothelial growth factor (VEGF) permit tumor cell adaptation to hypoxia. We attempted to elucidate the correlation of these markers with variable clinicopathological factors and overall prognosis.

Methods

Immunohistochemistry for CA IX, GLUT-1, and VEGF was performed on formalin-fixed, paraffin-embedded tissues from 125 cases of ovarian epithelial cancer (OEC).

Results

CA IX expression was significantly associated with an endometrioid and mucinous histology, nuclear grade, tumor necrosis, and mitosis. GLUT-1 expression was associated with tumor necrosis and mitosis. VEGF expression was correlated only with disease recurrence. Expression of each marker was not significant in terms of overall survival in OECs; however, there was a significant correlation between poor overall survival rate and high coexpression of these markers.

Conclusions

The present study suggests that it is questionable whether CA IX, GLUT-1, or VEGF can be used alone as independent prognostic factors in OECs. Using at least two markers helps to predict patient outcomes in total OECs. Moreover, the inhibition of two target gene combinations might prove to be a novel anticancer therapy.

Citations

Citations to this article as recorded by

Glucose-transporter 1 (GLUT1) as a prognostic biomarker: evidence from 14,966 human tumors across 134 cancer types
Seyma Büyücek, Katharina Möller, Florian Viehweger, Ria Schlichter, Anne Menz, Andreas M Luebke, Viktor Reiswich, Martina Kluth, Claudia Hube-Magg, Andrea Hinsch, Florian Lutz, Sören Weidemann, Frank Jacobsen, Maximilian Lennartz, David Dum, Christian Ber
BMC Cancer.2026;[Epub] CrossRef
Evaluation of the effect of Endogenous and Exogenous Antioxidants on Hypoxia Induced Breast Adenocarcinoma Cell Invasion and Migration: In vitro
Subarnarekha Maitra, Poulami Sen, Dibya Sinha, Tathagata Roy
Research Journal of Pharmacy and Technology.2025; : 3153. CrossRef
Effect of Ultrasound Therapy at the ST11 on Sympathetic Nervous System Change: A Prospective Randomized Controlled Study
Shinwoo Kang, Dongho Keum
Journal of Korean Medicine Rehabilitation.2023; 33(4): 167. CrossRef
A systematic review verified by bioinformatic analysis based on TCGA reveals week prognosis power of CAIX in renal cancer
Zikuan Zhang, Bo Wu, Yuan Shao, Yongquan Chen, Dongwen Wang, Lucia Magnelli
PLOS ONE.2022; 17(12): e0278556. CrossRef
Effect of Acupuncture at the Field of the Auricular Branch of the Vagus Nerve on Autonomic Nervous System Change
Sunjoo An, Dongho Keum
Journal of Korean Medicine Rehabilitation.2021; 31(2): 81. CrossRef
Responses of Autonomic Nervous System and Gastrointestinal Function to Acupuncture at Abdominal Anterior Cutaneous Nerve : A Pilot Study
Seohyun Park, Hojun Kim, Dongho Keum
Journal of Korean Medicine.2019; 40(1): 99. CrossRef
Omega-3 polyunsaturated fatty acid docosahexaenoic acid and its role in exhaustive-exercise-induced changes in female rat ovulatory cycle
Abeer F. Mostafa, Shereen M. Samir, R.M. Nagib
Canadian Journal of Physiology and Pharmacology.2018; 96(4): 395. CrossRef
Clear cell carcinomas of the ovary and kidney: clarity through genomics
Jennifer X Ji, Yi Kan Wang, Dawn R Cochrane, David G Huntsman
The Journal of Pathology.2018; 244(5): 550. CrossRef
Prognostic Significance of Carbonic Anhydrase IX Expression in Cancer Patients: A Meta-Analysis
Simon J. A. van Kuijk, Ala Yaromina, Ruud Houben, Raymon Niemans, Philippe Lambin, Ludwig J. Dubois
Frontiers in Oncology.2016;[Epub] CrossRef
Review of Research Topics on Abdominal Examination
Jihye Kim, Jeong Hwan Park, Keun Ho Kim
Journal of Korean Medicine.2016; 37(3): 1. CrossRef
Expression of hypoxic markers and their prognostic significance in soft tissue sarcoma
JEUNG IL KIM, KYUNG UN CHOI, IN SOOK LEE, YOUNG JIN CHOI, WON TACK KIM, DONG HOON SHIN, KYUNGBIN KIM, JEONG HEE LEE, JEE YEON KIM, MEE YOUNG SOL
Oncology Letters.2015; 9(4): 1699. CrossRef
Evaluation of a Hypoxia Regulated Gene Panel in Ovarian Cancer
Amanda F. Baker, Scott W. Malm, Ritu Pandey, Cindy Laughren, Haiyan Cui, Denise Roe, Setsuko K. Chambers
Cancer Microenvironment.2015; 8(1): 45. CrossRef
Sulforaphane reduces molecular response to hypoxia in ovarian tumor cells independently of their resistance to chemotherapy
MICHAL PASTOREK, VERONIKA SIMKO, MARTINA TAKACOVA, MONIKA BARATHOVA, MARIA BARTOSOVA, LUBA HUNAKOVA, OLGA SEDLAKOVA, SONA HUDECOVA, OLGA KRIZANOVA, FRANCK DEQUIEDT, SILVIA PASTOREKOVA, JAN SEDLAK
International Journal of Oncology.2015; 47(1): 51. CrossRef
Overexpression of Glucose Transporter-1 (GLUT-1) Predicts Poor Prognosis in Epithelial Ovarian Cancer
Hanbyoul Cho, You Sun Lee, Julie Kim, Joon-Yong Chung, Jae-Hoon Kim
Cancer Investigation.2013; 31(9): 607. CrossRef
Towards Lipidomics of Low-Abundant Species for Exploring Tumor Heterogeneity Guided by High-Resolution Mass Spectrometry Imaging
Jonathan Cimino, David Calligaris, Johann Far, Delphine Debois, Silvia Blacher, Nor Sounni, Agnès Noel, Edwin De Pauw
International Journal of Molecular Sciences.2013; 14(12): 24560. CrossRef

Update on the Proposal for Creating a Guideline for Cancer Registration of the Gastrointestinal Tumors (I-2): Eun Sun Jung, Yun Kyung Kang, Mee-Yon Cho, Joon Mee Kim, Won Ae Lee, Hee Eun Lee, Sunhoo Park, Jin Hee Sohn, So-Young Jin; Korean J Pathol. 2012;46(5):443-453. Published online October 25, 2012; DOI: https://doi.org/10.4132/KoreanJPathol.2012.46.5.443

11,821 View
188 Download
18 Crossref

Abstract PDF

Background

Cancer registries play a fundamental role in cancer control and multicenter collaborative research. Recently, the need for reassessment of cancer registry criteria has arisen due to the newly released 2010 World Health Organization (WHO) classification. Accordingly, development of new coding guidelines for cancer is necessary to improve the quality of cancer registries, as well as to prevent conflicts that may arise when seeking medical insurance compensation.

Methods

With funding from the Management Center for Health Promotion, 35 members of the Gastrointestinal Pathology Study Group and the Cancer Registration Committee of the Korean Society of Pathologists (KSP) participated in a second workshop for gastrointestinal tumor registration in Korea.

Results

The topics of gastric epithelial tumor, colonic intramucosal carcinoma, neuroendocrine tumor (NET), gastrointestinal stromal tumor (GIST) and appendiceal mucinous tumor were discussed for new coding guidelines. A survey was then conducted among 208 members of the KSP for a consensus of the guidelines proposed in the workshop.

Conclusions

Although a few issues were set aside for further discussion, such as coding for non-gastric GIST and some types of NET, the members agreed upon most of the proposed guidelines. Therefore, we suggest using the newly revised International Classification of Diseases for Oncology, 3rd edition (ICD-O-3) coding guidelines for registering gastrointestinal tumors in Korea.

Citations

Citations to this article as recorded by

Gastrointestinal Stromal Tumor: History, Molecular Subtypes, and Risk Stratification
In Hye Song, Soomin Ahn, Hyung-Don Kim, Jeong-Hyeon Jo, Jinho Shin, Min-Hee Ryu, Young Soo Park
Journal of Gastric Cancer.2026;[Epub] CrossRef
Variation in mitotic counting and risk classification practices for gastrointestinal stromal tumors: a survey of pathologists in South Korea
In Hye Song, Soomin Ahn, Jeong-Hyeon Jo, Young Soo Park
Journal of Pathology and Translational Medicine.2025; 59(5): 348. CrossRef
Different miRNAs Related to FBXW7 Mutations or High Mitotic Indices Contribute to Rectal Neuroendocrine Tumors: A Pilot Study
Ho Suk Kang, Ha Young Park, Hyun Lim, Il Tae Son, Min-Jeong Kim, Nan Young Kim, Min Jeong Kim, Eun Sook Nam, Seong Jin Cho, Mi Jung Kwon
International Journal of Molecular Sciences.2023; 24(7): 6329. CrossRef
Clinicopathologic Impact of Peptide Hormonal Expression in Rectal Neuroendocrine Tumors
Jisup Kim, Dong-Hoon Yang, HaeSung Jung, HyungJun Cho, Hyeung-Jin Jang, Changhoon Yoo, In Ja Park, Baek-Yeol Ryoo, Jin-Sook Ryu, Seung-Mo Hong
Archives of Pathology & Laboratory Medicine.2023; 147(7): 797. CrossRef
Prognostic nomogram and novel risk-scoring system for small cell lung cancer with different patterns of metastases
Hongli Ruan, Huali Sun, Yu Guo, Yan Ding, Yanmei Liu, Shenpeng Ying, Peipei Lin
General Thoracic and Cardiovascular Surgery.2022; 70(12): 1022. CrossRef
Development of a nomogram model to predict survival outcomes in patients with primary hepatic neuroendocrine tumors based on SEER database
Ziteng Zhang, Xin Zhao, Zhiyan Li, Youchun Wu, Yao Liu, Zhiwei Li, Guobao Li
BMC Cancer.2021;[Epub] CrossRef
Standardization of the pathologic diagnosis of appendiceal mucinous neoplasms
Dong-Wook Kang, Baek-hui Kim, Joon Mee Kim, Jihun Kim, Hee Jin Chang, Mee Soo Chang, Jin-Hee Sohn, Mee-Yon Cho, So-Young Jin, Hee Kyung Chang, Hye Seung Han, Jung Yeon Kim, Hee Sung Kim, Do Youn Park, Ha Young Park, So Jeong Lee, Wonae Lee, Hye Seung Lee,
Journal of Pathology and Translational Medicine.2021; 55(4): 247. CrossRef
Analysis of the Incidence and Clinical Features of Colorectal Nonadenocarcinoma in Korea: A National Cancer Registry-Based Study
Soomin Nam, Dongwook Kim, Kyuwon Jung, Yoon Jung Choi, Jung Gu Kang
Annals of Coloproctology.2020; 36(6): 390. CrossRef
Novel Finding of Paired Box 5 (PAX5) Cytoplasmic Staining in Well-differentiated Rectal Neuroendocrine Tumors (Carcinoids) and Its Diagnostic and Potentially Prognostic Utility
Zhiyan Fu, Chunlai Zuo, Christine E. Sheehan, Deepa T. Patil, Jingmei Lin, Zhaohai Yang, Hwajeong Lee
Applied Immunohistochemistry & Molecular Morphology.2019; 27(6): 454. CrossRef
Lymphovascular invasion as a prognostic value in small rectal neuroendocrine tumor treated by local excision: A systematic review and meta-analysis
Ho Suk Kang, Mi Jung Kwon, Tae-Hwan Kim, Junhee Han, Young-Su Ju
Pathology - Research and Practice.2019; 215(11): 152642. CrossRef
Management Colorectal Gastrointestinal Stromal Tumors (Gists) in Surabaya
Yuda Handaya, Sutamto Wibowo, Iwan Kristian
Open Journal of Gastroenterology.2016; 06(04): 97. CrossRef
Non-L-cell Immunophenotype and Large Tumor Size in Rectal Neuroendocrine Tumors Are Associated With Aggressive Clinical Behavior and Worse Prognosis
Joo Young Kim, Ki-Suk Kim, Kyung-Jo Kim, In Ja Park, Jong Lyul Lee, Seung-Jae Myung, Yangsoon Park, Young Soo Park, Chang Sik Yu, Jin Cheon Kim, Eunsil Yu, Hyeung-Jin Jang, Seung-Mo Hong
American Journal of Surgical Pathology.2015; 39(5): 632. CrossRef
Diagnostic Coding for Intramucosal Carcinoma and Neuroendocrine Tumor in the Colorectum: Proposal for Avoiding Confusing Coding in Korea
Dong Soo Han, Jin Hee Sohn, Jeong-Sik Byeon, Hwang Choi, Joon Mee Kim
Clinical Endoscopy.2015; 48(3): 216. CrossRef
Prognostic Significance of Defining L-Cell Type on the Biologic Behavior of Rectal Neuroendocrine Tumors in Relation with Pathological Parameters
Jin Hee Sohn, Mee-Yon Cho, Yangsoon Park, Hyunki Kim, Woo Ho Kim, Joon Mee Kim, Eun Sun Jung, Kyoung-Mee Kim, Jae Hyuk Lee, Hee Kyung Chan, Do Youn Park, Mee Joo, Sujin Kim, Woo Sung Moon, Mi Seon Kang, So-Young Jin, Yun Kyung Kang, Sun Och Yoon, HyeSeung
Cancer Research and Treatment.2015; 47(4): 813. CrossRef
Diminutive and Small Colorectal Polyps: The Pathologist's Perspective
Yun Kyung Kang
Clinical Endoscopy.2014; 47(5): 404. CrossRef
Highlights from the 50th Seminar of the Korean Society of Gastrointestinal Endoscopy
Eun Young Kim, Il Ju Choi, Kwang An Kwon, Ji Kon Ryu, Seok Ho Dong, Ki Baik Hahm
Clinical Endoscopy.2014; 47(4): 285. CrossRef
Early Colorectal Epithelial Neoplasm in Korea: A Multicenter Survey of Pathologic Diagnosis
Yun Kyung Kang, So-Young Jin, Mee Soo Chang, Jung Yeon Kim, Gyeong Hoon Kang, Hye Seung Lee, Jin Hee Sohn, Ho Sung Park, Kye Won Kwon, Mi Jin Gu, Young Hee Maeng, Jong Eun Joo, Haeng Ji Kang, Hee Kyung Kim, Kee-Taek Jang, Mi Ja Lee, Hee Kyung Chang, Joon
Korean Journal of Pathology.2013; 47(3): 245. CrossRef
Expression of metallothionein‐1 and metallothionein‐2 as a prognostic marker in hepatocellular carcinoma
Yangsoon Park, Eunsil Yu
Journal of Gastroenterology and Hepatology.2013; 28(9): 1565. CrossRef

Clinicopathologic Implications of PIWIL2 Expression in Colorectal Cancer: Sun-Ju Oh, Su-Mi Kim, Young-Ok Kim, Hee-Kyung Chang; Korean J Pathol. 2012;46(4):318-323. Published online August 23, 2012; DOI: https://doi.org/10.4132/KoreanJPathol.2012.46.4.318

8,792 View
63 Download
34 Crossref

Abstract PDF

Background

There are no established reports about the expression of the Piwil gene, a subfamily of the Piwi gene involved in RNA silencing and self-renewal, in colorectal carcinomas. It is known that the degree of PIWIL2 expression is higher in colorectal carcinomas. But its clinicopathologic significance remains undetermined. This study reassessed the relationship between PIWIL2 expression and the clinicopathologic parameters in colorectal carcinomas.

Methods

An immunohistochemistry of PIWIL2 expression was done in 60 cases of colorectal carcinoma. This was followed by an analysis of the correlation between PIWIL2 expression and clinicopathologic features and a survival analysis.

Results

There were 44 cases (73.3%) where the degree of PIWIL2 expression was relatively higher. The high degree of PIWIL2 expression was significantly correlated with the lower degree of differentiation (p=0.039), deep invasion (p=0.019) and perineural invasion (p=0.027). The overall survival was longer in patients with the lower degree of PIWIL2 expression than in those with the higher degree of PIWIL2 expression.

Conclusions

Our results showed that the degree of PIWIL2 expression was relatively higher in colorectal carcinomas and it was significantly correlated with variable clinicopathologic indicators for a poor prognosis. This indicates that PIWIL2-positive cells contribute to the progression of colorectal cancer.

Citations

Citations to this article as recorded by

Piwil-2 represents a poor prognosticator in Merkel cell carcinomas that regulates oncoproteins, cell cycle arrest and SOX-2 expression
Stefan Janik, Johannes Pammer, Elisabeth Simader, Ulana Kotowski, Stefan Grasl, Roland Houben, Dragan Copic, Michael Mildner, Goran Mitulovic, Martin Bilban, Sophia Derdak, Markus Unterwurzacher, Klaus Kratochwill, Boban M. Erovic
Scientific Reports.2025;[Epub] CrossRef
Critical appraisal of the piRNA-PIWI axis in cancer and cancer stem cells
Elena Garcia-Borja, Frantisek Siegl, Rosana Mateu, Ondrej Slaby, Aleksi Sedo, Petr Busek, Jiri Sana
Biomarker Research.2024;[Epub] CrossRef
PIWI-interacting RNAs (PiRNAs) as emerging biomarkers and therapeutic targets in biliary tract cancers: A comprehensive review
Sahar Ahmadi Asouri, Esmat Aghadavood, Hamed Mirzaei, Alireza Abaspour, Mohammad Esmaeil Shahaboddin
Heliyon.2024; 10(13): e33767. CrossRef
Piwi-interacting RNAs (piRNAs) and Colorectal Carcinoma: Emerging Non-invasive diagnostic Biomarkers with Potential Therapeutic Target Based Clinical Implications
Suman Kumar Ray, Sukhes Mukherjee
Current Molecular Medicine.2023; 23(4): 300. CrossRef
piRNA: A promising biomarker in early detection of gastrointestinal cancer
Melika Ameli Mojarad, Mandana Ameli Mojarad, Bahador Shojaee, Ehsan Nazemalhosseini-Mojarad
Pathology - Research and Practice.2022; 230: 153757. CrossRef
The function of novel small non‐coding RNAs (piRNAs, tRFs) and PIWI protein in colorectal cancer
Mandana AmeliMojarad, Melika AmeliMojarad, Jian Wang
Cancer Treatment and Research Communications.2022; 31: 100542. CrossRef
Morbid Obesity in Women Is Associated with an Altered Intestinal Expression of Genes Related to Cancer Risk and Immune, Defensive, and Antimicrobial Response
Ailec Ho-Plágaro, Cristina Rodríguez-Díaz, Concepción Santiago-Fernández, Carlos López-Gómez, Sara García-Serrano, Flores Martín-Reyes, Francisca Rodríguez-Pacheco, Alberto Rodríguez-Cañete, Guillermo Alcaín-Martínez, Luis Vázquez-Pedreño, Sergio Valdés,
Biomedicines.2022; 10(5): 1024. CrossRef
Emerging roles of PIWI-interacting RNAs (piRNAs) and PIWI proteins in head and neck cancer and their potential clinical implications
Trisha Chattopadhyay, Priyajit Biswal, Anthony Lalruatfela, Bibekanand Mallick
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2022; 1877(5): 188772. CrossRef
Cytokine-mediated crosstalk between cancer stem cells and their inflammatory niche from the colorectal precancerous adenoma stage to the cancerous stage: Mechanisms and clinical implications
Guanglin Cui, Ziqi Wang, Hanzhe Liu, Zhigang Pang
Frontiers in Immunology.2022;[Epub] CrossRef
piRNAs and PIWI proteins: From biogenesis to their role in cancer
Negar Balmeh, Samira Mahmoudi, Anasik Karabedianhajiabadi
Gene Reports.2021; 22: 101013. CrossRef
Epigenetic roles of PIWI proteins and piRNAs in colorectal cancer
Fatemeh Sadoughi, Seyyed Mehdi Mirhashemi, Zatollah Asemi
Cancer Cell International.2021;[Epub] CrossRef
PIWI interacting RNAs perspectives: a new avenues in future cancer investigations
Pooneh Mokarram, Maryam Niknam, Mohammadamin Sadeghdoust, Farnaz Aligolighasemabadi, Morvarid Siri, Sanaz Dastghaib, Hassan Brim, Hassan Ashktorab
Bioengineered.2021; 12(2): 10401. CrossRef
PIWI family proteins as prognostic markers in cancer: a systematic review and meta-analysis
Alexios-Fotios A. Mentis, Efthimios Dardiotis, Nicholas A. Romas, Athanasios G. Papavassiliou
Cellular and Molecular Life Sciences.2020; 77(12): 2289. CrossRef
Identification of Genomic Alterations of Perineural Invasion in Patients with Stage II Colorectal Cancer

Hao Su, Chen Chang, Jiajie Hao, Xin Xu, Mandula Bao, Shou Luo, Chuanduo Zhao, Qian Liu, Xishan Wang, Zhixiang Zhou, Haitao Zhou
OncoTargets and Therapy.2020; Volume 13: 11571. CrossRef
Biological function and molecular mechanism of piRNA in cancer
Ghanbar Mahmoodi Chalbatani, Hassan Dana, Feridon Memari, Elahe Gharagozlou, Shirin Ashjaei, Peyman Kheirandish, Vahid Marmari, Habibollah Mahmoudzadeh, Farnaz Mozayani, Ali Reza Maleki, Ehsan Sadeghian, Elham Zainali Nia, Seyed Rohollah Miri, Neda zainal
Practical Laboratory Medicine.2019; 13: e00113. CrossRef
Molecular and Functional Characterization of the Somatic PIWIL1/piRNA Pathway in Colorectal Cancer Cells
Assunta Sellitto, Konstantinos Geles, Ylenia D’Agostino, Marisa Conte, Elena Alexandrova, Domenico Rocco, Giovanni Nassa, Giorgio Giurato, Roberta Tarallo, Alessandro Weisz, Francesca Rizzo
Cells.2019; 8(11): 1390. CrossRef
Emerging roles of piRNAs in cancer: challenges and prospects
Ye Cheng, Qian Wang, Wei Jiang, Yonghua Bian, Yang zhou, Anxing Gou, Wenling Zhang, Kai Fu, Weihong Shi
Aging.2019; 11(21): 9932. CrossRef
Differential expression of PIWIL2 in papillary thyroid cancers
Ibrahim Halil Erdogdu, Onder Yumrutas, M. Ozgur Cevik, Ibrahim Bozgeyik, Miyase Erdogdu, Hacı Mehmet Inan, Haydar Bagis
Gene.2018; 649: 8. CrossRef
High expression of PIWIL2 promotes tumor cell proliferation, migration and predicts a poor prognosis in glioma
Jinquan Li, Li Xu, Zhen Bao, Peng Xu, Hao Chang, Jingjing Wu, Yuanqi Bei, Liuwan Xia, Peizhang Wu, Gang Cui
Oncology Reports.2017; 38(1): 183. CrossRef
The meaning of PIWI proteins in cancer development
Monika Litwin, Anna Szczepańska-Buda, Aleksandra Piotrowska, Piotr Dzięgiel, Wojciech Witkiewicz
Oncology Letters.2017; 13(5): 3354. CrossRef
An unusual intragenic promoter ofPIWIL2contributes to aberrant activation of oncogenicPL2L60
Shan-Shan Liu, Ning Liu, Meng-Yao Liu, Lei Sun, Wu-Yan Xia, Hong-Min Lu, Yu-Jie Fu, Guo-Liang Yang, Juan-Jie Bo, Xiao-Xing Liu, Haizhong Feng, Hailong Wu, Lin-Feng Li, Jian-Xin Gao
Oncotarget.2017; 8(28): 46104. CrossRef
Manipulations in HIWI level exerts influence on the proliferation of human non-small cell lung cancer cells
YUGUANG WANG, JIA LIU, GUANGYAO WU, FANG YANG
Experimental and Therapeutic Medicine.2016; 11(5): 1971. CrossRef
High expression of piwi-like RNA-mediated gene silencing 1 is associated with poor prognosis via regulating transforming growth factor-β receptors and cyclin-dependent kinases in breast cancer
JIWEI CAO, GANG XU, JING LAN, QINGQING HUANG, ZUXIONG TANG, LIPING TIAN
Molecular Medicine Reports.2016; 13(3): 2829. CrossRef
PIWI-Interacting RNAs in Gliomagenesis: Evidence from Post-GWAS and Functional Analyses
Daniel I. Jacobs, Qin Qin, Michael C. Lerro, Alan Fu, Robert Dubrow, Elizabeth B. Claus, Andrew T. DeWan, Guilin Wang, Haifan Lin, Yong Zhu
Cancer Epidemiology, Biomarkers & Prevention.2016; 25(7): 1073. CrossRef
Hiwi downregulation, mediated by shRNA, reduces the proliferation and migration of human hepatocellular carcinoma cells
YINGJUN XIE, YONGSHENG YANG, DEGANG JI, DAN ZHANG, XIAOXIAO YAO, XUEWEN ZHANG
Molecular Medicine Reports.2015; 11(2): 1455. CrossRef
Emerging roles for PIWI proteins in cancer
Y. Tan, L. Liu, M. Liao, C. Zhang, S. Hu, M. Zou, M. Gu, X. Li
Acta Biochimica et Biophysica Sinica.2015; 47(5): 315. CrossRef
Genetic variants in noncoding PIWI‐interacting RNA and colorectal cancer risk
Haiyan Chu, Liping Xia, Xiaonan Qiu, Dongying Gu, Linjun Zhu, Jing Jin, Gaoyun Hui, Qiuhan Hua, Mulong Du, Na Tong, Jinfei Chen, Zhengdong Zhang, Meilin Wang
Cancer.2015; 121(12): 2044. CrossRef
Piwil2 modulates the invasion and metastasis of prostate cancer by regulating the expression of matrix metalloproteinase-9 and epithelial-mesenchymal transitions
YANFENG YANG, XUEPEI ZHANG, DONGKUI SONG, JINXING WEI
Oncology Letters.2015; 10(3): 1735. CrossRef
Piwil 2 Expression Is Correlated with Disease-Specific and Progression-Free Survival of Chemotherapy-Treated Bladder Cancer Patients
Helge Taubert, Sven Wach, Rudolf Jung, Michael Pugia, Bastian Keck, Simone Bertz, Elke Nolte, Robert Stoehr, Jan Lehmann, Carsten-H. Ohlmann, Michael Stöckle, Bernd Wullich, Arndt Hartmann
Molecular Medicine.2015; 21(1): 371. CrossRef
Overexpression of Hiwi Promotes Growth of Human Breast Cancer Cells
Da-Wei Wang, Zhao-Hui Wang, Ling-Ling Wang, Yang Song, Gui-Zhen Zhang
Asian Pacific Journal of Cancer Prevention.2014; 15(18): 7553. CrossRef
Lactobacillus acidophilus and Lactobacillus crispatus Culture Supernatants Downregulate Expression of Cancer-testis Genes in the MDA-MB-231 Cell Line
Rosa Azam, Soudeh Ghafouri-Fard, Mina Tabrizi, Mohammad-Hossein Modarressi, Reza Ebrahimzadeh-Vesal, Maryam Daneshvar, Maryam Beigom Mobasheri, Elahe Motevaseli
Asian Pacific Journal of Cancer Prevention.2014; 15(10): 4255. CrossRef
Expression Profiles of PIWIL2 Short Isoforms Differ in Testicular Germ Cell Tumors of Various Differentiation Subtypes
Ildar V. Gainetdinov, Yulia V. Skvortsova, Elena A. Stukacheva, Oksana S. Bychenko, Sofia A. Kondratieva, Marina V. Zinovieva, Tatyana L. Azhikina, Jian-Xin Gao
PLoS ONE.2014; 9(11): e112528. CrossRef
PIWIL2 induces c-Myc expression by interacting with NME2 and regulates c-Myc-mediated tumor cell proliferation
Youlin Yao, Chao Li, Xiaoyan Zhou, Yu Zhang, Yilu Lu, Jianhui Chen, Xulei Zheng, Dachang Tao, Yunqiang Liu, Yongxin Ma
Oncotarget.2014; 5(18): 8466. CrossRef
Novel dimensions of piRNAs in cancer
Yuping Mei, David Clark, Li Mao
Cancer Letters.2013; 336(1): 46. CrossRef

Case Report

Papillary Carcinoma of Thyroid Metastatic to Adenocarcinoma In Situ of Lung: Report of an Unusual Case: Kyoung Min Kim, Yo Na Kim, Hyun Hee Chu, Heung Yong Jin, Min Ho Kim, Myoung Ja Chung; Korean J Pathol. 2012;46(3):282-286. Published online June 22, 2012; DOI: https://doi.org/10.4132/KoreanJPathol.2012.46.3.282

9,265 View
53 Download
6 Crossref

Abstract PDF

The tumor-to-tumor metastasis is a rare event. The lung tumors are the most common donor tumors in tumor-to-tumor metastasis, but are exceedingly rare as a recipient. Here, we report a case of papillary thyroid carcinoma (PTC) metastasizing to adenocarcinoma in situ (AIS, formerly bronchioloalveolar carcinoma) of the lung in a 44-year-old woman who underwent total thyroidectomy for PTC 8 years ago. To the best of our knowledge, the present case is the first case reporting on PTC metastasized to AIS. A review of the relevant literature is presented.

Citations

Citations to this article as recorded by

A case of colorectal cancer with intratumoral metastasis to primary lung cancer
Yasushi Cho, Mitsuhito Kaji, Shunsuke Nomura, Yusuke Motohashi, Masaaki Sato, Motoya Takeuchi
The Journal of the Japanese Association for Chest Surgery.2021; 35(5): 576. CrossRef
Tumor-to-tumor metastasis: metastatic invasive lobular carcinoma of the breast within adenocarcinoma of the lung
Myoung Jae Kang, Ae Ri An, Myoung Ja Chung, Kyoung Min Kim
Journal of Pathology and Translational Medicine.2020; 54(2): 188. CrossRef
Metastatic Renal Cell Neoplasm Within a Papillary Thyroid Carcinoma as Incidental Finding in an Asymptomatic Patient: a Case Report
Maria-Rosa Bella-Cueto, Mireia Pascua-Solé, Albert Cano-Palomares, M. Àngels Cabezuelo-Hernandez, Maria-Rosa Escoda-Giralt, Santiago Barcons-Vilaplana, Paula Serret-Miralles, Carmen Caral-Vanaclocha, Xavier Guirao-Garriga, Joan Prats-Lopez, Meritxell Meda
SN Comprehensive Clinical Medicine.2020; 2(7): 978. CrossRef
A Rare Case of Tumor-to-Tumor Metastasis of Thyroid Papillary Carcinoma within a Pulmonary Adenocarcinoma
Taebum Lee, Yoon Jin Cha, Sangjeong Ahn, Joungho Han, Young Mog Shim
Journal of Pathology and Translational Medicine.2015; 49(1): 78. CrossRef
Tumour-to-tumour metastasis from papillary thyroid carcinoma withBRAFmutation to lung adenocarcinoma withEGFRmutation: the utility of mutation-specific antibodies
Yuki Katsuya, Akihiko Yoshida, Shun-ichi Watanabe, Koji Tsuta
Histopathology.2015; 67(2): 262. CrossRef
Pulmonary metastasis of a papillary thyroid carcinoma and primary lung adenocarcinoma: two coincident carcinomas at the same location
Liyan Xue, Zhonghua Luan, Ying Liu, Shuangmei Zou, Jun Jiang, Ning Wu, Ning Lu, Dongmei Lin
Diagnostic Pathology.2013;[Epub] CrossRef

Original Articles

Proposal for Creating a Guideline for Cancer Registration of Microinvasive Tumors of the Breast and Ovary (II): Jin Hee Sohn, Gyungyub Gong, Kyu Rae Kim, Chang Suk Kang, Youn Soo Lee, Jin Man Kim, Woo Hee Jung, Kwang Sun Suh; Korean J Pathol. 2012;46(3):226-232. Published online June 22, 2012; DOI: https://doi.org/10.4132/KoreanJPathol.2012.46.3.226

11,372 View
63 Download
2 Crossref

Abstract PDF

Background

Cancer registration in Korea has a longer than 30-years of history, during which time cancer registration has improved and become well-organized. Cancer registries are fundamental for cancer control and multi-center collaborative research. However, there have been discrepancies in assigning behavior codes. Thus, we intend to propose appropriate behavior codes for the International Classification of Disease Oncology, 3rd edition (ICD-O-3) for microinvasive tumors of the ovary and breast not only to improve the quality of the cancer registry but also to prevent conflicts.

Methods

As in series I, two pathology study groups and the Cancer Registration Committee of the Korean Society of Pathologists (KSP) participated. To prepare a questionnaire on provisional behavior code, the relevant subjects were discussed in the workshop, and consensus was obtained by convergence of opinion from members of KSP.

Results

Microinvasive tumor of the breast should be designated as a microinvasive carcinoma which was proposed as malignant tumor (/3). Serous borderline tumor with microinvasion of the ovary was proposed as borderline tumor (/1), and mucinous borderline tumor with microinvasion of the ovary as either borderline (/1) or carcinoma (/3) according to the tumor cell nature.

Conclusions

Some issues should be elucidated with the accumulation of more experience and knowledge. Here, however, we present our second proposal.

Citations

Citations to this article as recorded by

Update on the Proposal for Creating a Guideline for Cancer Registration of the Gastrointestinal Tumors (I-2)
Eun Sun Jung, Yun Kyung Kang, Mee-Yon Cho, Joon Mee Kim, Won Ae Lee, Hee Eun Lee, Sunhoo Park, Jin Hee Sohn, So-Young Jin
Korean Journal of Pathology.2012; 46(5): 443. CrossRef
A Proposal for Creating a Guideline for Cancer Registration of the Fibromatosis, PEComa Group, Malignant LymphomaIn Situand Dendritic Cell Tumors (III)
Changyoung Yoo, Chang Suk Kang, Yoon La Choi, Hye Yoon Kang, Jin Man Kim, Young Hye Koh, Joo Hee Lee, Seung Sook Lee, In Sun Kim, Dong Hoon Kim, Yong Ku Park, Jin Hee Sohn
Korean Journal of Pathology.2012; 46(5): 436. CrossRef

Detection of BRAF^V600E Mutations in Papillary Thyroid Carcinomas by Peptide Nucleic Acid Clamp Real-Time PCR: A Comparison with Direct Sequencing: Dongjun Jeong, Yujun Jeong, Sungche Lee, Hyeran Lee, Wanju Lee, Hyungjoo Kim, Doosan Park, Soyoung Park, Wenxia Mu, Hyun-Deuk Cho, Mee-Hye Oh, Sung Soo Lee, Seung-Ha Yang, Chang-Jin Kim; Korean J Pathol. 2012;46(1):61-67. Published online February 23, 2012; DOI: https://doi.org/10.4132/KoreanJPathol.2012.46.1.61

13,882 View
78 Download
19 Crossref

Abstract PDF

Background

Papillary thyroid carcinoma (PTC) of the thyroid is the most common endocrine malignancy. High prevalence of an activating point mutation of BRAF gene, BRAF^V600E, has been reported in PTC. We assessed the efficiency of peptide nucleic acid clamp real-time polymerase chain reaction (PNAcqPCR) for the detection of BRAF^V600E mutation in PTC in comparison with direct sequencing (DS).

Methods

A total of 265 thyroid lesions including 200 PTCs, 5 follicular carcinomas, 60 benign lesions and 10 normal thyroid tissues were tested for BRAF^V600E mutation by PNAcqPCR and DS.

Results

The sensitivity and accuracy of the PNAcqPCR method were both higher than those of DS for the detection of the BRAF^V600E mutation. In clinical samples, 89% of PTCs harbored the BRAF^V600E mutation, whereas 5 follicular carcinomas, 50 benign lesions and 10 normal thyroid tissues lacked the mutation. The mutation was associated with aggressive clinical behaviors as extrathyroid invasion (p=0.015), lymph node metastasis (p=0.002) and multiple tumor numbers (p=0.016) with statistical significance.

Conclusions

The PNAcqPCR method is efficiently applicable for the detection of the BRAF^V600E mutation in PTCs in a clinical setting.

Citations

Citations to this article as recorded by

Diagnostic utilities of washout CYFRA 21-1 combined with washout thyroglobulin for metastatic lymph nodes in thyroid cancer: a prospective study
Joonseon Park, Solji An, Kwangsoon Kim, Jeong Soo Kim, Chan Kwon Jung, Ja Seong Bae
Scientific Reports.2024;[Epub] CrossRef
BRAFV600E Positivity-Dependent Effect of Age on Papillary Thyroid Cancer Recurrence Risk
Joonseon Park, Solji An, Kwangsoon Kim, Ja Seong Bae, Jeong Soo Kim
Cancers.2023; 15(22): 5395. CrossRef
TROP-2 and 5hmC expression in follicular-patterned thyroid neoplasm emphasizing tiny well-formed papillae
Jae Yeon Seok, Xuemo Fan
Annals of Diagnostic Pathology.2022; 57: 151903. CrossRef
Null Association between BRAF V600E Mutation and Tumor Recurrence in Patients with Papillary Thyroid Microcarcinoma in South Korea
Ji Yoon Kim, Kyoung Jin Kim, Jae Hyun Bae, Joo Hyung Kim, Nam Hoon Kim, Hee Young Kim, Hoon Yub Kim, Seung-Kuk Baek, Sin Gon Kim, Kwang Yoon Jung, Kyeong Jin Kim
International Journal of Thyroidology.2021; 14(2): 135. CrossRef
Evaluation of the expression levels of BRAFV600E mRNA in primary tumors of thyroid cancer using an ultrasensitive mutation assay
Tien Viet Tran, Kien Xuan Dang, Quynh Huong Pham, Ung Dinh Nguyen, Nhung Thi Trang Trinh, Luong Van Hoang, Son Anh Ho, Ba Van Nguyen, Duc Trong Nguyen, Dung Tuan Trinh, Dung Ngoc Tran, Arto Orpana, Ulf-Håkan Stenman, Jakob Stenman, Tho Huu Ho
BMC Cancer.2020;[Epub] CrossRef
The Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape
Irene Vanni, Enrica Teresa Tanda, Francesco Spagnolo, Virginia Andreotti, William Bruno, Paola Ghiorzo
Frontiers in Molecular Biosciences.2020;[Epub] CrossRef
Highly prevalent BRAF V600E and low-frequency TERT promoter mutations underlie papillary thyroid carcinoma in Koreans
Sue Youn Kim, Taeeun Kim, Kwangsoon Kim, Ja Seong Bae, Jeong Soo Kim, Chan Kwon Jung
Journal of Pathology and Translational Medicine.2020; 54(4): 310. CrossRef
Molecular pathology of thyroid tumours of follicular cells: a review of genetic alterations and their clinicopathological relevance
Giorgia Acquaviva, Michela Visani, Andrea Repaci, Kerry J Rhoden, Dario de Biase, Annalisa Pession, Tallini Giovanni
Histopathology.2018; 72(1): 6. CrossRef
Development of ultra-short PCR assay to reveal BRAF V600 mutation status in Thai colorectal cancer tissues
Nunthawut Chat-Uthai, Pichpisith Vejvisithsakul, Sutthirat Udommethaporn, Puttarakun Meesiri, Chetiya Danthanawanit, Yannawan Wongchai, Chinachote Teerapakpinyo, Shanop Shuangshoti, Naravat Poungvarin, John Souglakos
PLOS ONE.2018; 13(6): e0198795. CrossRef
T-blocker: a Simple and Robust Probe-Free Quantitative PCR Assay to Detect Somatic Mutations Down to 0.1% Frequency
Hanyoup Kim, Aaron E Ruby, Harini G Shandilya, Arvind K Virmani, Nandita Rahman, Christina M Strange, Jarkko Huuskonen
BioTechniques.2018; 65(4): 205. CrossRef
The usefulness of a novel fully automated PCR-based Idylla test for detection of the BRAF V600E mutation in thyroid tissue: comparison with PNA-clamping PCR, real-time PCR and pyrosequencing
Min-Kyung Yeo, Min-Kyu Jung, Su-Yel Lee, Yong-Moon Lee, Gang Min Hur, Jin-Man Kim
Journal of Clinical Pathology.2017; 70(3): 260. CrossRef
KRAS mutation analysis of washing fluid from endoscopic ultrasound-guided fine needle aspiration improves cytologic diagnosis of pancreatic ductal adenocarcinoma
Joo Kyung Park, Yoon Jung Lee, Jong Kyun Lee, Kyu Taek Lee, Yoon-La Choi, Kwang Hyuck Lee
Oncotarget.2017; 8(2): 3519. CrossRef
Application of Peptide Nucleic Acid-based Assays Toward Detection of Somatic Mosaicism
Christopher S Hong, Chunzhang Yang, Zhengping Zhuang
Molecular Therapy - Nucleic Acids.2016; 5: e314. CrossRef
Prediction Table and Nomogram as Tools for Diagnosis of Papillary Thyroid Carcinoma
Seo Ki Kim, Jun Ho Lee, Jung-Woo Woo, Inhye Park, Jun-Ho Choe, Jung-Han Kim, Jee Soo Kim
Medicine.2015; 94(21): e760. CrossRef
The association between BRAF V600E mutation and pathological features in PTC
Xin Liu, Kangkang Yan, Xuejun Lin, Longyu Zhao, Wenxiu An, Chunpeng Wang, Xiaodong Liu
European Archives of Oto-Rhino-Laryngology.2014; 271(11): 3041. CrossRef
Recurrent Thyroid Papillary Carcinoma in Children Under Ten Years Old: Report of Two Cases and Literature Review
Byeong-Joo Noh, Ji-Youn Sung, Youn-Wha Kim, Yong-Koo Park
Korean Journal of Pathology.2014; 48(4): 297. CrossRef
KRASMutation Detection in Non-small Cell Lung Cancer Using a Peptide Nucleic Acid-Mediated Polymerase Chain Reaction Clamping Method and Comparative Validation with Next-Generation Sequencing
Boram Lee, Boin Lee, Gangmin Han, Mi Jung Kwon, Joungho Han, Yoon-La Choi
Korean Journal of Pathology.2014; 48(2): 100. CrossRef
VE1 immunohistochemistry in pituitary adenomas is not associated with BRAF V600E mutation
Jan Sperveslage, Midea Gierke, David Capper, Jürgen Honegger, Bence Sipos, Rudi Beschorner, Jens Schittenhelm
Acta Neuropathologica.2013; 125(6): 911. CrossRef
BRAF Mutations in Iranian Patients with Papillary Thyroid Carcinoma
Nastran Ranjbari, Sara Almasi, Javad Mohammadi-asl, Fakher Rahim
Asian Pacific Journal of Cancer Prevention.2013; 14(4): 2521. CrossRef

Detection of Survivin and COX-2 in Thyroid Carcinoma: Anaplastic Carcinoma Shows Overexpression of Nuclear Survivin and Low COX-2 Expression: Young A Kim, Meesoo Chang, Young Joo Park, Ji Eun Kim; Korean J Pathol. 2012;46(1):55-60. Published online February 23, 2012; DOI: https://doi.org/10.4132/KoreanJPathol.2012.46.1.55

10,098 View
66 Download
5 Crossref

Abstract PDF

Background

Overexpression of survivin, a member of the inhibitors of apoptosis protein, has been reported in various carcinomas, and its interaction with cyclooxygenase 2 (COX-2) results in accelerated tumor progression. The purpose of this study is to investigate the immunohistochemical expression of survivin and COX-2 in benign and malignant thyroid tissues and to define its association with pathologic and clinical features.

Methods

We examined expression of survivin and COX-2 by immunohistochemistry in 334 benign and malignant thyroid tissues and evaluated their clinical significance.

Results

Expression of survivin showed an increase along the spectrum of thyroid carcinoma progression; rarely positive in adenomatous goiter, moderately positive in papillary carcinoma, and strongly positive in anaplastic carcinoma (AC). Papillary microcarcinoma revealed the highest COX-2 positivity and AC demonstrated the lowest positivity among thyroid cancers. Node negative carcinomas showed higher COX-2 expression than node positive tumors. Survivin expression did not correlate with COX-2.

Conclusions

Our findings suggest that survivin overexpression may be related to the pathogenesis of AC and can be a predictor of disease progression. COX-2 may be involved in the early phase of thyroid carcinoma.

Citations

Citations to this article as recorded by

Survivin as a diagnostic and therapeutic marker for thyroid cancer
Mohammad-Reza Mahmoudian-Sani, Arash Alghasi, Ali Saeedi-Boroujeni, Akram Jalali, Mohammad Jamshidi, Ali Khodadadi
Pathology - Research and Practice.2019; 215(4): 619. CrossRef
TFAP2B overexpression contributes to tumor growth and progression of thyroid cancer through the COX-2 signaling pathway
Xiaoyan Fu, Huayong Zhang, Zhipeng Chen, Zhongyuan Yang, Dingbo Shi, Tianrun Liu, Weichao Chen, Fan Yao, Xuan Su, Wuguo Deng, Miao Chen, Ankui Yang
Cell Death & Disease.2019;[Epub] CrossRef
Expression of nm23-H1 and COX-2 in thyroid papillary carcinoma and microcarcinoma
Marija Milkovic Perisa, Bozena Sarcevic, Koraljka Gall Troselj, Kresimir Grsic, Sanda Sitic, Sven Seiwerth
Oncology Letters.2017; 13(5): 3547. CrossRef
The Diagnostic Usefulness of HMGA2, Survivin, CEACAM6, and SFN/14-3-3 δ in Follicular Thyroid Carcinoma
Min Hye Jang, Kyeong Cheon Jung, Hye Sook Min
Journal of Pathology and Translational Medicine.2015; 49(2): 112. CrossRef
Evaluation of survivin expression and its prognostic value in papillary thyroid carcinoma
Sonja Selemetjev, Tijana Isic Dencic, Ilona Marecko, Jelena Jankovic, Ivan Paunovic, Svetlana Savin, Dubravka Cvejic
Pathology - Research and Practice.2014; 210(1): 30. CrossRef

Review

CpG Island Hypermethylation in Gastric Carcinoma and Its Premalignant Lesions: Gyeong Hoon Kang; Korean J Pathol. 2012;46(1):1-9. Published online February 23, 2012; DOI: https://doi.org/10.4132/KoreanJPathol.2012.46.1.1

10,683 View
50 Download
19 Crossref

Abstract PDF

Gastric cancers arise through a multistep process characterized by the progressive accumulation of molecular alterations in which genetic and epigenetic mechanisms have been implicated. Gastric cancer is one of the human malignancies in which aberrant promoter CpG island hypermethylation is frequently found. Helicobacter pylori and Epstein-Barr virus, which are known carcinogens for gastric cancer, are closely associated with enhanced hypermethylation of CpG island loci in gastric non-neoplastic epithelial cells and cancer cells, respectively. Aberrant CpG island hypermethylation occurs early in the multistep cascade of gastric carcinogenesis and tends to increase with the step-wise progression of the lesion. Approximately 400 genes that are actively expressed in normal gastric epithelial cells are estimated to be inactivated in gastric cancers as a result of promoter CpG island hypermethylation. In this review, a variety of information is summarized regarding CpG island hypermethylation in gastric cancer.

Citations

Citations to this article as recorded by

Pathogenicity of Helicobacter pylori-associated gastric cancer
Shamshul Ansari, Nada Ahmed
World Journal of Clinical Oncology.2025;[Epub] CrossRef
Genome-wide characterization of extrachromosomal circular DNA in gastric cancer and its potential role in carcinogenesis and cancer progression
Xianming Jiang, Xiaoguang Pan, Wenchao Li, Peng Han, Jiaying Yu, Jing Li, Haoran Zhang, Wei Lv, Ying Zhang, Yulong He, Xi Xiang
Cellular and Molecular Life Sciences.2023;[Epub] CrossRef
Analysis of DNA methylation in endometrial biopsies to predict risk of endometrial cancer
Francesco Multinu, Jun Chen, Joseph D. Madison, Michelle Torres, Jvan Casarin, Daniel Visscher, Viji Shridhar, Jamie Bakkum-Gamez, Mark Sherman, Nicolas Wentzensen, Andrea Mariani, Marina Walther-Antonio
Gynecologic Oncology.2020; 156(3): 682. CrossRef
Helicobacter pylori severely reduces expression of DNA repair proteins PMS2 and ERCC1 in gastritis and gastric cancer
Yasir Raza, Ayaz Ahmed, Adnan Khan, Arif Ali Chishti, Syed Shakeel Akhter, Muhammad Mubarak, Carol Bernstein, Beryl Zaitlin, Shahana Urooj Kazmi
DNA Repair.2020; 89: 102836. CrossRef
Genomic and Epigenomic Profiling of High-Risk Intestinal Metaplasia Reveals Molecular Determinants of Progression to Gastric Cancer
Kie Kyon Huang, Kalpana Ramnarayanan, Feng Zhu, Supriya Srivastava, Chang Xu, Angie Lay Keng Tan, Minghui Lee, Suting Tay, Kakoli Das, Manjie Xing, Aliya Fatehullah, Syed Muhammad Fahmy Alkaff, Tony Kiat Hon Lim, Jonathan Lee, Khek Yu Ho, Steven George Ro
Cancer Cell.2018; 33(1): 137. CrossRef
Decreased Methylation of IFNAR Gene Promoter from Peripheral Blood Mononuclear Cells Is Associated with Oxidative Stress in Chronic Hepatitis B
Jing-wen Wang, Jing-wei Wang, Jun Zhang, Chen-si Wu, Yu Fang, Wei-wei Su, Yu-chen Fan, Kai Wang
Journal of Interferon & Cytokine Research.2018; 38(11): 480. CrossRef
Genomic landscape of gastric cancer: molecular classification and potential targets
Jiawei Guo, Weiwei Yu, Hui Su, Xiufeng Pang
Science China Life Sciences.2017; 60(2): 126. CrossRef
Hypermethylation of the galectin-3 promoter is associated with poor prognosis of acute-on-chronic hepatitis B liver failure
Jing Zhao, Yu-Chen Fan, Xin-Yuan Liu, Ze-Hua Zhao, Feng Li, Kai Wang
Digestive and Liver Disease.2017; 49(6): 664. CrossRef
Proteomics-Based Identification and Analysis of Proteins Associated with Helicobacter pylori in Gastric Cancer
Jianjiang Zhou, Wenling Wang, Yuan Xie, Yan Zhao, Xian Chen, Wenjie Xu, Yan Wang, Zhizhong Guan, Hiromu Suzuki
PLOS ONE.2016; 11(1): e0146521. CrossRef
Lack of Correlation between Aberrant p16, RAR-β2, TIMP3, ERCC1, and BRCA1 Protein Expression and Promoter Methylation in Squamous Cell Carcinoma Accompanying Candida albicans-Induced Inflammation
Yui Terayama, Tetsuro Matsuura, Kiyokazu Ozaki, Javier S Castresana
PLOS ONE.2016; 11(7): e0159090. CrossRef
Helicobacter pylori CagA induces tumor suppressor gene hypermethylation by upregulating DNMT1 via AKT-NFκB pathway in gastric cancer development
Bao-gui Zhang, Lei Hu, Ming-de Zang, He-xiao Wang, Wei Zhao, Jian-fang Li, Li-ping Su, Zhifeng Shao, Xiaodong Zhao, Zheng-gang Zhu, Min Yan, Bingya Liu
Oncotarget.2016; 7(9): 9788. CrossRef
Promoter methylation status and expression of PPAR-γ gene are associated with prognosis of acute-on-chronic hepatitis B liver failure
Ze-Hua Zhao, Yu-Chen Fan, Qi Zhao, Cheng-Yun Dou, Xiang-Fen Ji, Jing Zhao, Shuai Gao, Xin-You Li, Kai Wang
Clinical Epigenetics.2015;[Epub] CrossRef
Role of Epigenetics in EBV Regulation and Pathogenesis
Hans Helmut Niller, Zsófia Tarnai, Gábor Decsi, Ádám Zsedényi, Ferenc Bánáti, Janos Minarovits
Future Microbiology.2014; 9(6): 747. CrossRef
Helicobacter pylori Induces Hypermethylation of CpG Islands Through Upregulation of DNA Methyltransferase: Possible Involvement of Reactive Oxygen/Nitrogen Species
Hye-Kyung Na, Jeong-Hwa Woo
Journal of Cancer Prevention.2014; 19(4): 259. CrossRef
Mallory–Denk Body (MDB) formation modulates ufmylation expression epigenetically in alcoholic hepatitis (AH) and non-alcoholic steatohepatitis (NASH)
Hui Liu, Ming Gong, Barbara A. French, Jun Li, Brittany Tillman, Samuel W. French
Experimental and Molecular Pathology.2014; 97(3): 477. CrossRef
RETRACTED ARTICLE: Role of p16 gene promoter methylation in gastric carcinogenesis: a meta-analysis
He-Ling Wang, Ping-Yi Zhou, Peng Liu, Yu Zhang
Molecular Biology Reports.2014; 41(7): 4481. CrossRef
Exportin 4 gene expression and DNA promoter methylation status in chronic hepatitis B virus infection
F. Zhang, Y.‐C. Fan, N.‐N Mu, J. Zhao, F.‐K. Sun, Z.‐H. Zhao, S. Gao, K. Wang
Journal of Viral Hepatitis.2014; 21(4): 241. CrossRef
Microarray-based DNA methylation study of Ewing’s sarcoma of the bone
HYE-RIM PARK, WOON-WON JUNG, HYUN-SOOK KIM, YONG-KOO PARK
Oncology Letters.2014; 8(4): 1613. CrossRef
Pathologic Diagnosis of Gastric Intestinal Metaplasia
Nari Shin, Do Youn Park
The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2013; 13(2): 84. CrossRef

Original Articles

Histologic Parameters Predicting Survival of Patients with Multiple Non-small Cell Lung Cancers.: Joo Young Kim, Hee Jin Lee, Jun Kang, Se Jin Jang; Korean J Pathol. 2011;45(5):506-515.; DOI: https://doi.org/10.4132/KoreanJPathol.2011.45.5.506

3,511 View
19 Download

Abstract PDF: BACKGROUND
In multiple lung cancers (MLCs), distinction between intrapulmonary metastases and multiple primary tumors is important for staging and prognosis. In this study, we have investigated histopathologic prognostic factors of patients with MLCs.
METHODS
Histologic subtype, size differences, lobar location, lymphovascular invasion (LVI), size of the largest tumor, nodal status, number of tumors, morphology of tumor periphery, and immunohistochemical profiles using eight antibodies, were analyzed in 65 patients with MLCs.
RESULTS
There was no significant difference in the survivals of patients with multiple primary tumors and intrapulmonary metastases, as determined by the Martini-Melamed criteria (p=0.654). Risk grouping by four histologic parameters, LVI, margin morphology, size differences, and lobar locations of paired tumors were prognostic. The patients with one or two of aforementioned parameters had significantly longer survival than those with three or four parameters (p=0.017). In patients with largest mass (< or =5 cm), the risk grouping was found to be an independent prognostic factor (p=0.022). However, differences in immunohistochemical staining were not related to patients' survival.
CONCLUSIONS
A risk grouping of MLC patients by using combinations of histologic parameters can be a useful tool in evaluating the survival of patients with MLCs, and may indicate clonal relationship between multiple tumors.

The Stromal Overexpression of Decay Accelerating Factor (DAF/CD55) Correlates with Poor Clinical Outcome in Colorectal Cancer Patients.: Tae Hwa Baek, Joo Heon Kim, Mee Ja Park, Hye Kyung Lee, Hyun Jin Son, Hyun Ki Soon, Chang Nam Kim, Che Myong Ko, Dong Wook Kang; Korean J Pathol. 2011;45(5):445-454.; DOI: https://doi.org/10.4132/KoreanJPathol.2011.45.5.445

4,446 View
40 Download
1 Crossref

Abstract PDF

BACKGROUND
Decay accelerating factor (DAF/CD55), regulates the complement system by accelerating decay of the C3 convertase, has been described in several malignancies, however, the clinicopathologic significance of CD55 and its receptor CD97 has not been fully investigated. We examined the expression patterns of both CD55 and CD97 and their association with clinicopathologic parameters in colorectal cancers (CRCs).
METHODS
Expression patterns of CD55 and CD97 in the stroma and tumor cells at tumor center and invasive front were examined in 130 CRCs, and their significance was statistically evaluated.
RESULTS
CD55-high stroma was correlated with tumor border (p=0.006) and invasion depth (p=0.013). CD55-high tumor cells at tumor center and invasive front were correlated with histologic grade, and CD55-high tumor cells at invasive front with tumor, node and metastasis (TNM) stage (p<0.05). CD97-high stroma was correlated with lymph node metastasis (p=0.016) and TNM stage (p=0.030). CD97-high tumor cells at tumor center and invasive front were correlated with tumor size and CD97-high tumor cells at tumor center with tumor border (p<0.05). Patients with CD55-high stroma showed poor overall and recurrence-free survival (p<0.05) in univariate analysis, and were independently associated with short recurrence-free survival (p=0.025) in multivariate analysis.
CONCLUSIONS
Stromal CD55 overexpression would be an indicator of adverse clinical outcome and a useful prognostic factor.

Citations

Citations to this article as recorded by

Non-canonical extracellular complement pathways and the complosome paradigm in cancer: a scoping review
Camila de Freitas Oliveira-Tore, Amarilis Giaretta de Moraes, Helena Musetti B. S. Plácido, Nathalia M. D. L. Signorini, Pamela Dias Fontana, Tatiane da Piedade Batista Godoy, Angelica Beate Winter Boldt, Iara de Messias
Frontiers in Immunology.2025;[Epub] CrossRef

The Usefulness of p16INK4a Immunocytochemical Staining in ASC-H Patients.: Kwang Il Yim, Yeo Ju Kang, Tae Eun Kim, Gyeongsin Park, Eun Sun Jung, Yeong Jin Choi, Kyo Young Lee, Chang Seok Kang, Ahwon Lee; Korean J Pathol. 2011;45(3):290-295.; DOI: https://doi.org/10.4132/KoreanJPathol.2011.45.3.290

4,670 View
26 Download
1 Crossref

Abstract PDF

BACKGROUND
The grey zone of cervical cytology, and in particular atypical squamous cells, cannot exclude HSIL (ASC-H) causes diagnostic difficulties and increases medical expenses. We analyzed p16INK4a expression in ASC-H liquid-based cytology specimens (LBCS) to develop more effective methods for the management of ASC-H patients.
METHODS
We carried out p16INK4a immunostaining with 57 LBCS of ASC-H diagnostic categories, all of which were histologically cofirmed and 43 cases of which were compared with the results of a human papillomavirus (HPV) chip test.
RESULTS
p16INK4a immunostaining with ASC-H LBCS was positive in 20% (3/15) of cervicitis, 25.0% (3/12) of tissue-low-grade squamous intraepithelial lesion, 75.0% (18/24) of tissue-high grade squamous intraepithelial lesion (HSIL), and 100% (6/6) of invasive cancer cases. The positivity of p16INK4a in LBCS was correlated with higher grade of histologic diagnosis (r=0.578, p=0.000). The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of p16INK4a immunostaining for the prediction of tissue-HSIL+ were 80.0%, 77.8%, 80.0%, and 77.8%, respectively. The sensitivity, specificity, PPV, and NPV of p16INK4a immunostaining plus HPV chip test for predicting tissue-HSIL+ were 71.2%, 86.4%, 84.2%, and 79.2%.
CONCLUSIONS
p16INK4a immunostaining as well as HPV chip testing with remaining LBCS with ASC-H are useful objective markers for the prediction of tissue-HSIL+.

Citations

Citations to this article as recorded by

Usefulness of p16INK4a Immunocytochemical staining for the Differentiation between Atrophy and ASCUS in Diagnosis of Uterine Cervical Cancer
Hye Ryoung Shin, Taekil Eom, Wan-Su Choi
Biomedical Science Letters.2023; 29(3): 144. CrossRef

Telomerase Activity in Urethane-Induced Mouse Lung Tumorigenesis.: Ji Sun Song, Soon Hee Jung, Sang Yeop Yi, Hwa Eun Oh, Mee Yon Cho, Kwang Hwa Park; Korean J Pathol. 2011;45(3):261-270.; DOI: https://doi.org/10.4132/KoreanJPathol.2011.45.3.261

4,174 View
25 Download
1 Crossref

Abstract PDF

BACKGROUND
Telomerase activity in precancerous conditions of lung adenocarcinomas has not been well studied. This study is designed to investigate the role of telomerase in premalignant lesions of urethane-induced mouse lung adenocarcinoma.
METHODS
We harvested A/J mouse lung tissues at 3, 6, 9, 12, 28, 41, and 48 weeks after intraperitoneal urethane treatment, and classified each lesion in terms of histologic findings. We examined telomerase activity using a modified version of the telomeric repeat amplification protocol assay using both gel-based and enzyme linked immunosorbent assay methods. An immunohistochemical analysis of proliferating cell nuclear antigen (PCNA) was performed.
RESULTS
In urethane-induced mouse lung tissues, it was sequentially developed from hyperplasia, adenoma, and eventually to adenocarcinoma. Telomerase activity began to show a positive level in tissues with no histologically visible nodule after urethane administration. It revealed a statistically significant increase in hyperplasia compared to the "control" lung tissue (p<0.05), which was proportionally elevated relative to adenoma and adenocarcinoma. There was a direct correlation between telomerase activity and the PCNA labeling index (p<0.05).
CONCLUSIONS
The elevation of telomerase activity in normal-appearing lung lesions is thought to be a possible marker of early detection of pulmonary adenocarcinoma.

Citations

Citations to this article as recorded by

Non-invasive quantification of cell-free DNA mutations in plasma during lung tumor progression in mice
Soo-Jin Kim, Eunhee Kim, Kyung-Taek Rim
Cancer Biomarkers.2017; 20(4): 477. CrossRef

Comparative Study of Metaplastic Breast Carcinoma and Triple-Negative Breast Carcinoma Using Histologic and Immunohistochemical Analyses.: Ji Yeon Kim, Taeeun Kim, Eun Yoon Cho; Korean J Pathol. 2010;44(6):605-612.; DOI: https://doi.org/10.4132/KoreanJPathol.2010.44.6.605

4,286 View
26 Download
1 Crossref

Abstract PDF

BACKGROUND
Metaplastic carcinoma of the breast is a rare subtype of breast cancer, which is characterized by estrogen receptor/progesterone receptor and HER2 negativity.
METHODS
Tissue specimens from 60 metaplastic breast cancer and 60 triple-negative breast cancer patients diagnosed at a single institution between 1995 and 2009 were analyzed. Immunohistochemistry for caveolin-1 (CAV-1), vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), c-kit, p53, Ki-67, breast cancer type 1 susceptibility protein (BRCA1), cytokeratin (CK)14, and CK17 were performed on both retained tissue sets.
RESULTS
Of the 60 metaplastic carcinomas, 15 tumors (25%) exhibited spindle cell component, 27 (45%) exhibited chondroid differentiation, and 18 (30%) exhibited squamous areas. Compared to triple-negative carcinomas, metaplastic carcinomas significantly more frequently expressed CK14 (p < 0.0001), CK17 (p = 0.002), EGFR (p < 0.0001), CAV-1 (p < 0.0001), and VEGF (p = 0.029). However, expressions of BRCA1, p53, c-kit, and Ki-67 were not significantly different between both groups.
CONCLUSIONS
The expression profile of metaplastic carcinoma of the breast is more homogeneous than that of other triple-negative tumors and frequently over-expresses basal markers, CAV-1, and VEGF. A typical "basal-like" phenotype and frequent expressions of CAV-1 and VEGF may justify specific therapeutic approaches.

Citations

Citations to this article as recorded by

Metaplastic Carcinoma of the Breast with Squamous Differentiation: A Case Report from the University Teaching Hospital of Kigali (CHUK), Rwanda
Delphine Uwamariya, Carine Nyampinga, Anne Yvette Nsenguwera, Belson Rugwizangoga, Piero Tosi
Case Reports in Pathology.2020; 2020: 1. CrossRef

Evaluation of the HPV ISH Assay in Cervical Cancer.: Jung Uee Lee, Jung Ha Shin, Jong Ok Kim, Yeong Jin Choi, Kyo Young Lee, Jong Sup Park, Won Chul Lee, Ahwon Lee; Korean J Pathol. 2010;44(5):513-520.; DOI: https://doi.org/10.4132/KoreanJPathol.2010.44.5.513

5,512 View
116 Download
3 Crossref

Abstract PDF

BACKGROUND
Human papillomavirus (HPV) infection can be detected by in situ hybridization (ISH), in which a punctate signal pattern indicates integrated HPV DNA and a diffuse pattern denotes the presence of episomal viral DNA. This study was conducted to evaluate the usefulness of an HPV ISH assay for invasive cervical cancer.
METHODS
The HPV ISH assay for high-risk HPV and immunohistochemical staining for p16(INK4a), p53, bcl-2, and Ki-67 were performed in a tissue microarray of 279 cervical cancers.
RESULTS
High-risk HPV ISH was positive in 194 (69.5%) of the samples. Punctate, diffuse, and mixed signal patterns were observed in 157 (56.3%), one (0.4%), and 36 cases (12.9%), respectively. Positive results in high-risk HPV ISH were associated with p16 and bcl-2 expression (p = 0.01 and p < 0.01, respectively). According to a Cox regression analysis, HPV infection and its surrogate immunohistochemical markers such as p16, bcl-2, and Ki-67 were not independent prognostic factors, but stage and grade were independent prognostic factors.
CONCLUSIONS
Our results confirm that an HPV ISH assay is reasonably sensitive for HPV infection and that it might be useful to identify integrated HPV DNA in formalin-fixed and paraffin-embedded specimens. Further study encompassing HPV type, E2/E6 ratio, and therapeutic modality is necessary to understand the clinical meaning of HPV status in cervical cancer.

Citations

Citations to this article as recorded by

Prevalence of human papillomavirus in eyelid carcinoma among Koreans: a clinicopathological study
Min Kyu Yang, Namju Kim, Hokyung Choung, Ji Eun Kim, Sang In Khwarg
BMC Ophthalmology.2023;[Epub] CrossRef
Cervical cancer screening by molecular Pap‐transformation of gynecologic cytology
Shaikhali M Barodawala, Kirti Chadha, Vikas Kavishwar, Anuradha Murthy, Shamma Shetye
Diagnostic Cytopathology.2019; 47(5): 374. CrossRef
Prognostic Significance of Amplification of thec-MYCGene in Surgically Treated Stage IB-IIB Cervical Cancer
Tae-Jung Kim, Ahwon Lee, Sung-Jong Lee, Won-Chul Lee, Yeong-Jin Choi, Kyo-Young Lee, Chang Suk Kang
The Korean Journal of Pathology.2011; 45(6): 596. CrossRef

Intron 1 Polymorphism, Mutation and the Protein Expression of Epidermal Growth Factor Receptor in Relation to the Gefitinib Sensitivity of Korean Lung Cancer Patients.: Mi Jin Kim, Kyeong Cheol Shin, Kwan Ho Lee; Korean J Pathol. 2009;43(6):509-516.; DOI: https://doi.org/10.4132/KoreanJPathol.2009.43.6.509

3,580 View
17 Download

Abstract PDF: BACKGROUND
Epidermal growth factor receptor (EGFR) intron 1 polymorphism in non-small cell lung cancer (NSCLC) has been found to have therapeutic implications for the patients treated with EGFR tyrosine kinase inhibitors. However, its clinical significance as related to gefitinib responsiveness is still controversial. We examined CA repeat polymorphism in intron 1 of the EGFR gene and its relation with the EGFR gene mutation in NSCLC patients who were treated with gefitinib. METHODS: Sixty seven patients who were treated with gefitinib were analyzed for intron 1 polymorphism in the EGFR gene, the EGFR mutations and the EGFR protein expression. Two hundred twenty seven samples of NSCLC were analyzed for EGFR mutations. RESULTS: CA repeat was low in 27 patients (40.3%) and high in 40 (59.7%) patients. The response rate for gefitinib therapy was higher in the patient population with a low number of CA repeats in the EGFR gene (p=0.047) and in the patients with the mutated type of EGFR (p=0.048), though these two factors were not related. Thirty four patients (15.0%) harbored EGFR mutations. CONCLUSIONS: This study suggests that the intron 1 CA repeat polymorphism of the EGFR gene may serve as a predictor of the clinical outcome of NSCLC patients treated with gefitinib, and this without regard for EGFR mutation. Our data further supports the importance of EGFR mutations with regard to a distinct clinical profile and the prognostic implications for NSCLC patients.

The Expression of Cyclooxygenase-2 and Survivin in Urinary Bladder Transitional Cell Carcinoma.: Tae Jung Jang, Kyung Seob Lee; Korean J Pathol. 2009;43(3):206-211.; DOI: https://doi.org/10.4132/KoreanJPathol.2009.43.3.206

4,506 View
29 Download
4 Crossref

Abstract PDF

BACKGROUND
The aim of this study was to investigate the expressions of cyclooxygenase-2 (COX-2) and survivin in bladder transitional cell carcinoma (TCC) that has different clinicopathologic characteristics, and we also wanted to determine if a relation exists between the COX-2 and survivin expressions.
METHODS
The expressions of COX-2 and survivin were investigated in 80 bladder TCCs by performing immunohistochemistry.
RESULTS
The normal bladder mucosa did not express COX-2 and survivin. COX-2 immunopositivity and cytoplasmic survivin immunopositivity were seen in 48% and 30% of bladder tumors, respectively. The expressions of COX-2 and survivin were closely related to the differentiation, depth and recurrence of bladder TCC, and there was a significant correlation in topographic distribution of COX-2 and survivin immunopositivity. In addition, COX-2 and survivin were predominantly expressed at the invasive front of tumors.
CONCLUSIONS
This data suggest that COX-2 and survivin may be involved in the progression of bladder TCC, and there is a close correlation between the expressions of COX-2 and survivin.

Citations

Citations to this article as recorded by

Assessment of survivin and p27 expression as potential prognostic markers in urothelial cell carcinoma of urinary bladder in Egyptian patients
Noha Said Helal, Zeinab Omran, Mona Moussa
African Journal of Urology.2022;[Epub] CrossRef
Cyclooxygenase-2 Expression in Urinary Bladder Transitional Cell Carcinoma and its Association with Clinicopathological Characteristics
Hedieh Moradi Tabriz, Golrokh Olfati, Seyed Ali Ahmadi, Sudabeh Yusefnia
Asian Pacific Journal of Cancer Prevention.2013; 14(8): 4539. CrossRef
High survivin expression in premalignant and malignant kidney lesions
Tahany M. Shams, Samaka M. Rehab, Mokhtar Metawea
Egyptian Journal of Pathology.2012; 32(1): 21. CrossRef
Reciprocal correlation between the expression of cyclooxygenase-2 and E-cadherin in human bladder transitional cell carcinomas
Tae Jung Jang, Woo Heon Cha, Kyung Seob Lee
Virchows Archiv.2010; 457(3): 319. CrossRef

Case Reports

Spontaneous Pneumothorax as an Initial Manifestation of Metastatic Papillary Thyroid Carcinoma.: Jong Im Lee, Jung Ran Kim, Soo Sung Kim; Korean J Pathol. 2009;43(1):83-87.; DOI: https://doi.org/10.4132/KoreanJPathol.2009.43.1.83

4,325 View
34 Download

Abstract PDF: Spontaneous pneumothorax occurs in a variety of lung diseases. Primary or metastatic lung cancers are rare, but important causes of pneumothorax. We report here on a case of pulmonary metastasis of thyroid papillary carcinoma that initially presented as spontaneous pneumothorax. A 32-year-old male with no history of thyroid disease underwent wedge resection of the lung due to recurrent pneumothorax. Histologically, the pleura and subpleural lung parenchyma revealed several micronodular lesions and randomly scattered glandular structures with mild cytological atypia. The cells were characterized by their overlapped hypochromatic nuclei with longitudinal grooves and inconspicuous nucleoli. On the additional sections, we found a few intranuclear inclusions and colloid-like material in the follicular structures. The glandular cells were immunoreactive for thyroglobulin, TTF-1, CK 7 and HMW-CK and they were focally immunoreactive for EMA, but they were negative for S100, chromogranin and CEA. The Ki-67 labelling index was 4%. Neck ultrasonography revealed an ill-defined hypoechoic nodule in the left lobe of the thyroid. The diagnosis of conventional, classical papillary carcinoma was made by both the cytology and the total thyroidectomy specimen. Pathologists should conduct a through histologic examination for the patients with recurrent spontaneous pneumothorax to search for the underlying causes.

Gastric Adenocarcinoma with Coexistent Hepatoid Adenocarcinoma and Neuroendocrine Carcinoma: A Case Report.: Aeri Kim, Sang Woon Kim, Sun Kyo Song, Young Kyung Bae; Korean J Pathol. 2009;43(1):79-82.; DOI: https://doi.org/10.4132/KoreanJPathol.2009.43.1.79

4,160 View
34 Download
2 Crossref

Abstract PDF

This report represents a very rare case of a gastric adenocarcinoma that was coexistent with hepatoid adenocarcinoma and neuroendocrine carcinoma. A 77-year-old man was admitted to our hospital due to a huge ulcerofungating mass identified at the proximal body of the stomach. After a pathological diagnosis of the tumor as a poorly differentiated adenocarcinoma was made, the patient underwent a total gastrectomy with lymph node dissection. Microscopically, the tumor consisted of three morphologically distinct components-tubular adenocarcinoma, hepatoid adenocarcinoma and neuroendocrine carcinoma. The hepatoid adenocarcinoma component resembled a hepatocellular carcinoma and produced alpha-fetoprotein. The neuroendocrine carcinoma component was positive for chromogranin and synaptophysin immunostains. This is an example of the diverse morphological and immunophenotypical differentiation of gastric carcinomas.

Citations

Citations to this article as recorded by

An Intestinal Type Gastric Neuroendocrine Tumor: A Case Report
Mohammad Abu-Jeyyab, Renata Kakish, Malak Alkatib, Leen Alshawabkeh, Rawan Bani Hamad, Mary Almadani, Ma'wia Santarisi, Mohammad Al-Jafari, Abdulqadir J. Nashwan
Case Reports in Oncology.2023; 16(1): 1113. CrossRef
Gastric adenocarcinoma is concurrent with metastatic neuroendocrine cancer treated with nivolumab and chemotherapy: A case report
Bing Yan, Meiqi Cui, Junhao You, Fang Li, Hui Liu
Molecular and Clinical Oncology.2018;[Epub] CrossRef

Original Article

Metaplastic Squamous Carcinoma of the Breast: Clinicopathologic Analysis of 17 Cases.: Sun Ah Lee, Kyung Eun Lee, Byung In Moon, Woon Sup Han, Sun Hee Sung; Korean J Pathol. 2009;43(1):20-25.; DOI: https://doi.org/10.4132/KoreanJPathol.2009.43.1.20

4,948 View
48 Download
2 Crossref

Abstract PDF

BACKGROUND
Squamous cell carcinoma of the breast is very rare and it is considered to arise from metaplastic change of ductal carcinoma. Metaplastic squamous cell carcinoma (MSC) of the breast includes pure squamous cell carcinoma, metaplastic adenosquamous carcinoma and low grade adenosquamous carcinoma. Most of the cases of MSC of the breast were reported to have lymph node metastasis and this has a worse prognosis than that of conventional invasive ductal carcinoma.
METHODS
We collected 17 cases of MSC of the breast from 1,173 cases of breast cancer and analyzed the clinicopathological characteristics.
RESULTS
The age range was 31 to 69 years (mean age: 47.2). The mean tumor size was 3.6 cm. Twelve cases (70.6%) had a negative nodal status. The majority of the cases were of a high nuclear grade (grade III: 76.5%), and a high histologic grade (grade III: 88.2%). All the cases had no amplification of HER2, and they were negative for hormonal receptors, except for 2 cases with weak positivity. All the cases showed positivity for EGFR (3+: 14 cases, 1+: 3 cases). Clinical relapse was found in 3 patients on follow up and two of them expired due to lung and bone metastasis.
CONCLUSIONS
MSC is associated with high nuclear and histologic grades, a high EGFR expression and they are triple negative for ER, PR, and HER2. The EGFR immunopositivity of MSC suggests a basal-like subtype.

Citations

Citations to this article as recorded by

Eccrine ductal and acrosyringeal metaplasia in breast carcinomas: report of eight cases
Tibor Tot
Virchows Archiv.2019; 474(3): 383. CrossRef
Significance of Foxp3 Positive Regulatory T Cell and Tumor Infiltrating T Lymphocyte in Triple Negative Breast Cancer
Hanna Kang, Harin Cheong, Min Sun Cho, Heasoo Koo, Woon Sup Han, Kyung Eun Lee, Byung In Moon, Sun Hee Sung
The Korean Journal of Pathology.2011; 45(1): 53. CrossRef

First
Prev
Page of 3
Next
Last

Search